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GENERAL INTRODUCTION 
 
SOMATOSTATIN, SOMATOSTATIN RECEPTORS AND 
PRINCIPLES OF GENE THERAPY 
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SOMATOSTATIN 
In 1973 Brazeau et al. isolated and identified a 14-amino acid peptide, named 
somatotropin-release inhibiting factor (SRIF), later changed to somatostatin (SS)(1). 
Subsequently, research showed that somatostatin had two forms of bioactive peptides, 
somatostatin 14 and somatostatin 28, and that SS was widely distributed throughout 
the body with a wide variety of effects on endocrine, gastrointestinal and central 
nervous systems. The diversity of effects mediated by SS led to the suggestion that the 
hormone could have a therapeutical purpose in a great number of indications. 
However, due to the short half-life of SS (approximately 2 minutes) there were some 
restrictions in the use of natural SS as a drug. Therefore, researchers began to 
synthesize more stable peptide analogs with a longer duration of action, such as 
octreotide (SMS 201-995), lanreotide (BIM 23014) and vapreotide(2). These analogs 
not only proved to be more stable, but had also different affinity for the five different 
somatostatin receptors (SSRs), making their mode of action also more selective. 
These new finding led to a broad use of SS and their analogs in a clinical setting.  
 
SOMATOSTATIN RECEPTORS 
At least five different human SSRs have been cloned, sst1 to sst5(2). The SSRs 
subtypes present a high degree of sequence identity. SS 14 and SS 28 bind with 
similar affinity for all SSRs, except sst5, which shows a 10 fold higher affinity for SS 
28. However, analogs show different affinities for the five receptor-subtypes. Analogs 
exhibit a high affinity for sst2 and sst5, whereas they bind with low affinity for sst1 and 
sst4 and bind with a moderate affinity for sst3(2; 3). Using radiolabeled SS and 
analogs indicated that SSRs were expressed in a wide number of normal tissue such as 
hypothalamus, pituitary, gastro-intestinal tract, pancreas, endocrine glands and 
lymphoid tissue(4-6). Furthermore, binding studies showed also high expression of 
SSRs in various tumors, like gastroenteropanctreatic (GEP) tumors, thyroid 
carcinomas, breast tumors, ovarian cancers and pituitary adenomas. Interestingly, 
these binding studies suggested that SSRs were preferentially expressed in well-
differentiated compared to less differentiated tumors(7; 8). These observations 
hypothesize that  SSRs may play a role in the differentiation in some cancers and it 
can be used clinically as a marker in the progression of cancers. Thus, since SSRs 
play an important role in the physiological control of cell proliferation, loss of SSR 
expression in tumor cells would confer a proliferative advantage to those cells and 
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their progeny. In regard of this point genes of the SSRs can be regarded as tumor 
suppressor genes. This suggestion is supported by the observation that a point 
mutation in the sst2 gene results in an increased proliferation of small cell lung cancer 
cells in vitro(9). 
Each receptor subtype is coupled to multiple intracellular transduction pathways via 
GTP binding proteins. To date, a total of three signaling pathways are identified. The 
first signaling pathway is the inhibition of the adenylate cyclase system leading to 
reduction of intracellular cAMP(2; 3). A second key plasma membrane signaling 
pathway involved in SS action concerns K+ and Ca2+ channels. Activation by SS 
causes hyperpolarization of the plasma membrane and leads to decreased Ca2+ influx 
and consequently to reduction of intracellular Ca2+ (10). SS can also decrease Ca2+ 
influx directly by inhibiting high voltage-dependent Ca2+ channels via G0α2 (2). Both 
of these two signal transduction pathways, inhibition of Ca2+ and to a lesser extent 
inhibition of cAMP, mediate the negative regulation of hormone secretions induced 
by SS. A third important membrane signaling pathway involves an activation of a 
number of protein phosphatases induced by SS and analogs. Sst1 to sst4 have been 
reported to stimulate tyrosine phosphatase activity when expressed in NIH 3T3 
fibroblast or CHO cells(11-13). 
 
EFFECT OF SOMATOSTATIN ON CELL GROWTH 
The effects of SS on tumor growth can be divided in indirect and direct effects. 
 
Indirect effects 
 Indirectly, SS can inhibit the secretion of growth-stimulating hormones and factors 
which can stimulate the growth of various tumors. For example, octreotide has been 
demonstrated to negatively control  the serum IGF-1 level by inhibiting GH secretion 
through sst2 and sst5(14).  
Also a direct effect on IGF gene expression has been demonstrated(15). Clinical 
studies have shown a reduction of IGF-1 gene expression and serum levels of IGF-1 
after treatment of breast cancers with octreotide(16).  
In addition, an increased expression and secretion of IGF-binding protein-1, which 
specifically binds IGF-1 and negatively regulates plasma IGF-1, has been 
reported(17).  
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SS and its analogs can also indirectly control tumor and metastasis development by 
inhibition of angiogenesis(18). In various types of cancers (colorectal, breast, renal 
cell and lung cancers) an expression of peritumoral vascular SSRs has been 
demonstrated. Moreover, the expression of SSRs in tumor vessels was independent of  
receptor expression on the tumor(19). This suggests that SS and SSRs may play a role 
in angiogenesis and other hemodynamic aspects of the tumor. 
 
Direct effects 
SS can also directly inhibit cell growth in various cancer cell lines which express 
SSRs. However, this SS induced cell growth arrest is still poorly understood. To date, 
three different mechanism are described. 
1. As a result of the blockade of mitogenic growth factor signal, SS may directly 
inhibit cell growth. This effect involves the stimulation of  a tyrosine 
phosphatase(20; 21). The SS-sensitive tyrosine phosphatase has recently been 
identified as SHP-1. SHP-1 is associated with various activated tyrosylated growth 
factor tyrosine kinase receptors and cytokine receptors. It has been reported in 
several studies that SHP-1 may have a role in terminating growth factor and 
cytokine mitogenic signals by dephosphorylating critical molecules(22). Lopez et 
al. have shown that that SHP-1 is required for the antiproliferative signal initiated 
by sst2(23). 
2. The antiproliferative effect of SS can also result from apoptosis. This has been 
reported to be induced by sst3 via a G protein-dependent signaling and to be 
associated with an intracellular acidification and activation of endonuclease and 
induction of p53 and Bax(24; 25). 
3. Also SS can inhibit directly syntheses and secretion of autocrine growth factors, 
cytokines and hormones involved in the proliferation of tumor cells(26; 27). This 
is mediated through inhibition of Ca2+ and cAMP production. Furthermore, SS can 
directly interfere with the exocytotic machinery by inhibiting the protein 
phosphatase calcineurin(28).  
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PRINCIPLES OF GENE THERAPY 
Gene therapy is defined as the transfer of nucleic acids (DNA) to cells which results 
in a therapeutic effect, by either correcting genetic defects or by overexpressing 
proteins that are therapeutically useful. 
 
Gene delivery vectors 
In order to transfer the DNA into cells a gene delivery vector is acquired. The gene 
delivery vectors can be divided in two groups: viral and non-viral vectors. 
 
1. Viral vectors: 
Viruses are able to effectively recognize and enter cells, traffic within the cytosol to 
the nucleus, translocate into the nucleus and express their genes in host cells. These 
properties made them among the first choices for gene delivery vectors. 
The most frequently used viral vectors are retroviruses and adenoviruses (table 1). 
Although, recently other viral vectors are in preclinical development, including 
adeno-associated virus (AAV)(29), herpes simplex virus (HSV (30), pox and 
lentivirus (31) etc..  
Retroviruses can lead to a stable integration of the transfected gene in the host 
genome, consequently leading to a ever-lasting gene transfer. Replication-deficient 
retroviruses are produced in vitro in specific packaging cells transfected previously 
with retroviral genes that have been deleted from the genome of the therapeutic 
retroviruses. Major limitations of the retroviral vectors are their low titres, their 
inability to infect non-dividing cells (this can be an advantage in the case of cancer 
gene therapy), and the potential risk of insertional mutagenesis(32). 
Adenoviruses can be produced in high titres. As they do not integrate stable into the 
host genome, they lead to a transient transgene expression. An advantage is the 
effective gene transfer in both dividing as non-dividing cells, but an disadvantage is 
the produced immunological and inflammatory response by themselves(33) or via the 
proteins encoded in the transgene(34). Adenoviruses are human pathogens, and most 
patients have already been exposed to them during their lifetime resulting in the 
presence of various levels of circulating neutralizing anti-viral antibodies. This may 
decrease the effectiveness of their systemic application. Use of viral vectors which are 
not human pathogens (e.g., various serotypes of adenoviruses, AAV, or non-human 
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adenoviruses) can avoid this problem. Immune response evoked by the first 
application of the viral vector, however, may interfere with their repeated application. 
 
2. Non-viral vectors 
The synthetic vectors (naked DNA, cationic liposomes, etc.) are far from being ideal 
delivery systems. Although they are less pathogenic and may have reduced toxicity 
compared to some of the viral vectors, depending on the dose injected, liposomes may 
aggregate in blood and can cause severe toxic reactions(35). Plasmid and liposome 
complexes are easy to produce and are safe, but they have low gene-transfer 
efficiency. However, in the future, the “perfect” gene delivery vector may be 
synthetic, incorporating many of the advantages of viruses (e.g., cell recognition, 
cellular uptake, etc.), but avoiding the unwanted properties of viruses (e.g. 
pathogenicity, cell toxicity, immune response, etc.). 
 
 
Table 1: Gene Therapy vehicles        
 
Vector  Advantages    Disadvantages    
Retrovirus - stabile transduction   - low transduction-efficacy 
- requires cell division for transduction - requires cell division for transduction 
  (advantegeous for cancer gene therapy) - limited DNA-packaging capacity 
- lower anti-viral immune response  - insertional mutagenesis? 
     - low production titres 
Adenovirus - high production titres   - transient transduction 
- transduction in dividing and non-  - higher anti-viral immune response 
  dividing cells    - low cell-specificity of transduction 
- high transduction-efficacy 
- large DNA-packaging capacity 
 
 
Gene delivery targeting 
Targeting of gene therapy vehicles is not only important for the improvement of the 
effectiveness of expression of the transfected gene, but can also play a vital role in 
toxicity of this treatment. Especially, when cancer gene therapy is concerned, most 
gene therapy vehicles transfect both dividing and nondividing cells, as a result of 
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which normal cells can also be transfected, leading to toxicity of the treatment. For 
these reasons a lot of research has been done in targeting the gene therapy vehicles. 
1. Physical targeting 
A variety of physical gene delivery methods have been introduced to achieve better 
local tissue targeting of vectors. The most simple manner of physical targeting is 
intramuscular, -intratumoral, intradermal delivery of the gene therapy vehicles. 
Another example of the effective physical targeting is catheter-mediated gene transfer 
to various regions of the circulation (e.g., liver, heart, limbs, etc.)(36-38). These 
delivery methods offer certain advantages in specific disease targets, but when a 
disease is more widely spread in the whole human body (e.g. metastasized cancer), 
this targeting strategy becomes obsolete. 
2. Transcriptional targeting 
As many target tissues or diseases have a specific property, this property can be used 
in order to achieve a targeted vector. Incorporation of a tissue- or disease-specific 
promotor into the vector allows therapeutic gene expression only in cells which 
express transcription factor proteins binding to these specific promotor sites. Some of 
the tissue- or disease specific promotors are prostate-specific antigen (PSA)(39), 
carcinoembryonic antigen (CEA)(40) and hypoxia response element (HRE) activated 
by hypoxia inducible factors (HIF) in hypoxic/ischemic tissue (e.g. tumors)(41). 
 
Cancer gene therapy 
There are at least five different approaches presently developed for cancer gene 
therapy: 
1. Gene replacement (tumor suppressor-genes) 
Transfer of tumor suppressor genes, like wild-type p53, into p53 mutant tumor cells 
can induce apoptosis in vitro and in animal studies(42-44). Other cell cycle regulatory 
genes like p16 or p21 are also potential targets for gene replacement. Replacement of 
tumor suppressor genes can be combined with chemo- or radiotherapy to increase 
apoptosis of tumor cells. Treatment of lung cancer patients with wild-type p53 
delivered locally with an adenovirus has shown promising result in a human clinical 
trial (45).  
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2.   Suicide gene therapy 
One of the most effective approaches of cancer gene therapy is suicide gene therapy, 
in which tumor cells are transduced with genes whose product convert a nontoxic 
prodrug into a toxic metabolite. Examples of such genes include the herpes simplex 
thymidine kinase (HSV-tk) gene and cytosine deaminase (CD) gene which convert the 
nontoxic drugs ganciclovir and 5-fluorocytosine to the toxic products ganciclovir-
tryphosphate and 5-fluorouracil, respectively(46). A key property of this approach is 
the so called “bystander effect” consisting in the induction of killing of nontransduced 
cells by neighboring transduced cells(47; 48). Explanations for the bystander effect 
include the transfer of toxic metabolites through gap junctions of cells and the 
induction of immune responses against tumor antigens released from dying cells(49; 
50). The bystander effect contributes to a significant increase of antitumor effect in 
cancer gene therapy 
3. Cytokine gene therapy 
Transduction of tumor or adjacent tissue with cytokine genes, generates an antitumor 
immunity by recruitment and stimulation of immune effector cells. Cytokine used to 
date include IL-2, IL-4, IL-6, IL-7, IL-12, GM-CSF, TNF-α and IFN-γ(51-58). 
Moreover, this strategy is often combined with suicide gene therapy, as the bystander 
effect induces a more intense antitumor effect (59). 
4. Drug resistance gene 
Transduction of the bone marrow with multidrug resistance (MDR-1) gene results 
protection of the bone marrow against chemotherapeutic agents, thus permitting the 
use of higher doses of chemotherapy (60; 61). MDR encodes for p-glycoprotein which 
functions as a cellular efflux pump extruding toxic drugs from out of transfected cells. 
Several clinical trials using this concept are currently under way. 
5. Anti-angiogenesis 
The growth of tumors is strongly dependent of angiogenesis to provide nutrients and 
oxygen to tumor cells. This process of neovascularization is modulated by tumor cells 
that produce angiogenic factors, such as vascular endothelial growth factor (VEGF) 
and basic fibroblast growth factor (bFGF). Specific inhibition of these genes or gene 
transfer of angiogenesis inhibiting factors like endostatin or angiostatin, could have a 
significant antitumoral effect and is currently under investigation(62-64). 
The therapeutic goal in any treatment modality for cancer is effective killing of most 
(if not all) cancer cells without serious damage to normal cells and tissues. Therefore, 
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gene therapy should also aim at effective and selective killing of cancer cells. So far, 
there has been a disappointing inability to reach cancer cells with sufficient efficacy to 
generate high enough levels of direct killing. Most successful results are in an 
experimental setting, although a few clinical trials are also under way and preliminary 
results are promising. 
 
SSR gene therapy 
As stated earlier the genes of the SSRs can be regarded as tumor suppressor genes. 
Zhang et al. observed that a point mutation in the sst2 gene resulted in an increased 
proliferation of small cell cancer cells (10). Also Delesque et al. showed that loss of 
the sst2 expression could lead to an increased tumorigenicity of pancreatic tumor cells 
(65). Through this observation a new approach was developed for the treatment of 
pancreatic cancer by means of sst2 gene transfer (66). By inducing the SSR on the 
tumor cells, antitumor effects were obtained which might be attributed to several 
mechanisms. First, an autocrine negative feedback loop in which transfected tumor 
cells start to produce SS, which binds in an autocrine manner to the induced SSR, may 
provide an inhibitory effect on tumor cell growth. Second, binding of the SS to sst2 
may upregulate p27, a tumor suppressor gene, which leads to cell cycle arrest in the 
G0-G1 phase, and subsequently causes apoptosis. Local and distant bystander effects 
have also been noted (67). The local bystander effect might be attributed in part to 
apoptosis, these cells release apoptotic vesicles and enzymes, which in turn might kill 
neighboring cells. The distant bystander effect may be explained by a paracrine effect. 
SS can upregulate the expression of sst1 on parental tumor cells, thereby rendering 
them sensitive to the antiproliferative effect of SS. All the abovementioned 
mechanisms may contribute to successful treatment of certain types of cancers with 
SSR gene therapy. 
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AIMS OF THE THESIS 
Somatostatin is a widely distributed peptide that negatively regulates a number of 
cellular processes, including growth of multiple epithelial cell types. Previous studies 
have shown that the somatostatin analog, octreotide, slightly suppress the growth of 
cancer cells expressing somatostatin receptors (SSRs). However, high radioactive 
doses with [111In-DTPA0]octreotide for peptide receptor radionuclide therapy (PRRT) 
could inhibit the growth of SSR positive liver metastases in a rat model strongly. The 
results of these experiments suggests that the antiproliferative effects were 
predominantly mediated by the specific SSR. 
Among the five cloned SSR-subtypes (sst1-5), subtype 2 was found to mediate the 
growth inhibitory effects of somatostatin analogs in vitro the strongest. A new 
targeted cytotoxic somatostatin analog, named AN-238, which could be more 
efficacious and less toxic than presently used systemic chemotherapeutic agents, also 
do have a high affinity for sst2. 
Moreover, PPRT with new radiolabelled somatostatin analogs, as [177Lu-DOTA0, 
Tyr3]octreotate, could have even stronger antitumor effects than [111In-
DTPA0]octreotide . 
In order to use PRRT and AN-238 in SSR-negative tumors, induction of the SSR 
(subtype 2) is necessary. 
The aims of this thesis are: 
 
1. Is sst2 in vitro transfection of CC531 SSR-negative colon carcinoma cells 
possible and  is the transfected SSR functional? 
2. Is PRRT with [111In-DTPA0]octreotide effective for the sst2-transfected CC531 
cells in a rat liver metastases model? 
3. Is PRRT with [177Lu-DOTA0, Tyr3]octreotate effective for sst2-positive 
CA20948 pancreas carcinoma cells in a rat liver metastases model? 
4. Is PRRT with [177Lu-DOTA0, Tyr3]octreotate effective for sst2-transfected 
CC531 cells in a rat liver metastases model? 
5. Is targeted therapy with the cytotoxic somatostatin analog, AN-238, effective 
for sst2-transfected CC531 cells in a rat liver metastases model? 

  
 
 
Alleen licht zie je beter in het donker. 
S. Brussaard 
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ABSTRACT 
Somatostatin receptors have been found on a variety of neuroendocrine tumors like 
carcinoids, paragangliomas, as well as on most pancreatic endocrine and breast 
tumors. Somatostatin receptor scintigraphy with a radionuclide labeled somatostatin 
analog, [111In-DTPA0]octreotide, is a sensitive and specific technique to visualise in 
vivo the presence of somatostatin receptors on various tumors. 
Material was identified from previous review articles, references citated in original 
papers and a Medline search of the literature. Additional material was obtained from 
recently published abstracts of meetings. 
Somatostatin receptor imaging of neuroendocrine tumors is essential in the diagnostic 
work up for most of these tumors. The expression of somatostatin receptors in vivo 
not only predicts the outcome of somatostatin analog treatment but also opens the 
possibility for new therapeutic strategies. Since better information about spread of the 
disease can be obtained, more justified therapy options can be proposed. 
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SOMATOSTATIN RECEPTOR EXPRESSION  
Somatostatin (SS) is a small regulatory peptide, isolated in the ovine hypothalamic 
gland in 1973 as a growth hormone (GH) release inhibiting factor1. SS is widely 
distributed in the human body and not only in the hypothalamus, but also in various 
parts of the gastro-intestinal tract, indicating that inhibition of GH is not its only 
function2. Apart from its function as a neurotransmitter in the central nervous system 
(CNS), SS also has inhibitory effects on the secretion of hormones by the pancreatic 
islands (insulin, glucagon) and on the exocrine pancreatic function. Also, somatostatin 
inhibits normal gastrin production and consequently gastric acid and pepsin 
production3. A number of observations have also suggested an anti-proliferative effect 
of SS and its stable analogs4-6. Critical to all these actions is the expression of 
somatostatin receptors (SSRs) on the cell membrane. These SSRs subserve two 
functions: (1) to recognise the ligand and bind it with high affinity and specificity, and 
(2) to generate a transmembrane signal that evokes a biological response. Large 
number of SSRs were found on most tumors with amine precursor uptake and 
decarboxilation (APUD) characteristics and neuroendocrine properties, such as 
carcinoids, paragangliomas, pheochromocytomas, medullary thyroid cancers and 
endocrine pancreatic tumors. In addition, large numbers of binding sites with high 
affinity for SS were also found on breast and brain tumors as well as on various cells 
of the immune system7-10. At least five different human SSR subtypes have been 
cloned11. All subtypes bind SS with high affinity, while their affinity for the SS 
analog octreotide differs considerably. Octreotide binds with high affinity to 
somatostatin receptor subtype 2 (sst2) and sst5, to a lesser degree sst3, while no 
binding to sst1 and sst4 occurs. Other somatostatin analogs, that are in clinical use like 
BIM 23014 (Lanreotide) and RC-160 (Vapreotide) as well as the hexapeptide MK678 
bind to three of the five SSR subtypes displaying also high affinity for sst2 and sst5 
and moderate affinity for sst312.  
Somatostatin receptor mRNA subtypes are widely expressed in neuroendocrine 
tumors, but their distribution is not necessarily correlated with SSR subtype 
expression. Furthermore SSR subtypes show a differential subcellular localisation in 
human SSR positive tumors13. The majority of human endocrine pancreatic tumors 
such as gastrinomas, glucoganomas, VIPomas and “non-functioning” islet cells 
tumors express sst2. In vitro studies have shown that 72% of the insulinomas express 
SSRs, however, these receptors are mainly sst3, which has low affinity for 
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octreotide14,15. Although SSRs have been demonstrated on exocrine pancreatic cells in 
experimental animals mainly on the acinar cells, neither SSRs nor neuroendocrine 
properties could be confirmed on human exocrine pancreatic adenocarcinomas16. 
Carcinoids, paragangliomas, pheochromocytomas and medullary thyroid cancers all 
have a mixed distribution of the SSR subtypes but sst2 is most frequently expressed. 
The presence of different combinations of SSR subtypes may explain the variable 
clinical response to SS analogs and the difference in successful localisation by 
somatostatin receptor scintigraphy (SRS) of these tumors. Metastases of primary SSR 
positive tumors initially do express also the same SSR subtype, however loss of these 
receptors have been described after dedifferentiation of tumor cells or after 
chemotherapy17. In addition, SSR overexpression was identified in peritumoral veins 
of primary tumors and veins surrounding lymph node, bone and lung metastases18.  
 
SOMATOSTATIN RECEPTOR SCINTIGRAPHY 
The optimal management of patients with neuroendocrine tumors requires accurate 
imaging and staging. For the visualisation of SSR positive tumors somatostatin 
receptor scintigraphy (SRS) with [111In-DTPA0]octreotide (Octreoscan®) (DTPA = 
diethylenetriaminopentaacetic-acid) has been used for more than 10 years19,20. The 
efficacy of SRS using [111In-DTPA0]octreotide in patients with histologically or 
biochemically proven endocrine pancreatic tumors or carcinoids was evaluated in a 
European multicenter trial21. The highest success rates of SRS were observed with 
glucagonomas (100%), vipomas (88%), gastrinomas (73%),“non-functioning” islet 
cells tumors (82%) and carcinoids (87%). Insulinomas were detected in only 46% due 
to the low incidence of sst2 on insulinoma cells. The low sensitivity in this study 
found for some tumors may be related to important differences in scanning procedures 
such as the amount of radioligand administered, the duration of the acquisition and the 
use of single photon emission computed tomography (SPECT)22. With SPECT, in 
which a rotating camera is used, image reconstructions can be made similar to spiral 
computed tomography (CT).  This technique renders additional visual information, 
especially on tumors in the liver and upper-abdomen23. With SPECT 25% more liver 
metastases are detected if compared to planar SRS.  
In a prospective study comparing the sensitivity of SRS with that of CT-scanning, 
magnetic resonance imaging (MRI), ultrasonography (US) and selective angiography 
in the detection of primary and metastatic gastrinomas, SRS altered clinical 
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management in 47% and had a superior sensitivity, and specificity24 (Table 1). Cadiot 
et al compared the results of SRS with those of conventional imaging techniques 
including endoscopic ultrasonography (EUS), and with surgical findings in 21 
consecutive patients with Zollinger-Ellison syndrome25. SRS added complementary 
information to other imaging techniques including EUS and improved the 
preoperative detection of extrapancreatic gastrinomas. By combining SRS with EUS 
they were able to detect 90% of the tumors in the upper duodenopancreatic area. SRS 
identified metastatic disease in 20-30% of patients after all other imaging techniques 
had failed23. An other study concerning 160 patients with biologically and/or 
histologically proven gastroenteropancreatic (GEP) tumors including pancreatic islet 
cell tumors, SRS changed the surgical therapeutic strategy in 40 (25%) patients (Table 
2)26. Unsuspected liver tumors were discovered only by SRS in 7 patients, 
contralateral liver tumors before hepatectomy in 2 and extrahepatic disease in 31 
patients. In 48 patients with histologically proven hepatic metastases of 
neuroendocrine tumors including carcinoids we compared conventional imaging 
methods (CIM) with SRS for the detection of extrahepatic disease. CIM consisted of  
US, CT thorax and abdomen and, when indicated, bone scanning. All patients were 
scanned according to our multiple spot (MS) views protocol. A minimal dose of 111In 
of 200 MBq and least 10 µg of peptide was administered as an iv. bolus and 
acquisition was performed 24 and 48 hours thereafter. Acquisition time was 15 min. 
and abdominal SPECT was used systematically with a triple head camera. SRS alone, 
according to this protocol, demonstrated 114 extra-hepatic lesions in 37 patients, 
whereas CIM visualised only 50 extra-hepatic lesions in 22 patients. (Table 
3)(manuscript in preparation). 
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Table 1 Imaging methods for the detection of liver metastases and extra- 
hepatic metastases in patients with Zollinger-Ellison syndrome 
Procedure Extra-hepatic tumor
 n = 80 
Liver metastases 
 n = 24 
 Percentage of patients positive 
Ultrasonography (US)  9% 46% 
Computed tomography (CT) 31% 42% 
Magnetic resonance imaging (MRI) 30% 71% 
Angiography (Angio) 28% 62% 
US + CT + MRI + Angio (CIM) 48% 83% 
SRS 58% 92% 
SRS + CIM 68% 96% 
SRS Only* 20% 12% 
CIM Only** 10% 4% 
 
Results of tumor localisation for the identification of liver metastases and an extra-hepatic  
tumor in patients with Zollinger-Ellison syndrome. Results are expressed as the percentage of 
 the 24 patients with proven liver metastases and of the 80 patients with extra-hepatic disease 
SRS: Somatostatine receptor imaging; CIM: Conventional imaging methods;  
SRS Only*: tumor detected only with SRS; CIM Only**: tumor detected only with CIM 
 
 
Table 2 Clinical impact of SRS in 160 patients with GEP tumors 
Initial Classification SRS Classification 
 N I II III 
I   No metastases 90 65 7 18 
II  Only liver metastases 59  46 13 
III Extra-hepatic metastases 11   11 
 
 
Table 3 Detection of extra-hepatic metastases; SRS vs CIM 
 CIM negative CIM positive Total 
SRS negative 11 - 11 
SRS positive 15 22 37 
   48 
 
Forty eight patients with histological proven hepatic metastases of neuroendocrine tumors. 
Table shows number of patients with extra-hepatic disease detected by [111In-
DTPA0]octreotide (SRS) or by conventional imaging methods (CIM) consisting of computed 
tomography, ultrasound and bone scanning. In 15 patients extra-hepatic metastases were 
detected with SRS only. Eleven patients were found to have no extra-hepatic disease. 
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In patients with paragangliomas SRS provides optimal information on potential other 
tumor sites in the body, since paragangliomas are often multicentric and 
asymptomatic27. For imaging of adrenal pheochromocytomas, scintigraphy with 
radiolabeled metaiodobenzylguanidine (MIBG) is more accurate than SRS, since the 
majority of benign pheochromocytomas are localised in the adrenal, which 
localisation is difficult to distinct from the kidney with SRS. Furthermore the majority 
of these benign lesions do not express SSRs. Recently, in a large European 
multicenter study, sensitivity of 131I-MIBG to detect benign pheochromocytomas was 
81%28, while the detection rate of SRS is only around 25%. The majority of malignant 
tumors (80%), in contrast, do express these receptors and therefore SRS could be used 
to characterise adrenal masses suspected to be malignant29. In the management of 
medullary thyroid cancer (MTC) patients SRS has a limited role. SRS could be useful 
for the detection of residual and recurrent disease after total thyroidectomy or in 
patients who present primarily with metastatic disease in order to study the feasibility 
to perform peptide receptor radionuclide therapy (PRRT)30,31. To optimalize the 
detection of metastases in patients with recurrent MTC the combination of SRS and 
technetium-99m dimercaptosuccinic acid (99Tc-DMSA) should be considered, since 
together they have a sensitivity of 84% for the diagnosis of MTC, whereas these 
percentages for either technique alone were 29% (SRS) and 69% acid (99Tc-
DMSA)32.  
Finally, the difference in SSR expression between islet cell tumors, especially “non-
functioning” tumors and pancreatic duct cancers offers the possibility to differentiate 
between these tumors preoperatively33. This is important, as palliative surgery in 
patients with islet cell tumors is not only of value to relieve clinical symptoms, but 
also because a decrease in tumor burden might enhance the effect of medical 
treatment, resulting in a better clinical condition and a longer survival.  
 
CLINICAL USE OF SOMATOSTATIN ANALOGS 
Most endocrine pancreatic tumors, with the exception of insulinomas, have a 
malignant potential and have already metastasesed at the time of diagnosis. These 
tumors are in general slow growing and most of the clinical distress is related to the 
hypersecretion of hormones, which often incapacitates the patient and causes long and 
repeated hospital stay. The clinical use of the somatostatin analog octreotide in this 
type of patients is of considerable help in controlling symptomatology. Debilitating 
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diarrhoea, dehydration and hypokalemia (VIPoma) and necrolytic skin lesions 
(glucagonoma) can be well controlled during chronic treatment with octreotide. There 
is no doubt that octreotide therapy is of great benefit for most of these patients and 
improves their quality of life dramatically34. In selected patients peptic ulceration with 
hyperplasia of fundic argyrophil cells (gastrinoma) and life-threatening attacks of 
hypoglycemia (metastatic insulinoma) octreotide could be of therapeutic benefit35,36. 
Clinical studies in patients with hormone producing islet cell tumors showed a close 
parallel between the presence of SSRs on the tumors and the in vivo and in vitro 
suppressive effects of octreotide on hormone release37. This indicates that SRS can 
predict a possible suppressive effect of octreotide on hormonal hypersecretion by 
endocrine pancreatic tumors. Although octreotide is able to inhibit gastrin release in 
Zollinger-Ellison syndrome patients, proton-pump inhibitors are currently the first 
choice, since more than 80% of patients are controlled by omeprazol, lansoprazole or 
pantoprazole. A major problem in the treatment of patients with islet-cell tumors and 
carcinoids with octreotide is that the inhibition of the secretion of tumor related 
hormones is transient. Most patients finally become insensitive to octreotide 
treatment, possibly by downregulation of SSR expression or outgrowth of SSR-
negative clones6,38,39. The beneficial effects on clinical symptomatology in patients 
with metastatic endocrine pancreatic tumor and carcinoids is highly variable. 
Increasing the dose of octreotide or intermittent administration reverses these 
problems in most patients. The median duration of improvement of diarrhoea and 
flushing attacks by octreotide in patients with metastatic carcinoid disease was more 
than 12 months40. 
In some patients with (metastatic) medullary thyroid cancer, continuous treatment 
with very high doses of octreotide can be of temporary relief.  Long-term therapy with 
somatostatin analogs of catecholamine-secreting (malignant) paragangliomas and 
pheochromocytomas has not shown clinical benefits41. 
The role of octreotide in the treatment of pancreatitis is controversial. A meta-
analasys of 6 studies showed a significant decrease in mortality in patients with mild 
or severe pancreatitis (6.3% octreotide vs 14% placebo)42. However Uhl et al did not 
find a significant difference in mortality-rate or complications in a large series of 302 
patients with acute pancreatitis43. The decrease of digestive enzyme secretion and the 
increase of intestinal water and electrolytes absorption by octrotide can be beneficial 
in the treatment of pancreatic and enterocutaneous fistula44,45. In elective surgery for 
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pancreatic carcinoma or chronic pancreatitis peri-operative administration of 
octreotide has demonstrated its value. In a study of 246 patients that underwent 
pancreatic surgery octreotide treatment reduced mortality and complication incidence 
compared to placebo (3.2% and 32% vs. 5.8% and 55% respectively)46. Finally 
somatostatin and octreotide infusion reduce portal pressure by decreasing splanchnic 
blood flow. Though the exact mechanisms of acute hemodynamic changes in patients 
with portal hypertension are unknown there is a rationale for the use of somatostatin 
and its derivatives in the control of acute oesophageal variceal bleeding47. Early 
infusion of somatostatin in cirrhotic patients with acute variceal haemorrhage 
decreases treatment failure and mortality and reduces active bleeding after 
sclerotherapy, thereby improving the efficacy of sclerotherapy for acute variceal 
bleeding episodes48. 
 
ONCOLOGIC APPLICATIONS OF SOMATOSTATIN ANALOGS 
The observation that somatostatin inhibits the release of various peptide hormones has 
stimulated the interest in its use as an anti-proliferative agent. In pre-clinical studies 
SS analogs inhibit the growth of a wide variety of SSR positive as well as SSR 
negative tumors in vivo and in vitro4,6,49. An indirect tumor growth inhibition may be 
achieved via the inhibition of circulating tumor growth-promoting circulating 
hormones (GH, Insulin like growthfactor-1, insulin) and inhibition of circulating, 
paracrine- and/or autocrine-secreted stimulatory growth factors. SS and its analogs 
can also modulate the activity of immune cells50 and potentially influence tumor 
blood supply, whereas Reubi et al. showed a high density of  SSRs on veins in the 
peritumoral zone of several types of malignant tumors51. A potentiation of the anti-
proliferative effect of octreotide has also been suggested52, however no beneficial 
effect of octreotide combined with tamoxifen was found in patients with metastatic 
breast cancer53. Critical to the direct antiproliferative effects of SS analogs is the 
presence of SSRs54. Both cAMP-dependent and –independent effector mechanisms 
have been suggested55-58, while stimulation of phosphotyrosine phosphatase activity 
may play an important role in the inhibition of growth factor-stimulated cell 
growth59,60. The results of clinical trials in patients with GEP tumors, using SS 
analogs alone or in combination with interferon-α are rather disappointing with a 
biochemical response in 77% of patients with a median duration of 15 months but 
without any reduction in tumor size61,62. Octreotide has been clinically the most 
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commonly applied SS analog, yielding a biochemical response rates between 30 – 70 
% but objective tumor shrinkage in less than 10%-15% of the patients5,63-66. Treatment 
with standard doses of the SS analog lanreotide does not appear to be better than with 
standard doses of octreotide. However tumor biopsies before and during treatment 
with high doses of lanreotide indicated apoptosis in responding patients67,68. Side 
effects of long-term administration of SS analogs are rare. The most relevant side effect 
is the development of gallstones, which is believed to derive from the inhibition of 
gallbladder emptying due to the inhibition of cholecystokinin release69. The incidence of 
developing cholelithiasis and/or gallbladder sludge is reported to be between 30% to 
60% and seems to be dose dependent70,71. Patients require cholecystectomy for either 
symptomatic disease or acute cholecystitis in 15% of cases, therefore prophylactic 
cholecystectomy is not indicated, unless it is performed during elective cytoreductive 
surgery71. Octreotide might also influence blood sugar levels in patients with diabetes 
mellitus. 
 
RADIONUCLIDE THERAPY: PRE-CLINICAL 
A new and fascinating application is the use of radiolabeled octreotide and other 
peptides for Peptide Receptor Radionuclide Therapy (PRRT), further referred to as 
radionuclide-therapy. After systemic injection of [111In-DTPA0]octreotide the 
radioligand is internalised and transported into the lysosomes by SSR specific and 
temperature dependent process starting with endocytosis72,73. The radionuclide as 
metabolite 111In-DTPA-D-Phe is not capable of passing the lysosomal membrane 
resulting in a biological half-life in human tumor tissue of > 700 hours74,75. 111In not only 
emits gamma-rays, which can be visualised during scintigraphy, but also emits internal 
conversion- and Auger electrons having a medium to short tissue penetration (200-550 
µm, 0.02-10 µm, respectively). Therefore, an effect on tumor cell proliferation could be 
expected, as the radiotoxicity of the radionuclide is very high if the DNA of the cell is 
within the particle range76,77. Three experimental studies demonstrated tumor growth-
inhibition of solid subcutaneous tumors by radiolabeled SS analogs in animal models78-
80.  We investigated the anti-proliferative effect of  [111In-DTPA0]octreotide on, SSR 
positive, CA20948 pancreatic tumor cells in a rat liver metastases model with intra-
portal tumor cell injections81. Treatment with 370 MBq (0.5 µg) [111In-DTPA0]octreotide 
was given on day 1 and/or day 8. After 21 days the number of tumor colonies was 
significantly decreased by all treatment regimens compared to control animals and 
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treatments on day 1 and 8 proved to be superior to single treatment on either day (Table 
4). In repeated experiments, most treated animals showed none or a few tumor colonies, 
an outcome that was not observed earlier in experiments using high doses of non-
radiolabeled octreotide54.  
 
Table 4  Effect of  PRRT with [111In-DTPA0]octreotide on SSR positive liver 
metastases 
 
 
 Number of animals with 0 - > 100 metastases 
Number of metastases 0 1 - 20 21 - 100 > 100 
Treatment     
Controls - - - 6 
PRRT day 1 - 4 1 - 
PRRT day 8 - 3 2 - 
PRRT day 1 and 8 3 2 - - 
Slooter et al Int J Cancer 1999;767-771 
 
Number of animals with given range of metastases (5 or 6 animals per group), 21 days after 
direct injection of SSR positive CA20948 tumor cells into the portal vein. Peptide Receptor 
Radionuclide Therapy  (PRRT) with 370 MBq (0.5 µg) [111In-DTPA0]octreotide was given on 
day 1 or 8 or on day 1 and 8. The effect of all treatment schedules was significantly different (p< 
0.01) from the effect of 0.5 µg "cold" [DTPA0]octreotide on day 1 and 8 (Controls). Treatment 
on day 1 and 8 was significantly different from treatment on day 8 alone (p<0.05). No significant 
difference was found between the effect of treatment on day 8 or day 1. 
 
We also demonstrated that this tumor growth inhibition is predominantly due to the 
specific binding of  [111In-DTPA0]octreotide to the SSR and not to a systemic or a 
secondary mechanism since pre-treatment with 1 mg of octreotide prior to treatment, 
resulting in saturation of the SSRs, almost completely abolished the effect of [111In-
DTPA0]octreotide on SSR positive cells. Furthermore, PRRT had no effect on the 
growth of SSR negative CC531 tumors in the same experiment81. During the 
experiments with PRRT there was no sign of toxicity in the animals and there was no 
histological damage to the kidneys, which is the first organ to be at risk82. We earlier 
demonstrated that liver regeneration after 70% partial hepatectomy (PHx) in this model 
accelerates tumor growth dramatically83. PRRT was found to completely annihilate this 
tumor growth stimulation of SSR positive tumor cells rendering only a few tumor 
colonies. In an experiment without tumor we found that [111In-DTPA0]octreotide does 
not influence liver regeneration or -function, suggesting that PRRT could also be a safe 
option for adjuvant treatment after liver resection or arterial embolisation. Although 
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PRRT with 111In-labeled somatostatin analogs could be a promising treatment option for 
patients with locally irresectable or disseminated GEP tumors, more PRRT experiments, 
in more advanced stages of tumor development, with different doses of  [111In-
DTPA0]octreotide or other radioligands are necessary. 
 
RADIONUCLIDE THERAPY: CLINICAL  
A phase 1 study on the side effects and antiproliferative effect of high, multiple 
radiotherapeutic doses of [111In-DTPA0]octreotide started in 199588. Thirty end-stage 
patients with mainly neuroendocrine tumors were included. After scoring tumor 
radioactivity uptake using scintigrams obtained 24 hr after the injection of a diagnostic 
dose (220 MBq) of [111In-DTPA0]octreotide treatment was initiated. All patients 
received doses of 6-7 GBq 111In incorporated in 40-50 µg [DTPA0]octreotide with at 
least 2 weeks intervals between administrations. A total of 8 injections was aimed at, 
with a possible extension to 12-14 administrations. Twenty-one patients received a total 
cumulative dose of at least 20 GBq [111In-DTPA0]octreotide with a maximum of 75 
GBq. Of the 9 patients treated with a total dose lower than 20 GBq, 7 had to stop 
prematurely because of too progressive disease despite treatment and 2 did not conclude 
the first course of four administrations at the time of the interim analysis With a 
maximum follow up of 26 months no major clinical side effects were observed except 
for a transient decline in platelets count and the number of white blood cells. Kidney 
function was only influenced slightly and without clinical relevance. Although in a 
number of patients temporary because of end-stage disease, impressive effects on the 
clinical condition of the patient and hormone or tumor marker production were observed 
after the administration of high doses of [111In-DTPA0]octreotide. Prior to the start of 
treatment all 21 patients had progressive disease. In 8 patients treatment resulted in 
stable disease and in 6 patients in actual tumor shrinkage, monitored with CT or MRI. In 
these patients beneficial effects on hormone production and clinical symptoms were 
found. There was a tendency towards better result of PRRT in patients whose tumors had 
a higher accumulation of the radioligand on their scoring scintigram, from PRRT with 
[111In-DTPA0]octreotide that have described smaller groups of patients with end stage 
GEP tumors. Table 5 summarises the results and characteristics of patients treated with 
PRRT with a minimal dose of 20 GBq [111In-DTPA0]octreotide that have been described 
in recent literature88-93. 
SSR imaging, therapy and new strategies 
___________________________________________________________________________________ 
 41
 For radiotherapeutic applications, besides 111In also other radionuclides like 90Y 
(yttrium) and 177Lu (lutetium) have been proposed for coupling to somatostatin analogs. 
90Y, with a half-life time of 2.7 days, is a pure high  β-emitter with a tissue range up to 1 
cm and 177Lu, with a half-life time of 6.7 days, emits besides gamma radiation, suitable 
for visualisation also intermediate β-particles with approximately 1 mm tissue 
penetration. For tumors with a heterogeneous distribution of  SSRs 90Y and 177Lu labeled 
somatostatin analogs might have additional extra beneficial characteristics, due to the 
effect of "cross-fire". Tumor cells lacking the SSR might then be hit by an electron 
coming from a neighbouring cell, which has internalised the radioligand. This may lead 
to a high and more homogeneous radiation dose in larger parts of the tumor. Studies with 
these radiolabeled somatostatin analogs are ongoing. 
 
 
Table 5 Results and characteristics of patients treated with 
   PRRT with  a minimal dose of 20 GBq [111In- 
   DTPA0]octreotide  
  Tumor size 
  Reduction Stable Progression 
 n    
Carcinoid 13 3 8 2 
Neuroendocrine tumor 6 2 2 2 
Gastrinoma 1 - 1 - 
Vipoma 1 1 - - 
Glucogonoma 1 1 - - 
Med. Thyroid cancer 3 - 1 2 
Pap. Thyroid cancer 1 - 1 - 
Glomus tumor 2 1 1 - 
Pheochromocytoma 2 - 1 1 
Astrocytoma 1  1  
Inflammatory breast cancer 1  1  
     
Total 32 8 17 7 
 
Data are from Krenning88, Caplin89, Fjalling90 and Tiensuu93, all phase 1 studies. 
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ABSTRACT 
Somatostatin receptors (SSRs) are found in various human tumors, especially in 
neuroendocrine tumors, but also breast tumors and malignant lymphomas. By use of 
SSR-scintigraphy, Octreoscan, it is possible to visualize these tumors. Moreover, 
Octreoscan can be administered in high dosage schemes, so SSR-targeted therapy can 
be given for these kind of tumors. This kind of treatment is named Peptide Receptor 
Radionuclide Therapy (PRRT). In previous experimental, but also clinical studies, 
successful and promising results were shown with PRRT. Unfortunately, not all 
human tumors express SSRs on their cell surface, thus consequently PRRT is not 
successful for these tumors. 
However, recent developments in molecular biology have made it possible to transfect 
the SSR-gene on SSR-negative tumor cells. In this study SSR-negative colon 
carcinoma cells (CC531) were transfected with a SSR-gene in vitro and named CC2B 
hereafter. Scatchard analysis showed high expression of SSRs and a high binding 
affinity of CC2B cells. Moreover, the transfected SSR was also functional as it could 
internalize radiolabeled octreotide. Growth speed and other growth characteristics of 
CC2B did not differ significantly in vitro compared with their parental tumor cell line 
CC531. 
All the above mentioned features of the CC2B cell line fulfil future to the conditions 
to apply this SSR-transfected cell line in an in vivo model to perform experiments, in 
which PRRT will be tested. 
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INTRODUCTION 
Somatostatin, a tetradecapeptide, is widely distributed in the body and functions in a 
variety of physiological processes. In the pituitary and pancreas, for example, 
somatostatin is a potent inhibitory regulator of various secretion processes1, and in the 
central nervous system somatostatin exerts both excitatory and inhibitory actions 
(2,3). Until now, five subtypes of somatostatin receptors (SSRs) have been cloned (8-
14) and is found in a wide variety of tissues. Also SSRs are found in different human 
tumors, especially in neuro-endocrine tumors2. By means of SSR scintigraphy 
(Octreoscan) it is possible to detect these SSR-positive tumors. Moreover, in several 
studies it is shown that high dosages of radiolabeled octreotide can be effective in the 
treatment of these SSR-positive tumors1-9. This kind of treatment is named Peptide 
Receptor Radionuclide Therapy (PRRT). After administration of radiolabeled 
octreotide the peptide adheres to the SSR on the tumor cell surface, after which it is 
internalized. As the radioligand is charged negatively, it is trapped in the tumor cell, 
resulting in a long residence time, which causes DNA damage and consequently can 
lead to cell death. Through this mechanism PRRT is not only highly effective, but 
also this kind of treatment is targeted. Unfortunately, not all tumors express SSRs, as 
a result of which PRRT can not be given. The aim of this study was to transfect a 
SSR-negative tumor cell line (CC531) with a SSR-type 2 gene in vitro, so in vivo 
experiments can be performed in the future when the transfection would be 
successful. In this study SSR-gene expression, functionality and growth 
characteristics were investigated after transfection. 
 
 
MATERIAL AND METHODS 
Tumor 
CC531 is a SSR-negative, moderately differentiated rat colon carcinoma, induced by 
1,2-dimethylhydrazine and is transplantable in syngeneic WAG/Rij rats 10. The tumor 
is maintained in tissue culture as a monolayer in RPMI 1640 medium (Gibco, Paisley, 
UK) supplemented with 5% fetal calf serum (FCS). Cells were harvested from 
stationary cultures by gentle trypsinisation (Boehringer, Mannheim, Germany.  
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SSR Transfection and Expression 
For expression of the SSR-subtype 2 (sstr2)  in CC531 cells, human sstr2 cDNA in 
pBluescript (pBS) (a kind gift of G.I. Bell, Howard Hughes Medical Institute, 
Chicago, IL, USA) was excised form pBS and inserted into the Nhe-1/Sali cloning 
site of the retroviral expression vector pCi-neo. Selection was made by the geneticine 
resistance gene (G418). This vector was used to stable transfect (using lipofectin) 
CC531 cells. Transfectants were selected and cultured in RPMI 1640 supplemented 
with 5% FCS and geneticine (0.5 mg/mL) (Gibco, Paisley, UK). Geneticine-resistant 
clones were examined for their ability to bind with [125I-Tyr3]octreotide. The clone 
with the highest expression (Scatchard analysis) of SSR was isolated and named 
CC2B. 
 
Immunocytochemical Staining of the SSR 
Immunocytochemical staining was performed as described previously 11. Briefly, 
CC531 cells and CC2B cells were fixed with paraformaldehyde (PF) and washed 
twice with PBS and incubated for 15 min in normal goat serum (1:10 dilution in PBS 
+ 5% BSA). Thereafter, the cells were incubated overnight at 4 C with SSR2A (R2-88) 
(a kind gift of Dr. A. Schonbrunn) antibodies in a dilution of 1:1000. Finally, a 
standard streptavidin-biotinylated-peroxidase complex (ABC) kit (Biogenix, San 
Ramon, CA, USA) was used according to the manufacturers to visualize the bound 
antibodies. 
 
In vitro Functionality of the SSR 
To test in vitro functionality of the SSR an internalization study was performed as 
described previously14. 
In short, on the day of the experiment, CC531 and CC2B cells were seeded at a 
density of 0.5 x 106 cells/well in 12-well multiwell plates (Costar, Cambridge, MA, 
USA) and grown in confluency for 2 days. 
On the day of the experiment, the cells were washed twice with internalization 
medium. The internalization medium consisted of Dulbecco’s Modified Eagle’s 
Medium supplemented with HEPES (30 mM) L-glutamine (2 mM), sodium pyruvate 
(1 mM), penicilline (105 U/L), fungizone (0.5 mg/L) and 0.2% BSA (fraction V, 
Sigma Chemical Co., St. Louis, MO, USA). The cells were allowed to adjust to the 
medium for 1 h at 37 C. Thereafter, approximately 10-10 M  [125I-Tyr3]octreotide 
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(home-made 15) were added to the medium, and cells were incubated at 37 C for a 
period of 4 h in quadruplicate, without or in excess of non-radiolabeled octreotide (10-
6 M) to determine non-specific internalization. After the incubation the cells were 
washed twice with ice-cold internalization medium. Thereafter 1 mL sodium acetate 
(20 mM) in Hanks' Balanced Salt Solution, pH 5.0 (HBSS-Ac), was added to the cells 
and the cells were incubated for 10 min at 37 C. After 10 min, the supernatant was 
collected. Finally, the cells were washed with HBSS-Ac, and the supernatant was 
pooled with the supernatant of the previous step. The pooled supernatant fraction, 
acid-extractable radioactivity, represented the membrane-bound ligand. At the end of 
the incubation, after the HBSS-Ac treatment, the cells were extracted in 1 N NaOH. 
The radioactivity in this fraction represents internalized radioligand.  
 
Radiolabeling and Quality Control of the Radioligand 
[DTPA0]octreotide (Pentetreotide, DRN 4920) and 111InCl3 (DRN 4901, 370 
MBq/mL in HCl, pH 1.5 to 1.9) were obtained from Mallinckrodt (Petten, The 
Netherlands). Octreotide was a gift of Novartis (Basle, Switzerland). Labeling was 
performed by diluting freeze-dried [DTPA0]octreotide in 1 mL saline and adding this 
to the 111InCl3. Thirty minutes after the start of this procedure, quality control was 
performed by instant thin-layer chromotography with silica gel and 0.1 M sodium-
citrate, pH 5, as eluent. The labeling efficiency of [111In-DTPA0]octreotide was over 
98%.  
 
In vitro Growth  and Growth Characteristics 
We determined in vitro growth and growth characteristics by DNA analysis described 
by Hofland et al. previously14. 
In brief, in 24-well culture plates (Costar, Badhoeverdorp, The Netherlands) 10.000  
CC531 or CC2B cells were cultures in 1 mL 1640 RPMI enriched with 1% fetal calf 
serum (FCS) (Life Technologies, Breda, The Netherlands) and placed in an incubator 
with a humidified atmosphere of 95% / 5% CO2 at 37 C. The next day all wells were 
washed twice with 0.9% NaCl in order to wash away superfluous non-adherent cells. 
Hereafter, the cells were incubated with the different growth factors in 1 mL medium 
with 1% FCS in an incubator. Concentrations of octreotide used were: 0.1, 1, 10, 100 
and 1000 nM. Concentrations of IGF used were: 0.1, 1, 5,10  and 100 nM. After 72 or 
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144 hours, the plates were collected by washing away superfluous non-adherent cells 
and kept at –20 C for DNA analysis. 
 
DNA analysis 
The total DNA content of each well was measured using bisbenzimide dye 
(Bhoehringer Diagnostics, La Jolla, California, USA) as described previously by 
Hofland et al.14. The DNA measured represents the total amount of cells per well. 
 
Statistical Analysis 
Statistical analysis of the data was performed using one-way analysis of variance. 
When significant effects were obtained by analysis of variance, multiple comparison 
were made by the Newmann-Keuls test. Statistical significance was defined as p< 
0.05. Data are expressed as mean ± SD. 
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RESULTS 
Expression and Functional Capacity of the transfected SSR 
Immunocytochemical staining with an antibody against the sst2A, clearly visualized 
this receptor subtype on CC2B cells, while absent on CC531 (fig. 1).  
 
 
 
 
 
 
 
 
 
 
Fig.1:  Immunocytochemical staining of the SSR (subtype 2A). Clearly staining on the 
membrane of  the CC2B (right) is seen, in contrast to wild-type CC531 (left). 
 
 
 
Scatchard analysis showed a maximum binding capacity (Bmax) of 760 fmol/mg per 
membrane protein with a dissociation constant (Kd) of 0.9 nM (fig. 2).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 : Scatchard analysis shows that CC2B has a Bmax of 760 fmol/mg membrane protein 
and a Kd of 0.9 nM. 
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 Internalization studies showed a high uptake of [125I-Tyr3]octreotide in the CC2B 
cells (66 ± 4 kcpm vs. 1 ± 0.2 kcpm in controls (p<0.001) (fig. 3). Non-specific 
binding was low in the presence of 10-6 M octreotide for CC2B cells, but in CC531 
cells this was equal for the specific. The ratio internalized/total radioactivity in CC2B 
cells was 0.85. 
 
internalized radioligand
CC531 CC2B
0
25000
50000
75000
12
5 I 
(c
pm
)
membrane bound radioligand
CC531 CC2B
0
25000
50000
75000
.
12
5 I 
(c
pm
)
125I-octreotide "cold" octreotide  
Fig.3: Amount of internalized (left) and mebrane bound (right) radioligand of CC2B and 
CC531 cells. (SD’s in some bars are too small to observe.) 
 
In vitro Growth and Growth Characteristics 
In order to elucidate wether growth of the transfected cell line was changed after 
transfection, 10.000 CC531 or CC2B cells were cultured in a 24-well plate containing 
1 mL 1640 RPMI enriched with 1% FCS. After 3 and 6 days the plates were collected 
for DNA analysis. No significant difference in growth was observed between the 
CC2B and CC531 cells (fig.4). 
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Fig. 4: No differences in growth were seen after SSR transfection between CC531 and CC2B 
cells. 
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Fig. 5 shows the effect of IGF on CC2B and CC531 cells. A comparable dose-
dependent growth-stimulation with a maximum of 144% and 152%, respectively (not 
significant), was observed.  
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Fig. 5: A comparable dose-dependent growth stimulation was seen after addition of IGF on 
CC2B and CC531 cells. 
 
In order to evaluate whether the transfected SSR could exert a growth inhibitory 
effect, 1000 nM octreotide was added to CC2B and CC531 cells. As expected no 
inhibition was seen in CC531 cells, however, also no inhibitory effect was seen in 
CC2B cells (fig. 6). 
 
 The effect of octreotide
on CC531
3 days 6 days
0
1000
2000
3000
4000
5000
m
e
a
su
re
d
 D
N
A
m
e
a
su
re
d
 D
N
A
m
e
a
su
re
d
 D
N
A
m
e
a
su
re
d
 D
N
A
(n
g
)
(n
g
)
(n
g
)
(n
g
)
The effect of octreotide
on CC2B
3 days 6 days
0
1000
2000
3000
4000
5000
m
e
a
su
re
d
 D
N
A
m
e
a
su
re
d
 D
N
A
m
e
a
su
re
d
 D
N
A
m
e
a
su
re
d
 D
N
A
(n
g
)
(n
g
)
(n
g
)
(n
g
)
no octreotide 1000 nM octreotide  
 
Fig. 6: No significant inhibitory effect of 1000 nM octreotide on CC531 and CC2B cells after 
3 and 6 days was observed compared with controls. 
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Lastly, 10 nM IGF in combination with different doses octreotide had also no 
inhibitory effect on the growth-stimulation of IGF on CC2B or CC531 cells (fig. 7). 
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Fig. 7:Different doses octreotide did not have an inhibitory effect on the growth stimulation of 
10 nM IGF on CC2B or CC531 cells. 
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DISCUSSION 
SSRs are found in various human tumors, especially in neuroendocrine tumors, but 
also breast tumors and malignant lymphomas. By use of SSR-scintigraphy, 
Octreoscan, it is possible to visualize these tumors2. When Octreoscan is administered 
in high dosage schemes, these kind of tumors can also be treated. This kind of 
treatment is named Peptide Receptor Radionuclide Therapy (PRRT). In previous 
experimental, but also clinical studies, successful and promising results were shown 
with PRRT2-4,9. Unfortunately, not all human tumors express SSRs on their cell 
surface, thus consequently PRRT is not successful for these tumors. 
By means of SSR-gene therapy, it is possible to make these SSR-negative tumor cells 
SSR-positive, so this kind of treatment can be given also to a larger population of 
patients with, for example, disseminated cancer disease, for which no ideal treatment 
is availible up to now. 
We successfully transfected the SSR on colon carcinoma cells. After the transfection a 
high amount of  SSRs (average 12.000 per cell, Bmax = 760 fmol/mg per membrane 
protein) was expressed with high binding affinity (Kd = 0.9). Moreover, the 
transfected receptor was functional as it also could internalize (radiolabeled) 
octreotide. In order to elucidate whether SSR gene therapy in itself could exert an 
inhibitory growth effect, we performed an in vitro growth study. No inhibitory growth 
effect was observed in CC2B cells. This in contrast to Rochaix et al, who also used  
SSR gene therapy in human pancreatic adenocarcinoma, which had lost the ability to 
express SSRs15. By reintroducing the SSR into human pancreatic cancer cells these 
cells started to produce somatostatin again. The somatostatin released by SSR 
transfected cells could exert not only local but also a distant inhibitory effect on non-
transfected tumor cells through an upregulation of the expression of SSR-subtype 1 on 
parental tumor cells, thereby rendering them sensitive to the antiproliferative effect of 
somatostatin. However, CC531 cells can not produce somatostatin after SSR gene 
therapy, as colon cells, in contrast to pancreatic cells, do not originally produce 
somatostatin. Moreover, also no inhibition of growth in vitro was seen after addition 
of 1000 nM octreotide. Probably, post-receptor cell signaling after internalization of 
octreotide does not function in a proper manner, so no antiproliferative effect is seen 
in CC2B cells. 
However, our concept of SSR gene therapy is different than the group of Rochaix. 
The transfected SSR functions as a target for our therapy with radiolabeled octreotide. 
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As long as the SSR is functional (internalization and trapment of radiolabeled 
octreotide) this concept can be successful. In order to elucidate wheter the growth 
characteristics of CC2B were comparable with their parental tumor cell line CC531, 
we performed another study in which growth of CC2B cells was stimulated with IGF. 
A maximum of 144% growth stimulation was achieved after an addition of 10 nM 
IGF, which is comparable with CC531. 
Lastly,  different doses of octreotide did not have an inhibitory effect on the growth 
stimulation of 10 nM IGF, indicating that tyrosine phosphatase is not stimulated after 
internalization of octreotide and thus consequently dephosporylation and inactivation 
of tyrosine kinase such as those activated by IGF do not occur. 
In conclusion, we transfected successfully the SSR on colon carcinoma cells with a 
high expression of SSRs and a high binding affinity. Moreover the transfected SSR 
was functional as it could internalize radiolabeled octreotide. Lastly, growth 
characteristics were comparable with their parental tumor cell line CC531.  
All the above mentioned features makes this SSR-transfected cell line usefull to 
perform in vivo studies in the future: CC2B tumor cells will be used in a rat liver 
metastases model in order to investigate whether PRRT is feasible for the treatment of 
SSR-transfected liver metastases. 
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ABSTRACT 
Previously, we have tested PRRT in a rat liver metastases model; successful treatment 
was only seen in SSR-positive tumors, while absent in SSR-negative tumors. 
Therefore the idea arose to transfect SSR-negative tumor cells with a SSR-subtype 2 
gene to make PRRT applicable for these tumors. Using the same in vivo tumor model, 
here we describe the effect of PRRT with 370 MBq (0.5 µg) [111In-DTPA0]octreotide 
on CC531 (SSR-negative) rat colon carcinoma cells transfected in vitro with a SSR-
gene further referred as CC2B. 
No significant difference in tumorscore was seen in rats treated with PRRT vs. control 
animals with CC531 liver metastases. However, also no significant diffence in 
tumorscore was seen in CC2B liver metastases (PRRT vs. control). Autoradiography 
confirmed high SSR expression in CC2B liver metastases tissue, while absent in 
CC531 liver metastases. High uptake and retention of radioactivity in CC2B tumor 
was measured, indicating that the transfected receptor was functional. Moreover, the 
measured radioactivity and radiation dose was comparable with our positive control 
tumor CA20948, indicating that at our given dosage CC2B is not radiosensitive, 
which we could demonstrate in a clonogenic assay of our tumor cell lines treated with 
external radiation. 
Although no antiproliferative effect of PRRT was seen on SSR transfected CC531 
cells, we conclude that (1) SSR adherence, (2) internalization and (3) retention of 
radioactivity in the tumor cell did take place, indicating we transfected a functional 
receptor, but unfortunely the cell line was radioresistant to the given dosages. 
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INTRODUCTION 
Somatostatin is a peptide hormone, which is widely distributed in the human body and 
can regulate many physiological processes. Somatostatin receptors (SSRs) are found 
in various tissues, like the hypothalamus and the intestines, but also in various tumors, 
like neuro-endocrine tumors, carcinoids and breast tumors1. The use of SSR 
scintigraphy with radiolabeled octreotide, [111In-DTPA0]octreotide (Octreoscan ®), is 
a sensitive and specific technique to visualize the presence of SSRs on various 
tumors. In addition, when radiolabeled octreotide is applied with high radioactive 
dosages it is also successful for peptide receptor radionuclide therapy (PRRT)2. 
Successful treatment of neuro-endocrine tumors with radiolabeled octreotide analogs 
with β-emitting radionuclides, such as 90Y and 177Lu, are described in several clinical 
trials 2-5.  
Recently, we reported the antiproliferative effect of PRRT with [111In-
DTPA0]octreotide in a rat liver metastasis model 6. The presence and function of the 
SSR on the tumor was essential, since antiproliferative effects was only seen in SSR-
positive tumor, while absent in SSR-negative tumor. Moreover, blocking of the SSR 
with an excess of octreotide, abolished this effect. 
Therefore the idea arose to transfect SSR-negative tumor cells with a SSR-gene, 
opening the possibilities for application of SSR-targeted PRRT. Using the same in 
vivo tumor model, here we describe the effects of PRRT on SSR-negative colon 
carcinoma cells (CC531) after transfection with a SSR-gene. 
 
MATERIAL AND METHODS 
Animals 
Male inbred Wag/Rij rats (Harlan-CPB, Horst, The Netherlands), 10 to 14 weeks old 
and 225 to 250 g, were kept under standard laboratory conditions (12 hr light/ 12 hr 
dark) and given a standard laboratory diet (Hope Farms, Woerden, The Netherlands) 
and water ad libitum. The experimental protocol adhered to the rules of the Dutch 
Animal Experimental Act and was approved by the Committee on Animal Research 
of the Erasmus University. 
 
Tumor 
CC531 is a SSR-negative, moderately differentiated rat colon carcinoma, induced by 
1,2-dimethylhydrazine and is transplantable in syngeneic WAG/Rij rats 7. The tumor 
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is maintained in tissue culture as a monolayer in RPMI 1640 medium (Gibco, Paisley, 
UK) supplemented with 5% fetal calf serum (FCS). Cells were harvested from 
stationary cultures by gentle trypsinisation (Boehringer, Mannheim, Germany). A 
suspension of 0.5 x 106 living cells was used for direct injection into the portal vein 6. 
The pancreatic tumor CA20948 was originally induced by azaserine. This SSR-
positive tumor is of acinar origin and is transplantable in syngeinic Lewis rats. The 
tumor is maintained in tissue culture as a monolayer in RPMI 1640 (Gibco, Paisley, 
UK) supplemented with 5% FCS. Cells were harvested from stationary cultures by 
gentle trypsinisation (Boehringer, Mannheim, Germany). 
 
SSR Transfection and Expression 
For expression of the SSR-subtype 2 (sstr2)  in CC531 cells, human sstr2 cDNA in 
pBluescript (pBS) (a kind gift of G.I. Bell, Howard Hughes Medical Institute, 
Chicago, IL, USA) was excised form pBS and inserted into the Nhe-1/Sali cloning 
site of the retroviral expression vector pCi-neo. Selection was made by the geneticine 
resistance gene (G418). This vector was used to stable transfect (using lipofectin) 
CC531 cells. Transfectants were selected and cultured in RPMI 1640 supplemented 
with 5% FCS and geneticine (0.5 mg/mL) (Gibco, Paisley, UK). Geneticine-resistant 
clones were examined for their ability to bind with [125I-Tyr3]octreotide. The clone 
with the highest expression (Scatchard analysis) of SSR was isolated and named 
CC2B. 
 
Immunohistochemical Staining of the SSR 
Five µm sections of formalin fixed and paraffin-embedded CC531 or CC2B liver 
metastases tissue were deparafinized, dehydrated, exposed to microwave heating (in 
citric acid buffer, 10 min at 100 C), rinsed in tap water (1x) and PBS (1x), and 
processed further as described above for the immunocytochemical staining (SSR2A 
antibody dilution 1:500). Negative controls for immunohistochemistry included 
omission of the primary antibody and preabsorption of the antibodies with the 
immunzing receptor peptide (at a concentration of 0.3 µg/mL = 100 nM) 
 
In vitro and ex vivo SSR Autoradiography 
In frozen tumor samples SSRs were measured by autoradiography on 10 µm cryostat 
sections. For in vitro SSR autoradiography 10-10 M [125I-Tyr3]octreotide (home made 
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8), as a radioligand, was used. Incubation and washing conditions were as described9. 
Non-specific binding was determined by adding an excess (10-6 M) of non-
radiolabeled octreotide. For in vitro SSR autoradiography, radioactivity was measured 
for 24 hours in a Cyclone Storage Phosphor Screen (Packard Bioscience company, 
Meriden, USA), while for ex vivo SSR autoradiography (samples taken from the 
biodistribution study) radioactivity was measured for 72 hours. The screens were 
analysed using a Cyclone Phospor Imager and a computer-assisted OptiQuant 03.00 
image processing system (Packard Instruments Co, Groningen, The Netherlands) 13.  
 
Radiolabeling and Quality Control of the Radioligand 
[DTPA0]octreotide (Pentetreotide, DRN 4920) and 111InCl3 (DRN 4901, 370 
MBq/mL in HCl, pH 1.5 to 1.9) were obtained from Mallinckrodt (Petten, The 
Netherlands). Octreotide was a gift of Novartis (Basle, Switzerland). Labeling was 
performed by diluting freeze-dried [DTPA0]octreotide in 1 mL saline and adding this 
to the 111InCl3. Thirty minutes after the start of this procedure, quality control was 
performed by instant thin-layer chromotography with silica gel and 0.1 M sodium-
citrate, pH 5, as eluent. The labeling efficiency of [111In-DTPA0]octreotide was over 
98%. Each administration of the radioligand consisted of 370 MBq 111In labeled with 
0.5 µg [DTPA0]octreotide, referred as 370 MBq (0.5 µg) [111In-DTPA0]octreotide. 
 
Experimental Procedure 
Under ether anesthesia, the abdomen was opened through a 2.5 cm midline incision. 
Then, 0.5 x 106 viable SSR-positive CC2B cells or SSR-negative CC531 cells in 0.5 
mL RPMI 1640 were injected slowly into the portal vein through a 0.4 x 12 mm 
needle. The abdominal wall was closed in one layer by a continuous silk suture6,86. 
The day after the operation, rats were randomized in an experimental and control 
group. Each group consisted of 8 or 9 rats. Rats of the experimental group were 
treated with 370 MBq (0.5 µg) [111In-DTPA0]octreotide i.v. on days 1 and 8. Rats in 
the control group did not receive treatment.  
All rats were sacrificed 28 days after inoculation of tumor cells. Livers were removed, 
washed and immersed in PBS. Tumor growth was determined by 2 independent 
investigators counting the number of metastases on the surface of the liver lobes (up 
to 100) while blinded for treatment modality. The number of metastases were 
subdivided in a semi-quantative tumorscore, with concordant ranking from 0 (no 
Chapter 5 
___________________________________________________________________________________ 
 70
metastases) up to 5 (>100 tumor colonies, with >50% of the liver affected as 
presented in table 1 and 2. Tumor tissue was snap frozen in liquid nitrogen for 
autoradiography to determine in vivo somatostatin receptor status of the tumor 
 
Biodistribution Study 
Under the same experimental procedure as described above, 12 rats were injected with 
0.5 x 106 viable CC2B cells into the portal vein to produce liver metastasis. After 27 
days 3 groups of 3 rats received a low dosage of 3 Mbq (0.5 µg) [111In-
DTPA0]octreotide i.v.. These rats were sacrificed after 4, 24 and 48 hours after 
injection. Another group of 3 rats was coinjected i.v. with 0.3 mg octreotide, in order 
to saturate the SSR and to determine non-specific binding of radioactivity. These rats 
were sacrificed 24 hours after injection. After sacrification livers were removed and 
tumor and liver tissue were separated for biodistribution of radioactivity in a well-type 
LKB-1282-Compugammasystem and also samples were snap frozen in liquid nitrogen 
for ex vivo autoradiography 8. 
 
Clonogenic Assay and Radiation 
6-wells plates (Costar, Badhoevedorp, The Netherlands) were coated with 1 mL poly-
l-lysine (Sigma, Zwijndrecht, the Netherlands) and were stored for 30 min at 4 C to 
harden. Hereafter, 200 CC531, CC2B or CA20948 tumor cells were seeded in six-plo 
for every measured radiation-dose in these coated plates with 3 mL medium and 5% 
FCS. The next day cells were irradiated with a Philips RT 250 x-ray machine at 1.5 
Gy/min. The used radiation-doses were: 0, 1, 2, 4, 8 and 10 Gy.  Irradiation was 
performed at room temperature. 10 days after culture, surviving fractions were fixed 
10 min with 1mL methanol (LabScan Ltd., Dublin, Ireland) / glacial acetic acid 
(Merck, Darmstadt, Germany) (3:1) and stained with 1 mL Haematoxylin (Dako, 
Glostrup, Denmark). Surviving fractions were determined by clonogenic assay. 
 
Statistical Analysis 
Statistical analysis of the data was performed using one-way analysis of variance. 
When significant effects were obtained by analysis of variance, multiple comparison 
were made by the Newmann-Keuls test. Statistical significance was defined as p< 
0.05. Data are expressed as mean ± SD. 
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RESULTS 
Expression and Functional Capacity of the transfected SSR 
Immunohistochemical staining with an antibody against the sst2A, clearly visualized 
this receptor subtype on CC2B paraffin-embedded sections, while absent on CC531 
paraffin-embedded sections (fig. 1). 
 
 
 
 
 
 
 
Fig. 1: Immunohistochemical staining of CC2B liver metastases (arrows) surrounded by 
normal liver parenchyma. Staining with: A. Heamtoxylin-eosin. B. SSR antibody. C. Non-
specific binding of the SSR in the presence of an excess of octreotide. 
 
Experimental Procedure 
PRRT with 370 MBq (0.5 µg) [111In-DTPA0]octreotide on day 1 and 8 did not have an 
effect on the number of CC531 liver metastases in comparison with the controls. 
Mean tumor scores were 4.0 and 3.3, respectively (not significant) (table 1). Also no 
effect on the number of liver metastases was seen in the CC2B group in comparison 
with controls. Mean tumor scores were 2.5 and 2.6, respectively (not significant) 
(table 2). 
BA C
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Number of animals with 0 to >100 CC531 metastases 
 0 1 – 20 21 – 50 51 – 100 >1001 >1002 
Rank 0 1 2 3 4 5 
Controls - - 1 5 2 1 
PRRT - - 1 1 3 3 
 
Table 1: Number of animals with given range of metastases, 28 days after direct injection of 
CC531 tumor cells into the portal vein. The effect of PRRT on days 1 and 8 with 370 MBq 
(0.5 µg) [111In-DTPA0]octreotide is not significantly different (p>0.05) from that of controls. 
1 >100 tumor colonies, but <50% of liver is affected 
2 >100 tumor colonies, and >50% of liver is affected 
 
Number of animals with 0 to >100 CC2B metastases 
 0 1 – 20 21 – 50 51 – 100 >1001 >1002 
Rank 0 1 2 3 4 5 
Controls - - 5 1 2 - 
PRRT - 1 4 2 - 1 
 
Table 2: Number of animals with given range of metastases, 28 days after direct injection of 
CC2B tumor cells into the portal vein. The effect of PRRT on days 1 and 8 with 370 MBq (0.5 
µg) [111In-DTPA0]octreotide is not significantly different (p>0.05) from that of controls. 
1 >100 tumor colonies, but <50% of liver is affected 
2 >100 tumor colonies, and >50% of liver is affected 
 
In vitro and ex vivo SSR Autoradiography 
Autoradiography of tumor tissue showed high expression of SSRs on CC2B tumors in 
contrast to CC531 tumors (fig. 2). The mean percentage uptake of radioactivity was 
approximately two decades higher in the CC2B group than in the CC531 control 
group (p<0.01). Also in the ex vivo autoradiography CC2B tumor tissue showed high 
uptake of radioactivity, in contrast to surrounding liver parenchyma tissue (data not 
shown). 
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CC531 
 
 
 
CC2B 
 
   H.E.  [125I]-Octr.        Block 
 
 
   H.E.  [125I]-Octr. Block 
Fig. 2. In vitro autoradiography of CC2B and CC531 liver metastases tissue. H.E. = 
haematoxylin-eosin staining, [125I]-Octr. = staining of the SSR with [125I, Tyr3]octreotide, 
Block = blocking of SSR with non-radiolabeled octreotide, before addition of [125I, 
Tyr3]octreotide 
 
Biodistribution Study 
Fig. 3, clearly shows the high uptake of radioactivity in the tumor after 4 hours, while 
uptake in liver tissue was significantly lower (p<0.01). After 24 and 48 hours the 
uptake of radioactivity was also higher compared to liver tissue (p<0.01). After 24 
hours after injection of the radioligand the total binding vs. non-specific binding was 
0.33% Injected Dose (ID)/g vs. 0.04% ID/g (p<0.01). 
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Fig. 3. The uptake of radioactivity after injection of [111In-DTPA0]octreotide expressed as 
percentage injected doses per gram tissue. Data of de Jong et al.18 (CA20948) are taken over 
and added in the graph, in order to make a comparison with a positive-control tumor. 
 
Clonogenic Assay and Radiation 
The clonogenic assay of the tumor cell lines with external radiation shows that CC2B 
and CC531 are clearly less radiosensitive then our positive control tumor, CA20948. 
The surviving fraction at 2 Gy (SF2) was 0.78 and 0.76 for CC531 and CC2B 
respectively, while 0.48 for CA20948 (p < 0.01) (fig. 4) 
 
Fig. 4. Clonogenic assay of CC531, CC2B and CA20948 after external radiation. Clearly 
CC531 and CC2B are less radiosensitive than CA20948 (p < 0.01). 
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DISCUSSION 
In previous studies we showed that PRRT was very effective in SSR-positive tumors, 
namely CA20948 rat pancreas carcinoma (Bmax = 110 fmol/mg per membrane protein, 
Kd = 0.6 nM), in a rat liver metastasis model6. In another study Slooter et al. showed 
that tumor growth was stimulated by performing a partial hepatectomy11. Even under 
these tumor growth-stimulating conditions PRRT could provide a strong 
antiproliferative effect 8. The SSR plays a crucial role in the mechanism of PRRT, as 
antiproliferative effects were only seen in SSR-positive liver metastases. When the 
SSR was blocked by giving an excess of non-radiolabeled octreotide before PRRT 
treatment, the antiproliferative effect was abolished. In this study SSR-positive 
CA20948 pancreas carcinoma cells versus SSR-negative CC531 colon carcinoma 
cells were used as tumors. By using two different tumors (CA20948 and CC531) in 
our PRRT model, we had two major drawbacks: 1. The difference in effects might be 
attributed to the fact that two different tumors were used, which can have differences 
in degrees of radiosensitivity 12,13. 2. The effects could be also influenced by using 
two different strains of rats, namely the Lewis rats (CA20948) and Wag/Rij rats 
(CC531). The aim of this study was to transfect SSR-negative tumor cells with a SSR-
gene, so SSR-targeted PRRT could also be applicable for these tumors. Also the two 
above mentioned drawbacks could be overcome by the transfection, as the transfected 
and the parental tumor cell have the same features (i.e. radiosensitivity) and can be 
tested in the same rat strain. 
In a previous study, we successfully transfected the SSR on colon carcinoma cells in 
vitro (hereafter named CC2B), with a high expression of SSRs and a comparable 
growth and growth features as the parental tumor cell line CC531. 
Through this result, in this study SSR-negative CC531 cells and SSR-positive CC2B 
cells can be compared in one tumor-model and in the same rat strain, in order to 
elucidate whether PRRT works or not in liver metastases model. 
As stated before [111In-DTPA0]octreotide is widely used for visualization of SSR-
positive tumors, like GEP tumors, with a gamma camera. However 111In also emits 
internal conversion electrons and Auger electrons with a medium to short tissue 
penetration (200-550 µm, 0.02-10 µm, respectively) 14,15. For in vivo PRRT therapy 
with [111In-DTPA0]octreotide, several successively steps are essential: the 
radiolabeled octreotide has to adhere to the SSR, after which it is internalized. 
Hereafter, the radioligand is trapped in the cell, since it is charged negatively, 
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resulting in a prolonged residence time of radioactivity in the tumor. The resultant 
DNA damage will consequently also be increased and can eventually lead to cell 
death 16. For example, in a human tumor the biological half life of retention was >700 
hours16,17. 
In our experiment PRRT did not have an antiproliferative effect on the CC2B cells. In 
vitro SSR autoradiography and a biodistribution study were performed to investigate 
whether adherence, internalization and (prolonged) residence of radiolabeled 
octreotide takes place. Immunohistochemical staining of the liver metastases showed 
SSR expression of CC2B liver metastases and no SSR expression in CC531 liver 
metastases. The in vitro SSR autoradiography confirmed high expression of SSR in 
CC2B cells, in contrast to normal CC531 cells, indicating that adherence of 
radiolabeled octreotide did occur.  
In the biodistribution study a clear uptake of radiolabeled octreotide was seen in rats 
sacrificed after 4 hours, indicating that in vivo internalization also takes place. Rats 
sacrificed after 24 or 48 hours showed a stable measurement of % ID/g tumor tissue 
(0.34%), indicating high retention of radioactivity in the CC2B tumor cells. When the 
SSR was blocked the tumoral radioactivity uptake was reduced to surrounding liver 
level: underlining the involvement of SSR-mediated internalization. Compared to the 
CA20948 tumor almost the same amount of radioactivity was measured in the CC2B 
tumor after 4, 24 and 48 hours (see fig. 6) 10. Despite of the same amount of 
radioactivity in the tumor cells and same radiation dose, no effect was seen on tumor 
growth, indicating that this tumor cell line apparently is less radiosensitive for our 
given dosage of radiolabeled octreotide. In order to elucidate the radiosensitivity of 
the cell lines, we performed clonogenic assays of the cell lines with external radiation. 
A poor radiosensitivity of the CC2B (and CC531) cells was seen in comparison with 
our positive control tumor CA20948, in which we previously had shown effiective 
therapy with radiolabeled octreotide. A possible explanation for this radioresistancy 
might be attributed to the p53 status of the tumor. Numerous in vitro and in vivo 
studies indicate that loss of p53 function increases post-irradiation clonogenic cell 
survival, which correlates with an abrogated G1 checkpoint and changes in 
apoptosis18. Introduction of the wild type p53-gene by gene therapy resulted in 
increased tumoral radiosensitivity and a concordant decrease of radiation survival of 
these cells, both in vitro and in vivo. Spitz et al showed that introduction of wild-type 
p53 did sensitize colorectal cancer cells to ionizing radiation. This radiosensitization 
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correlates with restoration of the G1 checkpoint and apoptosis 19. In addition, reducing 
radiation survival  in vitro, significantly increases apoptosis 20. This combination 
therapy also resulted in delayed in vivo tumor growth in their xenograft mouse model 
21. Recently Geutskens et al showed p53-deletion of CC531 cells, so this may explain 
why PRRT is not effective in this tumor 22. In theory, cotransfection of wild-type p53 
and the SSR-gene might also sensitize the radiation caused by PRRT in CC531 cells.  
Furthermore, a higher antiproliferative effects may be obtained by giving a higher 
and/or fractionated dosage of radiolabeled octreotide. However, toxic effects on 
kidney and bone marrow limit the height of the fractionated dosage 23.  
Another method to increase antiproliferative effects is to replace the 111In  with a 
radionuclide with higher energy emitting particles, such as 90Y or 177Lu. Through the 
emission of β-particles not only a higher energy is produced (Eβmax 90Y = 2.3 MeV, 
177Lu = 0.5 MeV), but also a concordant higher tissue penetration is achieved (90Y = 
12 mm, 177Lu = 2 mm), which might result in a more effective therapy. Currently 
clinical trials with [90Y-DOTA0]octreotide and [177Lu-DOTA, Tyr3]octreotate are 
ongoing with promising preliminary results 24,25 4,5,134,5, in which 90Y is more 
successful for larger bulky tumors and 177Lu is successfully used for therapy of 
micrometastases. Especially, when in vivo gene therapy is concerned, poor 
transduction rates results in poor efficacy of gene therapy. However, by using β-
emitting radionuclides, like 90Y or 177Lu, transduced cells and neighboring non-
transduced cells in a radius of a few mm are being radiated through the cross-fire of 
the β-particles, and can consequently result in a major cross-fire “bystander”-effect. 
Thus poor transduction efficacy might be overcome through strong antiproliferative 
effects with this strategy. 
In conclusion: the expected antiproliferative effect of PRRT on SSR transfected  
colon carcinoma cells was absent, although (1) SSR-mediated adherence,  (2) 
internalization and (3) retention of radioactivity in the tumor cell did take place. 
Furthermore clonogenic assays with external radiation showed a poor radiosensitivity 
of the CC2B cells. This means that we successfully transfected a functional receptor 
on radioresistent tumor cells. However, we still believe that SSR gene therapy 
followed by PRRT is promising. To prove the validity of this concept, we are 
currently transfecting a SSR-negative radiosensitive cell line and also are testing  
SSR-targeted PRRT with [177Lu-DOTA, Tyr3]octreotate in a rat liver metastasis 
model. 
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ABSTRACT  
Peptide receptor scintigraphy with [111In-DTPA0]octreotide (a stabilized radiolabeled 
somatostatin (SS) analog, OctreoScan) is widely used for the visualisation and 
staging of somatostatin receptor-positive tumors. The application of likewise 
somatostatin analogs as vehicle for the deliverance of radionuclides to somatostatin 
receptor-positive targets are now in use for Peptide Receptor-targeted Radionuclide 
Therapy (PRRT). Currently preclinical and clinical investigation are ongoing trying to 
find the optimal combination of radionuclide and ligand. The anti-tumoral effects of 
such combinations, like [90Y-DOTA0,Tyr3]octreotide and [177Lu-DOTA0, 
Tyr3]octreotate, on SSR-positive solid tumors have been reported.  
Aim: In this study we present the anti-tumor effects of 177Lu-DOTA-tate on  
a. a single SSR-positive cell model, and  
b. on a SSR-positive tumor in a rat liver micrometastatic model, mimicing 
disseminated disease. 
Results: 177Lu-DOTA-tate showed anti-tumoral effects in a. and in b., and significant 
survival in the PRRT-treated rats. 
In conclusion: 177Lu-DOTA-tate is a very promising new treatment modality for SSR-
positive tumors, including disseminated disease.  
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INTRODUCTION 
Somatostatin receptors (SSRs) have been demonstrated on a variety of human tumors 
[1]. At least 5 different human subtypes (sst1-5) have been cloned [2]. All subtypes 
bind somatostatin with high affinity, while octreotide, a somatostatin analog, binds 
with high affinity to sst2, and with decreasing affinity for sst5 and sst3 [3]. The vast 
majority of human SSR-positive tumors express SSR subtype 2 [3, 4]. SSR-positive 
tumors, like carcinoids, breast cancer and various neuroendocrine tumors, can be 
visualised with [111In-DTPA0]octreotide (OctreoScan). OctreoScan is nowadays 
recognised to be the imaging technique for the detection and staging of SSR-positive 
tumors. Peptide receptor radionuclide therapy (PRRT) with high dosages of [111In-
DTPA0]octreotide showed anti-tumor effects in a rat liver micrometastases model [5] 
and in patients with neuroendocrine tumors [6-9]. The disadvantage of 111In for PRRT 
is the short particle range and consequently small tissue penetration [10]. Therefore, 
other radionuclides, like 90Y and 177Lu, were coupled to DOTA-conjugated 
somatostatin analogs, such as [DOTA0,Tyr3]octreotide (DOTATOC), and [DOTA0, 
Tyr3]octreotate (see for a review [3]). These radionuclides emit high energy beta 
particles (2.27 and 0.5  MeV, resp.) with accordingly larger particle range of 10 and 2 
mm, respectively [3].  
Various studies showed favourable results of 90Y-DOTATOC and 177Lu-DOTA-tate 
in patients with neuroendocrine tumors [11-14]. PRRT with radionuclides emitting 
higher energy beta-particles (e.g. 90Y) are in theory and in practice advantageous for 
larger tumors (>1g), but not for smaller tumors (<1g). For uniform activity 
distribution in these larger tumors, almost all energy of the emitted electrons will be 
deposited in the target. However, for the smaller tumors only a small energy fraction 
from the emitted electrons will be deposited within the tumor. [15-18]. Recently we 
presented successful PRRT with 177Lu-DOTA-tate of SSR-positive solid tumors in 
rats [17] and also in patients[14]. However, still the question remains whether 177Lu 
has anti-tumor effects on SSR-positive micrometastases. In the here presented study 
we describe a PRRT study with 177Lu-DOTA-tate of SSR-positive tumor cells in an in 
vitro model (a) and in a rat liver micrometastatic model (b).  
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MATERIAL & METHODS 
Animals 
Male inbred Lewis rats, 10 to 14 weeks old with a body weight of 250 to 275 
g, were obtained from Harlan-CPB (Horst, The Netherlands). Animals were kept 
under standard laboratory conditions (12 hours light/ 12 hours dark) and given a 
standard laboratory diet (Hope Farms, Woerden, The Netherlands) and water ad 
libitum. The experimental protocol adhered to the rules of the Dutch Animal 
Experimental Act and was approved by the Committee on Animal Research of the 
Erasmus University. 
 
Tumor 
CC531 is a SSR-negative, moderately differentiated rat colon carcinoma, 
induced by 1,2-dimethylhydrazine, is transplantable in syngeneic WAG/Rij rats [5]. 
The tumor is maintained in tissue culture as a monolayer in RPMI 1640 medium 
(Gibco, Paisley, UK) supplemented with 5% fetal calf serum (FCS). Cells were 
harvested from stationary cultures by gentle trypsinisation (Boehringer, Mannheim, 
Germany). 
CA20948 is a SSR-positive, pancreatic tumor of acinar origin, which was 
originally induced by azaserine and is transplantable in syngeneic Lewis rats [16]. The 
tumor is maintained in tissue culture as a monolayer in RPMI 1640 medium (Gibco, 
Paisley, UK) supplemented with 10% FCS. For the in vitro experiments, cells were 
harvested from stationary cultures by gentle trypsinisation (Boehringer, Mannheim, 
Germany). To produce artificial liver metastases for the in vivo experiments, tumors 
were excised from donor rat livers, cleaned from normal liver tissue and pressed 
through sieves with decreasing mesh size. The resulting suspension was washed twice 
in RPMI 1640. Viability was measured with trypan-blue exclusion (0.3% in a 0.9% 
NaCl solution). A suspension of 2.5 x 106 living cells per  5 mL was used for direct 
injection into the portal vein [5, 19]. 
 
Radiolabeling and Quality Control of the Radioligand 
Reactor-produced 177Lu from 70% enriched 176Lu-target was obtained from 
IDB Holland (Baarle Nassau, The Netherlands). DOTA-tate was obtained from 
Mallinckrodt (St. Louis, Mo., USA). 177Lu-labeling of DOTA-tate was performed as 
previously described [17, 18, 20]. Measurement of the incorporation of the 
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radionuclide was performed in the presence of 4 mM DTPA pH 4 on ITLC-SG with 
0.1 M Na-citrate as eluens [17, 18]. The labeling yield always exceeded 99% and the 
radiochemical purity was higher than 90%. Post radiolabeling and prior to the 
administration of the radioligand-containing solution  4 mM DTPA pH 4 was added 
to a final mol/mol ratio (DTPA over DOTA-tate) of 30.  
 
In vitro PRRT 
One day before the experiment CC531 and CA20948 tumor cells were 
transferred to 6 well plates in a density of 200 and 400 cells per well. Cells were 
washed with PBS (Phosphate Buffered Saline) (37°C) and incubated for at least one 
hour in 1 mL incubation medium (RPMI-1640 medium without foetal calf serum 
(FCS) but with 1% bovine serum albumin and 20 mmol HEPES) containing 177Lu-
DOTA-tate. Control cells received only incubation medium for one hour. Thereafter, 
cells were thoroughly washed with PBS and allowed to form colonies during 2 days in 
growth medium. The medium was once refreshed after 3 days. At day 12 the cells 
were fixated with 1 mL methanol:glacial acid (3:1) for 15 minutes. Subsequently the 
cells were colored with haematoxylin (Dako, Glostrup, Denmark). Colonies that 
contained more than 50 cells per colony were scored as survivors.  
 
In vivo PRRT 
Under ether anaesthesia, the abdomen was opened through a 2.5 cm midline 
incision. 0.25 x 106 viable CA20948 cells in 0.5 mL RPMI 1640 were injected slowly 
into the portal vein through a 0.4 x 12 mm needle. The abdominal wall was closed in 
one layer by a continuous silk suture. The day after the operation, rats were 
randomised in an experimental and control group. Each group consisted of 12 rats. 
Rats of the experimental group were treated with 185 (1.9 µg) or 370 MBq (3.8  µg) 
[177Lu-DOTA0, Tyr3]octreotate iv. on day 8. Rats in the control group did not receive 
treatment. Body weight and animal condition (i.e.: lethargy, scruffy coat and 
diarrhoea) were determined at regular intervals at least twice a week. 
In order to evaluate anti-tumor effects, half of the rats were sacrificed 21 days 
after inoculation of tumor cells. Livers were removed, washed and immersed in PBS. 
Livers were weighed and 2 independent investigators counting the number of 
metastases on the surface of the liver lobes (up to 100) while blinded for treatment 
modality determined tumor growth. The number of metastases were subdivided in a 
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semi-quantitative tumor score, with concordant ranking from 0 (no metastases) up to 5 
(> 100 tumor colonies, with > 50% of liver affected) as presented in table 1.  
The remaining rats were used for a survival experiment. The experiment was 
ended 150 days post inoculation of the tumor, 150 days is the generally accepted 
equivalent of 5 years human survival. Body weight and animal condition was 
determined at regular intervals at least twice a week. When loss of body weight was 
more than 10% of original body weight, rats were sacrificed and livers examined.  
 
Statistical analysis 
Statistical analysis of the data was performed using one-way analysis of 
variance. When significant effects were obtained by analysis of variance, multiple 
comparison were made by the Newmann-Keuls test. Statistical significance was 
defined as p < 0.05. Data are expressed as mean ± SD. GraphPad Prism (GraphPad 
Prism Software, San Diego, CA) was used to plot survival curves for the different 
groups. 
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RESULTS 
In vitro PRRT 
 Fig 1 shows the % survival of CA20948  and CC531 cells after in vitro PRRT 
with various amounts of 177Lu-DOTA-tate. No differences were found between the 
experiments with 200 and 400 cells (data not shown). 
 
Fig 1. The percentage survival of CA20948  and CC531 cells (open bar) after in vitro PRRT 
with various amounts of 177Lu-DOTA-tate 
 
 
In vivo PRRT 
The results of PRRT with 185 MBq (1.9 µg) or 370 MBq (3.8 µg) [177Lu-
DOTA0, Tyr3]octreotate on day 8 on the growth of CA20948 liver metastases 
compared with rats of the control group are summarised in table 1. Both 185 MBq and 
370 MBq 177Lu-DOTA-tate had an anti-tumor effect on CA20948 liver metastases 
compared with controls. Mean tumor scores were 2.0 ± 1.3, 1.3 ± 0.8 and 5.0 ± 0.0, 
respectively (p <0.001 vs. controls). Liver weight was significant less in PRRT treated 
rats compared with controls: mean liver weights (in g) were 8.9 ± 0.9,  9.3 ± 0.7 and 
19.2 ± 2.0, respectively (p <0.001 vs. controls) (fig. 2). 
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Table 1. Effect of 185 or 370 MBq 177Lu-DOTA-tate on CA20948 liver metastases  
 
Number of animals with 0 to >100 CA20948 metastases 
 0 1 - 20 21 - 50 51 - 100 >1001 >1002 
Rank 0 1 2 3 4 5 
Controls - - - - - 6 
185 MBq 1 1 1 3 - - 
370 MBq 2 - 4 - - - 
 
Number of animals with given range of metastases, 21 days after direct injection of 
CA20948 tumor cells into the portal vein. Treated rats (185 or 370 MBq 177Lu-DOTA-
tate) with CA20948 liver metastases had significant less liver metastases compared 
with control rats (p <0.001). 
1 >100 tumor colonies, but <50% of liver is affected 
2 >100 tumor colonies, and >50% of liver is affected 
 
 
 
Figure 2. Liver weight of groups of rats with CA20948 liver metastases after indicated doses 
(expressed as mean ± SD, n=6). Mean liver weights of rats treated with 185 or 370 MBq 
177Lu-DOTA-tate are both significant less than control rats (p <0.001) 
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Survival curves for  the control and therapeutic groups are shown in figure 3. 
Tumors of the rats in the control grew excessively and no survival at 150 days was 
found. Treatment with a single dose of 185 MBq 177Lu-DOTA-tate resulted in a 
significant increase of the survival of the rats of this group. In all cases of sacrification 
livers were full of metastases. At 150 days after tumor inoculation, 2 of the 6 rats 
(33%) in this group were still alive and autopsy after sacrification showed no visible 
liver metastases in these 2 rats (p <0.05). Also animals that received a single injection 
of 370 MBq 177Lu-DOTA-tate showed a significant increase in survival compared 
with controls, however, no animals survived 150 days (p <0.05). 
In the in vivo experiments no overt signs of toxicity as weight loss, scruffy coat, 
lethargy or diarrhoea were observed. 
 
 
Figure 3. Survival curves of groups of rats with CA20948 liver metastases after indicated 
doses (n=6 per group). Both group of rats treated with 185 and 370 MBq 177Lu-DOTA-tate 
showed a significant increase in survival compared with controls (p <0.05). Two of the 6 rats 
treated with 185 MBq 177Lu-DOTA-tate survived 150 days and had no visible liver metastases 
after sacrifice. 150 days survival equals 5 human years 
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DISCUSSION 
Peptide receptor scintigraphy with [111In-DTPA0]octreotide is widely used for 
the visualisation and staging of SSR-positive tumors. The application of likewise 
ligands as vehicle for the deliverance of radionuclides to SSR-positive targets is now 
also in use for PRRT. Currently preclinical and clinical investigation are ongoing 
trying to find the optimal combination of radionuclide and ligand (with both their 
specific characteristics) for several parameters, including tumor volume. The anti-
tumoral effects of such a combination, 177Lu-DOTA-tate, on SSR-positive solid 
tumors have been reported [14, 17].  
In this study we present the anti-tumor effects of 177Lu-DOTA-tate:  
1. in vitro in a single SSR-positive cell model, and  
2. on a SSR-positive tumor in a rat liver micrometastatic model, mimicing 
disseminated disease. 
As shown in figure 1, SSR-positive CA20948 tumor cell survival decreases with 
increasing doses of 177Lu-DOTA-tate, and this in contrast to SSR-negative CC531 
tumor cells in a parallel experiment. We reported earlier on experiments performed to 
study internalisation of radiolabeled somatostatin analogs such as [111In-
DTPA0]octreotide and 90Y-DOTATOC in rat pancreatic tumor cells [21, 22]. This 
process was found to be receptor specific and temperature dependent [22, 23]. 
Furthermore, the amount of radioligand taken up in the tumor depends on the total 
amount of unlabeled peptide present and thus on changes in specific activity of the 
radiolabeled peptide [24, 25]. Therefore, the success of the therapeutic strategy relies 
on the total amount of radioligand that accumulates within tumor cells, which among 
other things depends on the receptor affinity and rate of internalisation of ligand and 
receptor. The physical characteristics of radioactivity accumulated within tumor cells 
determines also the dosimetric dose on neighbouring cells. As stated above, 177Lu 
emits β-particles with a maximum energy of 0.5 MeV and a high tissue penetration, 
with a maximum range of 2 mm. Assuming a cell diameter of 20 µm, this means, 
when internalized into the tumor cell, 177Lu is able to potentially kill cells at 
approximately 12 cell diameters from a cell in which it is internalized, with a 
maximum cell-killing potential of approximately 50 cell diameters [26]. This extra 
cell killing potential is also called a radiological bystander effect [27] and can be an 
additional advantage in the PRRT of tumors with a heterogenous expression of  
receptors with affinity for the radiolabeled peptide.  
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In table 1 and in figure 2 the tumor growth control by 177Lu-DOTA-tate is 
presented. Tumor growth in controls was excessive, 21 days post inoculation of the 
tumor cells, more than 100 tumor colonies were counted in the livers and, in addition, 
more than 50% of the liver was affected. The liver weight doubled (p <0.001) vs. the 
2 PRRT-treated groups of rats (Fig. 2). We recently reported that PRRT  with [111In-
DTPA0]octreotide had no effects on basic liver functions [28] in press). The effect of 
PRRT was also reflected in the survival curve: rats treated with 185 or 370 MBq 
177Lu-DOTA-tate had significantly lower tumor colonies present at day 21 (Fig. 2), 
and even 2 of 6 survived for 150 days, which is the generally accepted equivalent of 5 
human years. In the PRRT-treated rats a higher survival was found in the rats treated 
with the lower dose. The amounts of injected radioactivity in these 2 groups were 185 
and 370 MBq, and the concordant amount of injected ligand: 1.9 µg and 3.8 µg, resp. 
This increase in amount of injected ligand reduces the uptake in the SSR-positive 
targets: the uptake herein is a function of the injected mass [24, 25]. The uptake in 
SSR-positive tumor cells in rats injected with 1.9 µg is approximately 70% of the 
optimal uptake, and in the other group injected with 3.8 µg is 40%, resulting in no 
significant increase in radioactivity in the targets. So, although the radioactive dose 
was doubled, the uptake of radioactivity in these SSR-positive targets has not 
increased, and as a result, nor the dosimetric dose hereon.  The latter in contrast to the 
SSR-negative kidney and bone marrow. These organs are critical organs for PRRT 
with radiolabeled somatostatin analogs [3], and by definition determine the maximal 
tolerated dose hereof. Since the radiation dose has doubled, the dosimetric dose for 
these organs has doubled.  However, Lewis et al. recently reported no toxicity for 
177Lu-DOTA-tate, even up to doses of  4 GBq per kg, and up to 42 days post injection 
[29].  
A major advantage of PRRT using radiolabeled peptides is that radiation can be 
delivered selectively, not only to (large) primary tumors, but also to tumors and 
metastases, which are too small to be imaged and thereby treated by, for example, 
surgery or external beam radiotherapy. Even tumors of less than 1 g are not able to 
absorb all electron energy emitted by 90Y in their cells [10, 15, 18]. Therefore, 
patients bearing tumors of different sizes might be treated by a combination of 
radionuclides, e.g., the high-energy β-emitter 90Y for large tumors (> 1 g) and low-
energy ß-emitter, such as 177Lu, or an Auger electron emitter, such as 111In for smaller 
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(< 1 g) tumors and metastases. Preclinical and clinical PRRT experiments of SSR-
positive tumors are ongoing.  
In conclusion, 177Lu-DOTA-tate showed anti-tumor effects in an isolated SSR-
positive tumor cell model in vitro and in a rat liver SSR-positive micrometastic model 
setting, making it a very promising new treatment modality for SSR-positive 
disseminated disease. 
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ABSTRACT 
Objective: To evaluate the effect of Peptide Receptor Radionuclide Therapy (PRRT) 
on somatostatin receptor (SSR)-transfected colon carcinoma cells in a rat liver 
metastases model. 
Summary Background Data: Previously, we showed highly effective therapy with 
PRRT of SSR-positive tumors. This treatment is SSR-mediated, while successful 
treatment is only seen in SSR-positive tumors and no effect is seen in SSR-negative 
tumors. As many tumors lack this receptor, the idea arose to transfect SSR-negative 
tumor cells with a SSR-gene, in order to apply PRRT on these SSR transfected tumor 
cells. 
Methods: CC531 colon carcinoma cells (SSR-negative) were transfected in vitro with 
a SSR (subtype 2)-gene, further refered as CC2B. Liver metastases were developed 
after intraportal injection of these tumor cells in rats. On day 7, animals were treated 
with 185 or 370 MBq [177Lu-DOTA0, Tyr3]octreotate. After 21 days rats were 
sacrificed and liver metastases were counted.  
Results: Treatment with 370 MBq [177Lu-DOTA0, Tyr3]octreotate showed an 
impressive anti-tumor response in rats with CC2B liver metastases (SSR-positive) in 
comparison with controls (p<0.001), while no significant anti-tumor effect was seen 
in PRRT treated rats with CC531 liver metastases (SSR-negative). Also a (dose-
dependent) tumor response was seen in rats with CC2B liver metastases treated with 
lower dose, 185 MBq, [177Lu-DOTA0, Tyr3]octreotate compared with controls 
(p<0.01). In addition, rats with mixed liver metastases treated with 185 MBq [177Lu-
DOTA0, Tyr3]octreotate had significant less metastases compared with controls 
(p<0.05). 
Conclusion: We showed an impressive anti-tumor effect of SSR (subtype 2) 
transfected colon carcinoma cells with PRRT in a rat liver metastases model. 
Moreover, rats with mixed liver metastases had also significant less liver metastases 
compared with control rats, which may be due to a radiological bystander effect of 
[177Lu-DOTA0, Tyr3]octreotate. This phenomenon is beneficial in the concept of in 
vivo gene therapy. 
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INTRODUCTION 
Somatostatin receptors (SSRs) have been demonstrated on a variety of human tumors 
(1). At least 5 different human subtypes (SSR subtype 1 – 5) have been cloned (2). All 
subtypes bind somatostatin with high affinity, while octreotide, a somatostatin analog, 
binds with high affinity to SSR subtype 2 and 5 and to a lesser degree to SSR subtype 
3. Hofland et al. showed that the vast majority of human SSR-positive tumors express 
SSR subtype 2 (3). 
SSR-positive tumors, like carcinoids, breast cancer and various neuroendocrine 
tumors, can be visualized with a low dose of [111Indium-diethylenetriaminopenta-
acetic acid (111In-DTPA0)]octreotide (Octreoscan®). Octreoscan has proven to be very 
useful in the detection and staging of SSR-positive tumors. High dosages of [111In-
DTPA0]octreotide can also be given as a therapy to patients with these kind of tumors. 
Encouraging results have been reported in patients with progressive and metastasized 
neuroendocrine tumors, treated with high dosages of [111In-DTPA0]octreotide (4-7). 
This kind of treatment is called Peptide Receptor Radionuclide Therapy (PRRT). 
However, 111In is not ideal for PRRT, because of the short particle range and 
consequently small tissue penetration. Therefore, other radionuclides, like 90Yttrium 
(90Y) and 177Lutetium (177Lu), were coupled to somatostatin analogs. These 
radionuclides emit high energy beta-particles with accordingly larger particle range of 
10 and 2 mm, respectively. Various preliminary studies showed favorable results of 
[90Yttrium-tetracyclododecanetetraacetic acid, Tyrosine (90Y-DOTA0, 
Tyr3)]octreotide in patients with neuroendocrine tumors (8-10). Still the question 
remains whether 90Y is the most ideal radionuclide for targeted radiotherapy, since a 
high maximum energy (Emax 2.27 MeV) can be an advantage for larger tumors, but 
this characteristic can also have drawbacks, while renal toxicity after PRRT was also 
observed (8; 11). Furthermore, other radionuclides with lower energies may be more 
useful for smaller tumors or even micrometastatatic disease. An alternative 
radionuclide for PRRT is 177Lu (Emax 0.5 MeV). In a preliminary study by 
Kwekkeboom et al., successful results were obtained in patients with progressive 
neuroendocrine tumors (12). Also in animal studies reported by de Jong et al., 
convincing results were observed in rats bearing SSR-positive pancreatic carcinoma 
(13). However, since the uptake and internalization of this radioligand is SSR-
mediated and many tumors lack this receptor, the idea arose to transfect SSR-negative 
tumor cells with a SSR-gene, in order to apply PRRT on these SSR-transfected tumor 
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cells. Using a rat liver metastases model, here we describe the effects of [177Lu-
DOTA0, Tyr3]octreotate on SSR-negative colon carcinoma cells (CC531) and SSR-
transfected colon carcinoma cells (CC2B). 
 
MATERIAL AND METHODS 
Animals 
Male inbred Wag/Rij rats, 10 to 14 weeks old with a body weight of 250 to 275 g, 
were obtained from Harlan-CPB (Horst, The Netherlands). Animals were kept under 
standard laboratory conditions (12 hours light/ 12 hours dark) and given a standard 
laboratory diet (Hope Farms, Woerden, The Netherlands) and water ad libitum. The 
experimental protocol adhered to the rules of the Dutch Animal Experimental Act and 
was approved by the Committee on Animal Research of the Erasmus University. 
 
Tumor 
CC531 is a SSR-negative, moderately differentiated rat colon carcinoma, induced by 
1,2-dimethylhydrazine and is transplantable in syngeneic WAG/Rij rats (14). The 
tumor is maintained in tissue culture as a monolayer in RPMI 1640 medium (Gibco, 
Paisley, UK) supplemented with 5% fetal calf serum (FCS). Cells were harvested 
from stationary cultures by gentle trypsinisation (Boehringer, Mannheim, Germany). 
A suspension of 0.5 x 106 living cells was used for direct injection into the portal vein 
(15; 16). 
 
SSR Transfection and Expression 
For expression of the somatostatin receptor-subtype 2 in CC531 cells, human sstr2 
cDNA in pBluescript (pBS) (a kind gift of G.I. Bell, Howard Hughes Medical 
Institute, Chicago, IL, USA) was excised form pBS and inserted into the Nhe-1/Sali 
cloning site of the retroviral expression vector pCi-neo. Selection was made by the 
geneticine resistance gene (G418). This vector was used to stable transfect (using 
lipofectin) CC531 cells. Transfectants were selected and cultured in RPMI 1640 
supplemented with 5% FCS and geneticine (0.5 mg/mL) (Gibco, Paisley, UK). 
Geneticine-resistant clones were examined for their ability to bind with 
[125Iodine,Tyrosine (123I-Tyr3) ]octreotide. The clone with the highest expression 
(Scatchard analysis) of SSR was isolated and named CC2B (17). 
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Ex vivo and In vitro SSR Autoradiography 
In frozen tumor samples SSR’s were measured by autoradiography on 10 :m cryostat 
sections. The concentration of the radioligand, [125I-Tyr3]octreotide, was 10-10 M. 
Incubation and washing conditions were as described (18). Non-specific binding was 
determined by adding an excess (10-6 M) of non-radiolabeled octreotide (gift by 
Novartis, Basle, Switzerland). Radioactivity was measured 24 hours in a Cyclone 
Storage Phosphor Screen (Packard Bioscience company, Groningen, The 
Netherlands). 
  
Radiolabeling and Quality Control of the Radioligand 
Reactor-produced no carier added 177Lu was obtained from IDB Holland (Baarle 
Nassau, The Netherlands). 
[DOTA0, Tyr3]octreotate was obtained from Mallinckrodt (St. Louis, Mo., USA). 
177Lu-labeling of [DOTA0, Tyr3]octreotate was performed as previously described for 
[90Y-DOTA0, Tyr3]octreotate (19). The labeling yield always exceeded 99% and the 
radiochemical purity was higher than 90%. 
 
Experimental Procedure 
Under ether anesthesia, the abdomen was opened through a 2.5 cm midline incision. 
Experiment 1: 0.5 x 106 viable SSR-negative CC531 cells or SSR-positive CC2B cells 
in 0.5 mL RPMI 1640 were injected slowly into the portal vein through a 0.4 x 12 mm 
needle. The abdominal wall was closed in one layer by a continuous silk suture (15; 
16). The day after the operation, rats were randomized in an experimental and control 
group.  
Each group consisted of 7 rats. Rats of the experimental group were treated with 370 
MBq [177Lu-DOTA0, Tyr3]octreotate i.v. on day 7. Rats in the control group did not 
receive treatment.  
Experiment 2: in this experiment 0.5 x 106 viable SSR-positive CC2B cells in 0.5 mL 
RPMI 1640 were injected slowly in the portal vein. The day after the operation, rats 
were randomized in an experimental and control group. Each group consisted of 8 or 
9 rats. Rats of the experimental group were treated with 185 MBq [177Lu-DOTA0, 
Tyr3]octreotate i.v. on day 8. Rats in the control group did not receive treatment. 
Experiment 3: in this experiment 0.25 x 106 viable SSR-negative CC531 cells mixed 
with 0.25 x 106 viable SSR-positive CC2B cells in 0.5 mL RPMI 1640 were injected 
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slowly in the portal vein. The day after the operation, rats were randomized in an 
experimental and control group. Each group consisted of 8 or 9 rats. Rats of the 
experimental group were treated with 185 MBq [177Lu-DOTA0, Tyr3]octreotate i.v. on 
day 8. Rats in the control group did not receive treatment. 
Body weight and animal condition (i.e.: lethargy, scruffy coat and diarrhea) were 
determined at regular intervals at least twice a week. 
In the three experiments all rats were sacrificed 21 days after inoculation of tumor 
cells. Livers were removed, washed and immersed in PBS. Tumor growth was 
determined by 2 independent investigators counting the number of metastases on the 
surface of the liver lobes (up to 100) while blinded for treatment modality. The 
number of metastases were subdivided in a semi-quantitative tumor score, with 
concordant ranking from 0 (no metastases) up to 5 (>100 tumor colonies, with >50% 
of the liver affected as presented in table 1, 2 and 3. Tumor tissue was snap frozen in 
liquid nitrogen for autoradiography to determine in vivo somatostatin receptor status 
of the tumor.  
 
Statistical analysis 
Statistical analysis of the data was performed using one-way analysis of variance. 
When significant effects were obtained by analysis of variance, multiple comparison 
were made by the Newmann-Keuls test. Statistical significance was defined as p< 
0.05. Data are expressed as mean ± Standard Deviation (SD). 
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RESULTS 
In vivo PRRT 
Experiment 1: The results of PRRT with 370 MBq  [177Lu-DOTA0, Tyr3]octreotate on 
day 7 on the growth of CC531 and CC2B liver metastases are summarized in table 1. 
PRRT did not have a significant effect on the number of CC531 liver metastases in 
comparison with the controls. Mean tumor scores were 3.86 ± 0.38 and 4.14 ± 0.38 
respectively. However, PRRT had a strong anti-tumor effect on CC2B liver 
metastases compared with controls. Mean tumor scores were 1.57 ± 0.79 and 4.43 ± 
0.79 respectively (p<0.001). Examples of control and treated rats with CC2B liver 
metastases are shown in figure 1. 
 
TABLE 1:  
The effect of 370 MBq [177Lu-DOTA0, Tyr3]octreotate on CC531 or CC2B metastases 
No. of metastases 0 1 – 20 21 – 50 51 – 100 >1001 >1002 
Rank 0 1 2 3 4 5 
Control CC531 - - - - 6 1 
PRRT CC531 - - - 1 6 - 
Control CC2B - - - 1 2 4 
PRRT CC2B - 4 2 1 - - 
 
Table 1. Number of animals with given range of metastases, 21 days after direct injection of 
CC531 or CC2B tumor cells into the portal vein. Control received no treatmnent. PRRT 
received 370 MBq [177Lu-DOTA0, Tyr3]octreotate on day 7. 
1 >100 tumor colonies, but <50% of liver is affected 
2 >100 tumor colonies, and >50% of liver is affected 
 
Experiment 2: The results of PRRT with 185 MBq [177Lu-DOTA0, Tyr3]octreotate on 
day 8 on the growth of CC2B are summarized in table 2. Again, PRRT had an anti-
tumor effect on CC2B liver metastases compared with controls. Mean tumor scores 
were 2.63 ± 1.6 and 4.33 ± 0.71, respectively (p<0.01).  
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TABLE 2: The effect of 185 MBq [177Lu-DOTA0, Tyr3]octreotate on CC2B metastases 
No. of metastases 0 1 – 20 21 – 50 51 – 100 >1001 >1002 
Rank 0 1 2 3 4 5 
Control CC2B - - - 1 4 4 
PRRT CC2B - 3 1 1 2 1 
 
Table 2. Number of animals with given range of metastases, 21 days after direct injection of 
CC2B tumor cells into the portal vein. Control received no treatmnent. PRRT received 185 
MBq [177Lu-DOTA0, Tyr3]octreotate on day 8. 
1 >100 tumor colonies, but <50% of liver is affected 
2 >100 tumor colonies, and >50% of liver is affected 
 
Experiment 3: The results of PRRT with 185 MBq [177Lu-DOTA0, Tyr3]octreotate on 
day 8 on the growth of 50%/50% mixed CC2B/CC531 liver metastases are 
summarized in table 3. Also an anti-tumor effect, although less impressive, was found 
in PRRT treated rats with mixed (CC2B/CC531) liver metastases compared with 
controls. Mean tumor scores were 3.50 ± 1.20 and 4.78 ± 0.44, respectively (p<0.05). 
In all three experiment no overt signs of toxicity were observed after PRRT treatment 
(i.e.: weight loss, lethargy, scruffy coat and diarrhea). 
 
TABLE 3: The effect of 185 MBq [177Lu-DOTA0, Tyr3]octreotate on mixed metastases 
No. of metastases 0 1 – 20 21 – 50 51 – 100 >1001 >1002 
Rank 0 1 2 3 4 5 
Control mixed - - - - 2 7 
PRRT mixed - - 2 2 2 2 
 
Table 3. Number of animals with given range of metastases, 21 days after direct injection of 
50%/50% mixed (CC2B/CC531) tumor cells into the portal vein. Control received no 
treatmnent. PRRT received 185 MBq [177Lu-DOTA0, Tyr3]octreotate on day 8. 
1 >100 tumor colonies, but <50% of liver is affected 
2 >100 tumor colonies, and >50% of liver is affected 
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Ex vivo and in vitro SSR Autoradiography 
The results of the ex vivo and in vitro autoradiography are summarized in table 4. 
Ex vivo autoradiography did not show uptake of residual radioactivity in treated 
CC531, CC2B and mixed liver metastases. However, in vitro autoradiography of 
CC2B liver metastases tissue of control rats showed high expression of SSRs, in 
contrast to CC531 liver metastases tissue of control and treated rats (fig. 2). 
Moreover, when the SSR was blocked by an excess of non-radiolabeled octreotide 
non-specific binding was low. However, SSR expression of treated rats with CC2B 
liver metastases had a more heterogeneous uptake in the tumor colonies compared 
with control rats. This was also the case in control and treated rats with 50%/50% 
mixed liver metastases. 
 
TABLE 4: Results ex vivo and in vitro autoradiography 
      ex vivo  in vitro  
CC2B    controls n.r.r.a.        +   
    PRRT       -        ±   
CC531/CC2B (mixed) controls n.r.r.a.        ±   
    PRRT       -        ±   
CC531    controls n.r.r.a.        -   
    PRRT       -        -   
Table 4: Summarization of the results of the ex vivo and in vitro autoradiography. n.r.r.a. = 
no residual radioactivity, - = no SSR expression, ± = heterogeneous SSR expression, + = 
high SSR expression. 
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Figure 1: Examples of a liver of a control rat (A) and of a PRRT treated rat (B) with CC2B 
liver metastases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Examples of two frozen slides with liver metastases tissue of control rats with 
CC531 (up) and CC2B (down) liver metastases, respectively. (A). Hematoxylin-eosin staining 
shows the localization of the tumor colonies surrounded by normal liver parenchyma. (B). In 
vitro autoradiography clearly visualizes the SSRs on the  CC2B tumor colonies, in contrast to 
CC531 liver metastases tissue. (C). When the SSR is blocked by an excess of non-radiolabeled 
octreotide non-specific binding is low. 
A B
 
 
CC531 
CC2B
A B C
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DISCUSSION 
In previous studies, Slooter et al. showed strong growth inhibition of SSR positive 
CA20948 pancreatic liver metastases in rats treated with 370 MBq [111In-
DTPA0]octreotide (15; 16). This effect was abolished when the SSR was blocked by 
an excess of non-radiolabeled octretiode before PRRT treatment, indicating that 
radiolabeled octreotide was internalized specifically by the SSR. This SSR-mediated 
process was also underlined by the finding that no anti-tumor effects were seen in 
PRRT treated rats bearing SSR-negative CC531 colon carcinoma liver metastases. 
However, recent developments in molecular biology have made it possible to transfect 
SSR-negative CC531 cells with a SSR-gene, so SSR-mediated PRRT is also 
applicable in these tumors. We performed an retroviral in vitro transfection of tumor 
cells. The use of retrovirusses for in vitro transfection is highly efficient, although it 
has several drawbacks in its clinical use, like low production of its viral titres in the 
packaging lines, although  currently improving, are still not sufficient high enough for 
many therapeutic applications, and insertional mutagenesis may also occur, inducing 
new tumors. However, the use of retroviral vectors has also an advantage in the 
transduction of liver metastases, while only active dividing cells (tumor cells) are 
transducted and non-dividing cells (hepatocytes) not, resulting in a highly specific 
transduction of liver metastases. This advantage can be useful in the future when liver 
metastases can be transduced, for example by isolated hepatic perfusion with a 
retroviral vector.  
After retroviral in vitro transfection of the CC531 cells with a SSR (subtype 2)-gene, 
this cell line was named CC2B. This newly SSR transfected cell line had a high 
amount of SSR expression (Bmax 760 fmol/mg membrane protein) and a high binding 
affinity (Kd = 0.9 nM) (17). Moreover, we showed that the transfected receptor was 
also functional as it could internalize radiolabeled octreotide. However, in the same 
rat liver metastases model we did not see anti-tumor effect after PRRT treatment with 
370 MBq [111In-DTPA0]octreotide on CC2B liver metastases, despite the fact that we 
measured a high uptake of radioactivity inside these SSR-positive liver metastases 
after PRRT treatment (data not shown). In a previous study, we reported, as measured 
in a clonogenic assay with external radiation, that CC2B and CC531 are relatively 
radioresistant in comparison with our positive control tumor, CA20948, in which we 
previously shown highly effective therapy (17). Consequently, we decided to use 
another radionuclide than 111In, which emits internal conversion and Auger electrons, 
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with smaller tissue penetrations (200- 550 µm and 0.02 – 10 µm, respectively) and 
lower energy (0.15 – 0.24 MeV and 0.025 MeV, respectively). In contrast, 177Lu, a 
beta-emitting radionuclide, has a larger tissue penetration of a maximum of 2 mm and 
a Emax of 0.5 MeV. In addition, we used another somatostatin analog, namely 
[Tyr3]octreotate instead of [DTPA0]octreotide. This analog was found to have a very 
high affinity for the SSR(-type 2) (20), and high uptake of radioactivity in these SSR-
expressing tumors were found to be 3 to 4 times higher than [DTPA0]octreotide. De 
Jong et al. showed highly effective therapy with [177Lu-DOTA0, Tyr3]octreotate in a 
flank tumor model using the SSR-positive rat pancreatic CA20948 tumor cell line 
(13). All rats bearing small tumors showed complete regression of tumor mass after a 
total dose of 555 MBq [177Lu-DOTA0, Tyr3]octreotate. In this study, especially 
smaller tumors showed better results in comparison with larger tumors. In accordance 
with these findings, we were interested whether [177Lu-DOTA0, Tyr3]octreotate was 
also feasible, using the same SSR-positive tumor cell line, CA20948, in a rat liver 
metastases model. A strong anti-tumor effects on CA20948 liver metastases bearing 
rats was found after treatment with 370 or 185 Mbq [177Lu-DOTA0, Tyr3]octreotate 
(manuscript in preparation), which confirmed our hypothesis that [177Lu-DOTA0, 
Tyr3]octreotate is also feasible in this rat liver metastases model. Therefore, we were 
interested whether [177Lu-DOTA0, Tyr3]octreotate could also exert an anti-tumor 
effect on our relatively radioresistant cell line, CC2B, in this liver metastases model. 
In our first in vivo experiment, we injected a dose of 370 MBq [177Lu-DOTA0, 
Tyr3]octreotate i.v.. The results showed an impressive decrease in tumor score of 
CC2B liver metastases (p < 0.001). So, in contrast to our previous study, in which we 
injected 370 MBq [111In-DTPA0]octreotide, we were able to obtain an anti-tumor 
effect on SSR-transfected CC531 cells. The native cell line without SSR, CC531, did 
not show a decrease in tumor score after treatment with [177Lu-DOTA0, 
Tyr3]octreotate, again underlining the importance of the SSR in this process. While a 
significant anti-tumor effect (p<0.001) was obtained in the first in vivo experiment, 
we repeated our experiment, but this time we injected half of the dosage [177Lu-
DOTA0, Tyr3]octreotate, namely 185 MBq, in order to evaluate the tumor response 
with less radioactivity. Again, a (dose-dependent) significant anti-tumor effect was 
found (p<0.01), underlining the strength of the therapy even with lower dosages of 
[177Lu-DOTA0, Tyr3]octreotate.  
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As stated above, 177Lu emits β-particles with a maximum energy of 0.5 MeV (average 
of 0.133 MeV) and a high tissue penetration, with a maximum range of 2 mm. 
Assuming a cell diameter of 20 µm, this means, when internalized into the tumor cell, 
177Lu is able to potentially kill cells at approximately 12 cell diameters from a cell in 
which it is internalized, with a maximum cell-killing potential of approximately 50 
cell diameters (21). This extra cell killing potential is also called a radiological 
bystander effect and can be an additional advantage in the concept of gene therapy. As 
in many gene therapy trials a poor transduction rate in vivo results in a poor efficacy 
of the treatment. A bystander effect is vital to overcome this problem. The third in 
vivo experiment was performed, in order to evaluate the bystander effect of [177Lu-
DOTA0, Tyr3]octreotate in 50% mixed CC2B and CC531, i.e. half SSR-positive and 
half SSR-negative cell population. Again a significant anti-tumor effect was found 
(p<0.05). Although these results were significant, it is not clear whether the obtained 
anti-tumor effect is due to the killing of only the SSR-positive cells (CC2B) or in 
addition a bystander effect also killed surrounding CC531 (SSR-negative) cells. 
Autoradiographical studies of excised livers were performed, in order to investigate 
SSR-status of the treated and control tumors. Ex vivo autoradiography, which shows 
residual radioactivity after PRRT, showed no macroscopically uptake of radioactivity 
in treated CC2B or 50/50% tumor colonies. However, in vitro autoradiography of 
these slides showed heterogeneous uptake of radioactivity, indicating that both SSR-
positive and –negative cells are present in tumor colonies. In contrast, in vitro 
autoradiography of control rats with CC2B liver metastases showed high and uptake 
of radioactivity, indicating high (homogeneous) SSR expression. These findings 
suggests that mostly SSR-positive tumor cells are killed after PRRT and surviving 
tumor cells are mainly SSR-negative clones of the CC2B cell line. Since both in vitro 
autoradiograms of treated and control rats with 50%/50% mixed liver metastases 
showed macroscopically heterogeneous uptake of radioactivity in almost the same 
quantity, we conclude that SSR-positive cells were killed after PRRT, and in addition 
due to the cross-fire of beta-particles of internalized 177Lu also a large quantity of 
SSR-negative tumor cells were killed, resulting in a radiological bystander effect. 
However, we can not quantify the amount of uptake exactly, therefore the exact 
amount of bystander effect can not be calculated.  
In all three in vivo experiments no overt signs of toxicity were observed after 
treatment with 185 or 370 MBq [177Lu-DOTA0, Tyr3]octreotate. Comparable results 
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in toxicity were found in experiments reported by de Jong et al., in which Lewis rats 
were injected with 277.5 or 555 MBq [177Lu-DOTA0, Tyr3]octreotate (13). In 
addition, kidney and bone marrow are the critical organs for PRRT with radiolabeled 
somatostatin analogs and determined the maximal tolerated dose hereof in other 
studies (data not shown). Moreover, Lewis et al. recently reported also no toxicity for 
[177Lu-DOTA0, Tyr3]octreotate, even up to doses of 4 GBq/kg in rats, and up to 42 
days post injection (22). High dosages of [177Lu-DOTA0, Tyr3]octreotate up to 130 
mCi/kg did not give a significant change in platelet counts, hemoglobin, blood urea 
nitrogen, creatinine or alanine aminotransferase. In the gross necropsy and 
histopathological examinations of selected tissues, there were no apparent lesions, 
showing the lack of gross or histological signs of toxicity. The only sign of toxicity 
was a dose-dependent change of WBC in rats treated with 50 up to 130 mCi/kg. 
However, this change of WBC recovered in all cases within 35 days. Since our rats 
received a maximum dose of 370 MBq (= 1480 MBq/kg = 40 mCi/kg), we can 
conclude that our rats had a impressive tumor response with no overt signs of toxicity. 
We assume that higher or fractionated dosages may even give better results. 
Especially, when the bystander effect is concerned, higher and or fractionated dosages 
may result in more convincing bystander effect compared with our present results in 
experiment 3.  
In conclusion, we found an impressive anti-tumor effect of SSR-transfected liver 
metastases after treatment with PRRT with both 185 and 370 MBq [177Lu-DOTA0, 
Tyr3]octreotate, while no anti-tumor effect was seen in SSR-negative liver metastases, 
indicating that this therapy is targeted. Moreover, rats with mixed liver metastases had 
also significant less liver metastases compared with control rats, which may be caused 
by a radiological bystander effect of [177Lu-DOTA0, Tyr3]octreotate. This proves that 
the combination of gene therapy followed by PRRT is an interesting concept, that 
might open possibilities in the treatment of micrometastases of the liver in the future. 
 
ACKNOWLEDGMENTS 
We are thankful to A. van Gameren, S. Verwijnen and B.F. Bernard for their excellent 
technical assistance. 
 
177Lu-DOTA-octreotate on CC2B  liver metastases 
___________________________________________________________________________________ 
  
 111
REFERENCE LIST 
1.  Reubi JC, Laissue J, Krenning E, et al SW. Somatostatin receptors in human cancer: incidence, 
characteristics, functional correlates and clinical implications.  J Steroid Biochem Mol Biol 
1992;43:27-35. 
2.  Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an 
implication for the efficacy of somatostatin analog SMS 201-995 in treatment of human endocrine 
tumors.  J Clin Invest 1994;93:1321-5. 
3.  Hofland LJ, Lamberts SW. Somatostatin analogs and receptors. Diagnostic and therapeutic 
applications.  Cancer Treat Res 1997;89:365-82. 
4.  Krenning EP, Valkema R, Kooij PP, et al. The role of radioactive somatostatin and its analogs in 
the control of tumor growth.  Recent Results Cancer Res 2000;153:1-13. 
5.  McCarthy KE, Woltering EA, Espenan GD, et al. In situ radiotherapy with 111In-pentetreotide: 
initial observations and future directions.  Cancer J Sci Am 1998;4:94-102. 
6.  Caplin ME, Mielcarek W, Buscombe JR, et al. Toxicity of high-activity 111In-Octreotide therapy 
in patients with disseminated neuroendocrine tumors.  Nucl Med Commun 2000;21:97-102. 
7.  Meyers MO, Anthony LB, McCarthy KE, et al. High-dose indium 111In pentetreotide 
radiotherapy for metastatic atypical carcinoid tumor.  South Med J. 2000;93:809-11. 
8.  Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results.  Eur J Nucl 
Med 1999;26:1439-47. 
9. Valkema R, Jamar F, Jonard P, et al. Targeted radiotherapy with 90Y-DOTA-Tyr(3)-octreotide 
(90Y-SMT487; OctreoTher): a phase I study.  J Nucl Med. 2000;41:111P 
10. Paganelli G, Zoboli S, Cremonesi M,  et al. Receptor-mediated radionuclide therapy with 90Y-
DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.  Cancer Biother 
Radiopharm 1999;14:477-83. 
11.  Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-
Phe1-Tyr3-octreotide.  Eur J Nucl Med 2001;28:426-34. 
Chapter 7 
___________________________________________________________________________________ 
 112
12.  Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOTAOTyr3]octreotate: comparison with 
[111In-DTPAo]octreotide in patients.  Eur J Nucl Med 2001;28:1319-25. 
13.  de Jong M, Breeman WA, Bernard BF, et al. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin 
receptor-targeted radionuclide therapy.  Int J Cancer 2001;92:628-33. 
14.  Marquet RL, Westbroek DL, Jeekel J. Interferon treatment of a transplantable rat colon 
adenocarcinoma: importance of tumor site.  Int J Cancer 1984;33:689-92. 
15.  Slooter GD, Breeman WA, Marquet RL, et al. Anti-proliferative effect of radiolabeled octreotide 
in a metastases model in rat liver.  Int J Cancer 1999;81:767-71. 
16.  Slooter GD, Aalbers AG, Breeman WA, et al. The inhibitory effect of radiolabeled octreotide on 
intrahepatic tumor growth after partial hepatectomy.  J Nucl Med. 2002;"in press" 
17.  Mearadji A, Breeman WA, Hofland LJ, et al. The effect of targeted therapy with radiolabeled 
octreotide on somatostatin receptor transfected colon carcinoma cells in a rat liver metastases 
model.  Eur Surg Res. 2001;33:164 
18. Reubi JC, Torhorst J. The relationship between somatostatin, epidermal growth factor, and steroid 
hormone receptors in breast cancer.  Cancer 1989;64:1254-60. 
19.  de Jong M, Bakker WH, Breeman WA, et al. Pre-clinical comparison of [DTPA0] octreotide, 
[DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-
targeted scintigraphy and radionuclide therapy.  Int J Cancer 1998;75:406-11. 
20.  de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogs 
for tumor scintigraphy and radionuclide therapy.  Cancer Res 1998;58:437-41. 
21.  Schlom J, Siler K, Milenic DE, et al. Monoclonal antibody-based therapy of a human tumor 
xenograft with a 177lutetium-labeled immunoconjugate.  Cancer Res 1991;51:2889-96. 
22.  Lewis JS, Wang M, Laforest R, et al. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in 
a rat model.  Int J Cancer 2001;94:873-7. 
 
CHAPTER 8 
 
 
 
 
AN-238, A CYTOTOXIC SOMATOSTATIN ANALOG: AN 
INTRODUCTION 
 
A. Mearadji1, L.J. Hofland2 and C.H.J. van Eijck1 
 
Erasmus Medical University Center, Rotterdam, The Netherlands 
1 Department of Surgery 
2 Department of Internal Medicine 
Chapter 8 
___________________________________________________________________________________ 
 114
INTRODUCTION 
Chemotherapy has been the most important modality for treatment of advanced or 
disseminated cancers in the past 50 years1,2. Also chemotherapy can be used in an 
adjuvantal setting after surgery and/or radiotherapy. However, treatment of cancer 
with conventional chemotherapy is limited by the development of drug resistance in 
cancer cells, a phenomena called multi-drug resistance (MDR), and toxicity of normal 
cells1,2. There are two options to increase the effectiveness of chemotherapy: 
modification of drug resistance or more selective delivery. Alterations in signal 
transduction involving cell differentiation, proliferation and death are involved in the 
pathogenesis of cancer. Increased understanding of the pathways by which 
chemotherapeutic drugs interact with mechanisms underlying signal transduction may 
lead to developments of drugs which may sensitize cancers to chemotherapy. 
Combinations of chemotherapeutic agents with signal transduction inhibitors or anti-
signaling drugs are to be expected to combat MDR in a synergystic or additional 
manner.  
A more selective delivery of the chemotherapy to the tumor cells allows a dose 
escalation and reduces the systemic toxicity. Methods such as isolated limb or isolated 
liver perfusion showed more effective treatment of cancer with low toxicity of normal 
cells3-5. However, this method needs invasive procedures before treatment can be 
started with also higher morbidity and mortality rates. A more preferable method is to 
target cytotoxic agents to their receptors on tumor cells. Almost 100 years ago Paul 
Ehrlich received the Nobel Prize in Medicine for his concept of the “magic bullets”: 
based on the assumption that tumor cells possess specific antigens, specific antibodies 
could deliver toxic compounds to tumor cells and eradicate them6.  In accordance with 
this concept the group of Schally et al. composed chemotherapy linked to various 
peptides which binds to their receptors on tumors, like cytotoxic LHRH analogs, 
cytotoxic analogs of bombesin/gastrin releasing peptide and cytotoxic somatostatin 
analogs. As with radiolabeled somatostatin analogs, the cytotoxic somatostatin 
analogs showed impressive  anti-tumor effect with low peripheral toxicity in several 
tumor cell lines expressing SSRs7-15. A doxorubicin (DOX) derivate, 2-pyrrolino-
DOX (AN-201), was coupled to the somatostatin analog, RC-121 and named AN-
23816. In this small review the synthesis, mechanism of action and therapeutic 
application  of AN-238 will be discussed.  
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SYNTHESIS 
AN-201 can be formed by reacting DOX with a 5- to 10-fold excess of 4-
iodobutyraldehyde in dimethylformamamide. The conversion of DOX takes place 
within minutes and is virtually 100%. AN-201 was shown to be 500-1000 times more 
potent than DOX in vitro16.  
AN-201 was linked through a glutaric acid spacer to the amino terminal D-Phe 
residues of the somatostatin carrier, RC-121 and named AN-238 (Fig.1). 
 
Fig. 1: Molecular structure of AN-238 
 
MECHANISM OF ACTION 
Although no tissue distribution test with AN-238 are published in literature, it is 
believed that these cytotoxic hybrids can accumulate in both normal and cancerous 
cells expressing SSRs, as demonstrated for radioactive somatostatin analogs17-19. After 
binding and internalization of AN-23820, the cytotoxic radical may be released in the 
cells by carboxylesterase enzymes, which are ubiquitous21. It is also possible that the 
cytotoxic radical is released, in part, after binding but before internalization. This 
mechanism could still produce a higher concentration of the radical in SSR-positive 
tissue and, in addition, a “bystander effect”, affecting SSR-negative neighbouring 
cells. As a result of the “bystander effect”, it is very difficult to demonstrate targeting 
of these conjugates in vitro. Despite such difficulties, recently Schally et al. showed a 
more selective toxicity of AN-238 towards receptor-positive cells in mixed 
populations of SSR-negative and  SSR-positive cells, using cell-line specific 
microsatellite markers for semiquantitive analysis9,10. 
Chapter 8 
___________________________________________________________________________________ 
 116
Moreover, the esterase activity in plasma is an important factor in the efficacy of the 
treatment with AN-238, while release of radicals (AN-201) can occur in blood before 
the targeting is completed. A longer half-life of  the ester bond allows more binding of 
AN-238 on the SSRs, leading to more efficient therapy and also leading to less toxic 
side-effects such as myelodepression. Schally et al. showed a half-life of the ester 
bond in rats of more than 60 minutes12, while in mice the half life of ester bond was 
about 20 minutes19. Through this mechanism the difference in toxicity patterns 
between these two species can be explained. In addition, by means of an esterase 
inhibitor the plasma half-life of the ester bond was extended from 20 to 70 minutes in 
mice, resulting in a comparable tolerance pattern as in rats9,22. The half-life of the 
DOX-14-O-glutaryl ester bond in human plasma in vitro is approximately 2 hours, 
which allows a more complete targeting of the SSR-positive tumor cells, consequently 
resulting in a even more effecient treatment in a clinical setting compared to mice-
models used by the group of Schally22. 
 
ONCOLOGICAL STUDIES WITH AN-238 
SSRs are identified in various normal and neoplastic tissues, including brain tumors, 
pituitary tumors, gastro-intestinal tumors, breast cancers, colorectal cancers, prostate 
cancers and ovarian cancers23-27. Impressive results with radiolabeled somatostatin 
analogs were already shown in a experimental and clinical setting18,28-32. The group of 
Schally tested AN-238 on a wide variety of SSR-expressing tumor cell lines. In Table 
1 a short summarization of the results are shown. 
 
Prostate cancer 
AN-238 and AN-201 was first evaluated on androgen-independent Dunning R-3327-
AT-1 prostate carcinoma in Copenhagen rats. A dose of 300 nmol/kg AN-238 
produced a 80% decrease in tumor weight 4 weeks after treatment. In contrast, AN-
201 at a dose of 110 nmol/kg showed a weak effect and killed 9 of 10 rats at 115 
nmol/kg12. 
Similarly results were shown in nude mice bearing PC-3 human prostate cancers. A 
single dose of 200 nmol/kg or two injections of 150 nmol/kg AN-238 reduced tumor 
weight and burden by more than 60%, mainly due to a significant increase of 
apoptosis in tumor cells. Again AN-201 was ineffective and more toxic11. 
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Breast cancer 
 A number of studies have showed the expression of SSRs on primary breast cancers, 
especially invasive ductal carcinomas are positive33. To prove the effectiveness of AN-238 
Kahan et al. performed experiments with nude mice bearing various estrogen dependent 
MCF-7-MIII and estrogen-independent  MDA-MB-231  and MX-1 (DOX-resistant) breast 
cancers xenografts15. Single injection i.v. with AN-238 or AN-201 at 250 nmol/kg showed a 
tumor regression in 3 of 8 mices bearing MCF-7-MIII tumor xenografts treated with with AN-
238, in contrast all tumors grew steadily in the group treated with AN-201. In the group with 
MDA-MB-231 tumors, 4 of 13 mice showed an initial regression after AN-238 treatment for 
about 2 weeks. Again AN-201 had no anti-tumor effect. In the mice with MX-1 tumors, both 
AN-238 and AN-201 had tumor inhibition. After 60 days 5 of 10 animals in the AN-238 
group and only 1 of 9 animals in the AN-201 group were tumor free, indicating that AN-238 
(and AN-201) is also active in DOX-resistant tumor cells. 
 
Brain cancer 
Kiaris et al. investigated AN-238 treatment in mice bearing U-87 MG human glioblastomas 
(SSR-positive)14. Animals with large subcutaneous xenografts were treated with AN-238 or 
AN-201 at 150 nmol/kg i.v. At day 19, the group treated with AN-238 showed an 82% tumor 
growth inhibition compared with controls. After blocking te SSRs with a high dose of RC-160 
given prior to treatment this tumor inhibition could be reduced to 37%. AN-201 was not 
effective. In the same study, two injections of AN-238 at 150 nmol/mg gave also significant 
tumor inhibition in very large tumors, while AN-201 had no effect. Furthermore, orthopically 
grown U-87 MG tumors were treated succesfully after AN-238 i.v. injection, indicating that 
AN-238 can penetrate the blood-brain barrier. 
 
Renal cell carcinoma (RCC) 
About 70% of RCCs express SSRs35. AN-238 was tested on SW-839, 786-0 (both SSR-
postive) and CAKI-1 (SSR-negative) human RCC10. As expected, no anti-tumor effect was 
observed in mice bearing CAKI-1 tumors treated with AN-238. In contrast, the growth of 
SW-839 and 786-0 was inhibited significantly. In a 786-0 metastastic tumor model, 3 of 7 
mice treated with 3 i.v. injections of AN-238 at a dose of 150 nmol/kg biweekly were found 
to be tumor-free 6 weeks after initiation of treatment, and in 3 other animals the tumor mass 
was less than 30 mg. In one mouse, a mass of 320 mg was found which did not express SSRs. 
Moreover, no evidence of lymph nodes metastases were found in the AN-238 treated group, 
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except the mouse with SSR-negative tumor, while metastases were found in  5 of the 6 
animals in the control and AN-201 treated group. Again in all studies, AN-201 was 
ineffective and more toxic than AN-238. 
 
Pancreatic Cancer 
Krenning et al. already showed that most endocrine pancreatic cancers can be shown by 
Octreoscan18. Also a tumor growth inhibition effect of CA20948, a SSR-postive pancreatic 
tumor cell line, is shown by treatment with “cold” octreotide and radiolabeled 
octreotide29,30,36. AN-238 and AN-201 were administered in a nuce mice bearing SW-1990 
(SSR-positive) pancreatic cancers8. Two injections of AN-238 at a dose of 150 nmol/kg 
reduced tumor growth by 93% compared with controls, while the same treatment with AN-
201 reduced tumor growth with 68%. Pretreatment with RC-160 (high dose) followed by AN-
238 treatment reduced the efficacy of AN-238, resulting in an inhibition similar caused by 
AN-201 (69%). 
Moreover, loss of the SSR-type 2 expression in pancreatic cancers could be associated with 
the proliferation of cells. In order test this theory, Benali et al. transfected PC-1.0 pancreatic 
cancer in Syrian golden hamsters with a SSR-type 2 gene to produce PC-1.0/SSR2 cells37. PC 
1.0/SSR2 cells grew significantly slower than control PC-1.0 cells in an in vivo hamster 
model. In addition, when hamsters bearing SSR-expressing tumors received AN-238 at 100 
nmol/kg i.v., the tumor growth was further slowed down in comparison with untreated PC-
1.0/SSR2 tumors. Moreover, AN-238 had no effect on (SSR-negative) PC-1.0 tumors, 
demonstrating the importance of the SSR for the efficacy of the treatment of AN-238. 
 
Lung Carcinomas 
As small cell lung cancer (SCLC) is of neuroendocrine origin, most of the tumors and 
metastases have SSRs and thus can be visualized with Octreoscan18. Also non-SCLC can be 
visualized with Octreoscan, although the tumor cells itself do not express SSRs. The SSRs 
visualized by Octreoscan are mainly found in peritumoral tissue, like blood vessels and 
immune cells. 
AN-238 was found to be very effective treatment in mice bearing H-69 SCLC tumors, 
resulting in a >50% tumor growth inhibition when a single dosage of 200 nmol/kg or two 
injections of 150 nmol/kg was given. AN-201 was less effective and more toxic13. Also mice 
bearing non-SCLC tumors (H-157), which is SSR-type 2, 3 and 5 negative, showed a 91% 
tumor grwoth inhibition after treatment with 200 nmol/kg of AN-238 compared with controls. 
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Again AN-201 was less effective and more toxic than AN-238. In this study it was also 
showed that AN-238 can also be a target for tumor vasculature, as control tumors showed 
high expression of SSR-type 2 and 5 after RNA extraction. So even when a tumor itself is 
SSR-negative it can be treated with AN-238 by targeting of the SSRs on the tumor 
vasculature. 
 
Ovarian Cancer 
Also ovarian cancer can express SSRs 38. Plonowski et al. tested AN-238 in nude mice 
bearing UCI-107 ovarian cancer9. Two injections of 150 nmol/kg AN-238 gave a tumor 
weight reduction of 67% compared with controls, while AN-201 gave a nonsignificant effect 
on tumor weight. Moreover, in mice with inhibited  serum carboxylesterase activity and very 
large tumors (>50% larger than the first study), AN-201 at 400 nmol/kg was lethal, whereas 
AN-238 at a total dose of 800 nmol/kg caused only 22% mortality and reduced tumor weight 
by 69%. 
 
Colon Cancer 
Various studies have indicated that SSRs are present on colon carcinomas39-41. AN-238 was 
tested in four tumor cell lines: SSR positive, HCT-116, HCT-15 and HT-29, and SSR-
negative, LoVo. Moreover, HCT-116 and LoVo did express normal p53 tumor supressor 
gene, while HCT-15 and HT-29 had mutant p53 gene7. In vivo studies showed that AN-238, 
AN-201 and also DOX in equitoxic doses inhibited the growth of HCT-116 tumors that 
express wild-type p53. However, AN-238 also inhibited the growth of HCT-15 and HT-29 
cancer that express mutant p53, whereas AN-201 and DOX showed no effect. None of the 
compounds could suppress the proliferation of LoVo tumors, as it lacks the SSR. This 
indicates that AN-238 may have a higher therapeutic potential on SSR positive colorectal 
cancers compared with the non-tageted compounds AN-201 and DOX independently of the 
p53 status. 
 
CONCLUSIONS 
As radiolabeled octreotide, AN-238, showed a impressive tumor growth inhibition in various 
SSR-positive tumor cell lines, whereas AN-201 was less effective and more toxic. Moreover, 
the group of Schally showed that AN-238 can be targeted to SSR-negative tumors by 
targeting of peritumoral vasculature. Although the authors claim that the treatment is targeted 
no clear blockage experiment was convincingly shown. After blocking the SSRs with a high 
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dosage of RC-160 almost 50% of the antitumor effect can still be obseved. In addition, no 
explanation was given by the authors when they observed that AN-238, AN-201 and DOX in 
equitoxic doses had the same growth inhibition in HCT-116 colon carcinoma tumor model 
despite the fact that the tumor cell line was SSR-positive. 
Most of the preclinical studies, except the first study, were performed in nude mice, so human 
cancer lines could be tested. However, it would be also interesting to perform more studies in 
immune-competent animals in order to evaluate anti-tumor effect as a resultant of the immune 
system as well. 
Despite these critics AN-238 seems an interesting option in the treatment of (SSR-positive) 
cancers. 
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ABSTRACT 
In previous studies, the group of Schally et al. showed impressive results with the 
cytotoxic somatostatin analog, AN-238 in various tumors expressing somatostatin 
receptors (SSRs). AN-238, which consists of 2-pyrrolinodoxorubicin (AN-201) linked 
to the somatostatin carrier RC121, can be targeted to SSR-positive tumors. 
We investigated whether AN-238 could be used for treatment of in vitro SSR-
transfected colon carcinoma cells (CC2B) in a rat liver metastases model, in which we 
previously shown highly effective treatment with radiolabeled octreotide. 
SSR-positive (transfected) CC2B and their parental SSR-negative CC531 cell line 
were tested in vitro with AN-238, AN-201 and doxorubicin (DOX) with and without 
addition of cyclosporin A (CsA). Hereafter two in vivo experiments were performed 
in which CC2B or CC531 cells were injected in the portal vein of rats, after which 
liver metastases were caused. A single injection of AN-238 at 200 nmol/kg or PBS 
(controls) on day  7 was administered i.v. in the first experiment. In the second 
experiment two injections of AN-238 at 250 nmol/kg or PBS (controls) on day 5 and 
13 was administered i.v. WBC and body weight was measured twice a week to 
observe toxicity of the treatment. 
In vitro exposure of CC531 or CC2B cells with AN-238 showed an equal IC50 for 
both cell lines, despite the presence of SSRs on CC2B cells. An attempt to make both 
cell lines more sensitive for AN-201/AN-238 with the p-glycoprotein pump inhibitor, 
CsA, was not effective. The use of AN-238 in vivo had no anti-tumor effect in both 
experiments. The severe (myelo)toxicity observed in AN-238 treated rats in the 
second in vivo experiment even resulted in a significant higher tumorscore compared 
with controls. 
In conclusion, nor our in vitro either our in vivo data showed superior anti-tumor 
effect of AN-238 despite the presence of SSRs on CC2B cells compared with CC531 
cells.
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INTRODUCTION 
Colon carcinoma is the third most common cancer and second leading cause of cancer 
deaths in the United States1. Despite improvements in early diagnosis, surgical 
techniques, and adjuvant chemotherapy, at least one-third of patients operated “for 
cure” die of recurrent local disease and metastases2-4. Cancer chemotherapy is limited 
by multidrug resistance (MDR) of tumor cells and toxicity of normal cells5-7.  
Several drugs have been reported to reverse MDR in vitro. One of the most effective 
reverters is the immunosuppressive drug cyclosporin A (CsA)8. Many in vitro studies 
have shown an increase in cytotoxicity to MDR cell lines when CsA is added to drugs 
that are affected by the MDR cross-resistance pattern, like doxorubicin, vincristine 
and colchicines9-11. Chemosensitization by CsA is mediated by p-glycoprotein. The 
cytotoxicity to parental cell lines that do not express p-glycoprotein is not 
influenced12. 
To increase the effectiveness of chemotherapy doses can be escalated, but toxicity 
limits the height of the dose. A more selective delivery of chemotherapy to primary 
tumors and their metastases would allow a dose escalation and reduce the peripheral 
toxicity7. 
A well established method to deliver selectively chemotherapy to tumor cells is to 
attach chemotherapeutic compounds covalently to hormones, for which receptors or 
antibodies are present on tumor cells13,14 . 
Somatostatin receptors (SSRs) are expressed in most neuro-endocrine tumors, but also 
in lymphomas and breast cancer. The group of Schally et al. recently developed a 
cytotoxic somatostatin analog (AN-238)15. AN-238 is composed of the doxorubicin 
derivate, 2-pyrrolinodoxorubicin (AN-201), and is linked to the somatostatin analog, 
RC-121. AN-201 is 500 – 1000 times more active in vitro than its parent compound15. 
In numerous in vitro and in vivo studies Schally et al. showed strong tumor growth 
inhibition in various human and rat SSR-postive tumors after treatment with AN-238 
with low peripheral toxicity (transient fall of body weight and WBC)16-26. 
The aim of this study was to transfect SSR-negative tumor cells with a SSR-gene in 
order to make them feasible for therapy with AN-238 in rat liver metastases model. 
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MATERIAL AND METHODS 
Animals 
Male inbred Wag/Rij rats, 10 to 14 weeks old and 225 to 250 g, were obtained from 
Harlan-CPB (Horst, The Netherlands). Animals were kept under standard laboratory 
conditions (12 hr light/ 12 hr dark) and given a standard laboratory diet (Hope Farms, 
Woerden, The Netherlands) and water ad libitum. The experimental protocol adhered 
to the rules of the Dutch Animal Experimental Act and was approved by the 
Committee on Animal Research of the Erasmus University. 
 
Tumor 
CC531 is a SSR-negative, moderately differentiated rat colon carcinoma, induced by 
1,2-dimethylhydrazine and is transplantable in syngeneic WAG/Rij rats27. The tumor 
is maintained in tissue culture as a monolayer in RPMI 1640 medium (Gibco, Paisley, 
UK) supplemented with 5% fetal calf serum (FCS). Cells were harvested from 
stationary cultures by gentle trypsinisation (Boehringer, Mannheim, Germany). A 
suspension of 0.5 x 106 living cells was used for direct injection into the portal vein 
1,3. 
 
SSR Transfection and Expression 
For expression of the somatostatin receptor-subtype 2 (sstr2)  in CC531 cells, human 
sstr2 cDNA in pBluescript (pBS) (a kind gift of G.I. Bell, Howard Hughes Medical 
Institute, Chicago, IL, USA) was excised form pBS and inserted into the Nhe-1/Sali 
cloning site of the retroviral expression vector pCi-neo. Selection was made by the 
geneticine resistance gene (G418). This vector was used to stable transfect (using 
lipofectin) CC531 cells. Transfectants were selected and cultured in RPMI 1640 
supplemented with 5% FCS and geneticine (0.5 mg/mL) (Gibco, Paisley, UK). 
Geneticine-resistant clones were examined for their ability to bind with [125I-
Tyr3]octreotide. The clone with the highest expression (Scatchard analysis) of SSR 
was isolated and named CC2B. 
 
In vitro SSR Autoradiography 
In frozen tumor samples SSRs were measured by autoradiography on 10 µm cryostat 
sections. 10-10 M [125I-Tyr3]octreotide, as a radioligand, was used. Incubation and 
washing conditions were as described4. Non-specific binding was determined by 
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adding an excess (10-6 M) of non-radiolabeled octreotide. Radioactivity was measured 
72 hours in a Cyclone Storage Phosphor Screen (Packard Bioscience company, 
Meriden, USA.The screens were analysed using a Cyclone Phospor Imager (Packard 
Instruments Co, Groningen, The Netherlands)28.  
 
Chemicals 
AN-238, AN-201, RC121 was a kind gift of Dr. A. Nagy (Tulane University, New 
Orleans, Louisiana, USA). Cyclosporin A was obtained from Sandoz.(Basel, 
Switzerland). Doxorubicin (Adriblastina (10 mg / 5 mL) was obtained from 
Pharmacia and Upjohn (Woerden, The Netherlands). 
 
In vitro cytotoxicity 
We determined chemosensitivity in vitro by DNA analysis described by Hofland et 
al.29. 
In brief, in 24-well culture plates (Costar, Badhoeverdorp, The Netherlands) 10.000 
CC531 or CC2B cells were cultured in 1 mL 1640 RPMI enriched with 1% fetal calf 
serum (FCS) (Life Technologies, Breda, The Netherlands) and placed in an incubator 
with a humidified atmosphere of 95% / 5% CO2 at 37 C. The next day all wells were 
washed twice with 0.9% NaCl in order to wash away superfluous non-adherent cells. 
Hereafter, the cells were incubated with the different chemicals in 1 mL medium with 
1% FCS in an incubator. Concentration of AN-238 or AN-201 used were: 0.01, 0.1, 1, 
10 and 100 nM. Concentration of doxorubicin used were: 0.034, 0.34, 3.4, 34 and 340 
µM. Concentration of CsA used were: 0.5, 1 and 1.5 mM. After 72 hours , the plates 
were collected by washing away superfluous non-adherent cells and kept at –20 C for 
DNA analysis. 
 
DNA analysis 
The total DNA content of each well was measured using bisbenzimide dye 
(Boehringer Diagnostics, La Jolla, California, USA) as described previously by 
Hofland et al.29. The DNA measured represents the total amount of cells per well. 
 
Experimental Procedure 
Under ether anesthesia, the abdomen was opened through a 2.5 cm midline incision. 
Then, 0.5 x 106 viable SSR-positive CC2B cells or SSR-negative CC531 cells in 0.5 
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mL RPMI 1640 were injected slowly into the portal vein through a 0.4 x 12 mm 
needle. The abdominal wall was closed in one layer by a continuous silk suture30-32. 
The day after the operation, rats were randomized in an experimental and control 
group.  
Experiment 1: Each group consisted of 7 or 8 rats. Rats of the experimental group 
were treated with 200 nmol/kg AN-238 i.v. on day 7. Rats in the control group were 
injected with PBS i.v. 
Experiment 2: Each group consisted of 8 or 9 rats. Rats of the experimental group 
were treated with 250 nmol/kg AN-238 i.v. on days 5 and 13. Rats in the control 
group were injected with PBS i.v. 
For both experiments, twice a week body weight were measured and blood samples of 
all rats were taken by tailcut for WBC.  
All rats were sacrificed after 21 days after inoculation of tumor cells. Livers were 
removed, washed and immersed in PBS. Tumor growth was determined by 2 
independent investigators counting the number of metastases on the surface of the 
liver lobes (up to 100) while blinded for treatment modality. The number of 
metastases were subdivided in a semi-quantative tumorscore as presented in table 1. 
Tumor tissue was snap frozen in liquid nitrogen for autoradiography to determine in 
vivo somatostatin receptor status of the tumor 
 
Statistical Analysis 
Statistical analysis of the data was performed using one-way analysis of variance. 
When significant effects were obtained by analysis of variance, multiple comparison 
were made by the Newmann-Keuls test. Statistical significance was defined as p< 
0.05. 
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RESULTS 
In vitro cytotoxicity of CC531 and CC2B cells 
To evaluate the anti-tumor activity of AN-201 and AN-238 in vitro cytotoxicity 
experiments were performed. Exposure of CC531 or CC2B cells to these chemicals 
resulted in a dose response curve with an IC50 for AN-201 of 0.9 and 1.0 nM and an 
IC50 for AN-238 of 0.5 and 0.4 nM respectively (fig 1). Exposure of CC531 or CC2B 
to DOX resulted in an IC50 of approximately 0.2 µm (fig. 1b). As in previous studies 
van de Vrie et al.33 showed that CC531 cells have p-glycoprotein pump, which could 
be inhibited by CsA, therefore we performed these experiments in combination with 
different doses of CsA, in an attempt to make these cells more sensitive to AN-
201/AN-238. A dose depended growth reduction was observed when both CC531 and 
CC2B cells were exposed to CsA alone with a maximum reduction of  26% at 2 nM 
(Fig. 1b). However, addition of CsA to  AN-201 or AN-238 did not influence the 
sensitivity of the cells to AN-201 or AN-238 significantly (Fig.1a) 
 
Fig 1a: The effect of AN-201 or AN-238 with or without CsA on CC531 (A + C) and CC2B (B 
+ D) 
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Fig 1b: The effect of DOX on CC531 or CC2B (left) and the effect of CsA on CC531 and 
CC2B cells (right). 
 
 
In vivo experiments 
The effects of cytotoxic SS analog AN-238 on tumorscore, bodyweight (BW) and 
WBC in rats bearing CC531 or CC2B liver metastases are shown in table 1 and 2 and 
figure 1a and b, respectively. In the first experiment, AN-238 was tested in a single 
dose (200 nmol/kg) i.v. on day 7. As expected, no significant differences in 
tumorscores were seen between treated rats compared with control rats with CC531 
liver metastases (2.00 ± 0.82 vs. 1.78 ± 0.83). However, also no significant difference 
in tumorscores were seen between treated rats compared with control rats with CC2B 
liver metastases (3.00 ± 1.00 vs. 2.75 ± 0.71). 
None of the rats died of the toxicity of the treatment. BW in the treated rats was 
slightly lower than control rats on day 11 (4%) (fig. 2a). On day 12 treated rats had an 
average decrease of 27% in WBC compared with control rats (fig 2b). 
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Number of animals with 0 to >100 CC2B metastases 
No. of metastases 0 1 – 20 21 – 50 51 – 100 >1001 >1002 
Rank 0 1 2 3 4 5 
Controls - - 3 4 1 - 
AN-238 - - 3 1 3 - 
 
Table 1: Number of animals with given range of metastases, 21 days after direct injection of 
CC2B tumor cells in the protal vein. The effect of AN-238 (200 nmol/kg) injected on day 7 is 
not significantly different (p>0.05) from that of controls. 
1 >100 liver metastases, but <50% of the liver affected 
2 >100 liver metastases, but >50% of the liver affected 
 
Number of animals with 0 to >100 CC531 metastases 
No. of metastases 0 1 – 20 21 – 50 51 – 100 >1001 >1002 
Rank 0 1 2 3 4 5 
Controls - 3 2 2 - - 
AN-238 - 2 3 2 - - 
 
Table 2: Number of animals with given range of metastases, 21 days after direct injection of 
CC531 tumor cells in the protal vein. The effect of AN-238 (200 nmol/kg) injected on day 7 is 
not significantly different (p>0.05) from that of controls. 
1 >100 liver metastases, but <50% of the liver affected 
2 >100 liver metastases, but >50% of the liver affected 
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Fig 2: weight (table A) and WBC (table B) of the rats per group during the time of the 
experiment.         Indicates the day(s) of treatment. 
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While no anti-tumor effects were seen in experiment 1, we did another experiment, in 
which we injected two dosages of AN-238 (250 nmol/kg) i.v. on day 5 and day 13 
(Table 3 and 4). Again as expected, no significant differences in tumorscores were 
seen between treated rats compared with control rats with CC531 liver metastases 
(5.00 ± 0.00 vs. 4.33 ± 0.71). Surprisingely, in experiment 2 tumorscores of treated 
rats were significantly higher (p<0.05) compared with control rats with CC2B. 
Two treated rats of the CC2B group died of the toxicity of the treatment on day 21 
(just before sacrification). BW in the treated rats was 7% lower on day 9 and 11% 
lower on day 16 compared with control rats (fig 3a). This type of dosage scheme of 
AN-238 had severe myelotoxic effects, as shown by an average decrease in WBC of 
38% on day 12 and a 78% decrease on day 21 compared with control rats (fig 3b). 
 
Number of animals with 0 to >100 CC2B metastases 
No. of metastases 0 1 – 20 21 – 50 51 – 100 >1001 >1002 
Rank 0 1 2 3 4 5 
Controls - - 2 3 2 1 
AN-238 - - - 1 1 6 
 
Table 3: Number of animals with given range of metastases, 21 days after direct injection of 
CC2B tumor cells in the protal vein. Control rats had significantly less liver metastases 
(P<0.05) compared with rats treated with AN-238 (250 nmol/kg) injected on days 5 and 13. 
1 >100 liver metastases, but <50% of the liver affected 
2 >100 liver metastases, but >50% of the liver affected 
 
Number of animals with 0 to >100 CC531 metastases 
No. of metastases 0 1 – 20 21 – 50 51 – 100 >1001 >1002 
Rank 0 1 2 3 4 5 
Controls - - - 1 4 4 
AN-238 - - - - - 8 
 
Table 4: Number of animals with given range of metastases, 21 days after direct injection of 
CC531 tumor cells in the protal vein. The effect of AN-238 (250 nmol/kg) injected on days 5 
and 13 is not significantly different (p>0.05) from that of controls. 
1 >100 liver metastases, but <50% of the liver affected 
2 >100 liver metastases, but >50% of the liver affected 
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Figure 3: weight (table A) and WBC (table B) of the rats per group during the time of the 
experiment.          Indicates the day(s) of treatment. 
 
Autoradiography 
As figure 4 shows CC2B tumor colonies stain black after addition of [125I-
DOTA,Tyr3]octreotate, while no staining occurs on CC531 tumor colonies, indicating 
that the SSR is highly expressed on CC2B tumor colonies. When the SSR is blocked 
by an excess of non-radiolabeled octreotide and this experiment is repeated non-
specific binding is low. 
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Figure 4: Examples of two frozen slides with liver metastases tissue of control rats with 
CC531 (down) and CC2B (up) liver metastases, respectively. H.E.: Hematoxylin-eosin 
staining shows the localization of the tumor colonies surrounded by normal liver 
parenchyma. 125I-Octr. =  In vitro autoradiography clearly visualizes the SSRs on the  CC2B 
tumor colonies, in contrast to CC531 liver metastases tissue. Block = When the SSR is 
blocked by an excess of non-radiolabeled octreotide non-specific binding is low. 
CC2B 
CC531 
125I-Octr. BlockH.E. 
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DISCUSSION 
In previous studies we showed that therapy with radiolabeled octreotide and other 
somatostatin analogs could inhibit tumor growth strongly. This mechanism was SSR 
mediated, and succesfull treatment was only seen in tumors expressing SSRs. 
In recent studies chemotherapy targeted to hormone receptors on tumors was also 
used to achieve a more effective and selective drug delivery to these tumors and 
thereby reducing peripheral toxicity. Since treatment with radiolabeled octreotide was 
highly effective in SSR transfected tumors, we wanted to investigate whether 
treatment with AN-238, a doxorubicin derivate linked to a SS analog, was also 
feasible in our tumor model. Moreover, in previous studies, performed by the group of 
Schally, AN-238 was used in two or more different tumor cell lines (SSR-positive or 
–negative). The authors concluded that the obtained anti-tumor effect of AN-238 was 
the result of the expression of the SSRs on the tumor cell lines, since the SSR-positive 
tumor cell lines showed a significant anti-tumor effect after treatment of AN-238, in 
contrast to the SSR-negative tumor cell lines. However, the differences in anti-tumor 
effect might also be attributed to the fact that two or more different tumors were used, 
which can have differences in degrees of chemosensitivity. In order to overcome this 
problem a SSR-negative cell line can be transfected with a SSR-gene, after which 
AN-238 can be tested in this SSR-negative and –positive cell line with the same 
chemosensitivity, resulting in a honest comparison. 
Therefore,  we transfected CC531 (SSR-negative) cells with a SSR-gene, so CC2B 
(SSR-positive) and CC531 cells could be compared in one tumor model.  
First the in vitro cytotoxicity of AN-238 and AN-201 was tested. Both CC531 as 
CC2B showed a dose depended growth inhibition after addition of the 
chemotherapeutical drugs. Interestingly, AN-238 had a lower IC50 than AN-201 for 
both cell lines, despite the fact that CC531 is SSR-negative. In comparison to the cell 
lines used in a in vitro study by Nagy et al.15, the chemosensitivity of these cell lines 
was slightly better compared to our cell lines (IC50 ranged from 0.18 and 0.5 nM for 
both AN-201 and AN-238). In our data no advantage of the SSR expression was seen, 
while AN-238 had no significant difference in IC50 for CC531 and CC2B. As our 
chemotherapeutics were incubated for three days, we hypothesised that maybe the 
chemotherapeutical compounds may diffuse direcly into the cell in such a long 
incubation period in stead of a receptor mediated internalisation. In order to 
investigate whether a shorter incubation period could show a SSR mediated process, 
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we repeated our experiment, but this time the incubation period of the 
chemotherapeutical drugs was just 15 or 30 minutes. In this condition again no 
significant differences in IC50 could be shown (data not shown). Incubation of our 
tumor cells with DOX resulted in an IC50 of 0.2 µm, which means that AN-201 is 
about 200 – 400 times more potent in vitro compared with DOX. In contradictory, 
Nagy et al. claimed that AN-201 was 500 – 1000 times more potent than DOX. One 
of the reasons why we found  a less potent factor may be due to the p-glycoprotein 
pumps, that CC531 cells contain. In order to make our cell line more sensitive for 
AN-201 (and also AN-238), we performed another in vitro study, in which AN-201 
and AN-238 was tested with and without addition of different doses CsA, a strong p-
glycoprotein pump inhibitor34. However, no additional significant influence of CsA 
on the chemosensitivity of the tumor cells to AN-201 or AN-238 was found.  
Despite the fact no specific receptor mediated therapy could be shown in vitro, we 
performed an in vivo experiment, in order to elucidate whether a SSR mediated 
process could be shown in this case. In our first in vivo experiment no anti-tumor 
effect was seen with a single injection of AN-238 at 200 nmol/kg on day 7. In most of 
the in vivo studies performed by the group of Schally et al. strong anti-tumor effects 
were obtained in comparable dosages schemes16-26. While no anti-tumor effects were 
seen and the in vitro data showed a relatively poor chemosensitivity, we decided to 
perform another in vivo experiment, in which we escalated the dosages scheme to two 
injections of AN-238 at 250 nmol/kg on day 5 and day 13. Again, no anti-tumor effect 
was seen. Interestingly, even higher tumorscores of treated rats with CC2B liver 
metastases were seen compared with control rats. This can be attributed to the fact 
that CC531 (as CC2B) is an immunogenic tumor and a severe myelotoxic effect was 
seen in this dosage-scheme, resulting in a an immunosupressive status of the treated 
rats. Similar results were reported by van de Vrie et al.35, who showed enhancement 
of locoregional metastases after treatment with an immunosupressive drug, 
cyclosporin A. Also the treated rats with CC531 liver metastases in our second in vivo 
experiment had higher tumorscores, although these scores were not significant 
different, probably due to the fact that all rats in this group already had a maximum 
tumorscore of 5 and no higher tumorscore could be given to these treated rats. While 
no effect was seen in the treated rats, we evaluated the SSR-status of the SSR-
transfected liver metastases by an autoradiographical study. Clearly, a high expression 
of SSR was shown in CC2B liver metastases, which also could be specifically 
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blocked by non-radiolabeled octreotide. As expected, no SSR were visualized in 
CC531 liver metastases. Moreover, we previously showed that the transfected SSR 
was also functional in vitro and in vivo, as it could internalize radiolabeled 
octreotide36.  
A possible explanation why the treatment with AN-238 did not work in our model, 
might be attributed to the serum levels of carboxylesterases (CE). AN-201 is a 
cytotoxic doxorubicin derivate, which is linked to the somatostatin analog, RC-121. In 
these conjugates, the glutaric acid spacer is linked to the cytotoxic radicals through an 
ester bond that is sensitive to hydrolysis by CE in blood. However, it is known that 
difference in enzymatic activity can be different in various animals and species. In a 
preliminary study Nagy et al. reported different t½ of AN-152, an LH-RH analog 
containing doxorubicin, in the serum of nude mice, Copenhagen rats, and men was 
about 10, 30 and 120 minutes, respectively37. These difference were based on 
differences in enzymatic activity of CE in the various animals. The enzymatic activity 
of CE in WAG/Rij rats, used in our experiments, is not known, but a high enzymatic 
activity can lead to hydrolysis of the ester bond, leading to a toxic dose of AN-201, 
which is not targeted anymore, consequently leading to severe myelotoxic effects and 
enhancement of tumor growth. This can also explain why reasonable antitumor effects 
were seen in vitro, comparable with in vitro results of the group of Schally et al., 
which surprisingly were not observed in vivo. Diisopropyl fluorophosphate (DFP) can 
inhibit CE. Nagy et al. showed significantly prolonged t½ of AN-152 and less toxic 
effects of AN-238 in nude mice after addition of DFP37. In future experiments 
addition of DFP to AN-238 may also lead to a more effictive treatment in WAG/Rij 
rats. 
Another reason why our results were not comparible with the group of Schally et al., 
may be due to a difference in chemosensitivity of the used cell line. Although, in vitro 
data showed slightly less chemosensitivity, Geutskens et al. showed a large in-frame 
deletion, with junctions in exon 4 and 8, lacking the entire DNA-binding domain of 
the p53-gene38. Moreover, no wild-type p53 allele was retained and functional 
analysis showed that the mutated protein could repress the function of wild-type p53 
protein. These findings may explain that our used cell line is relatively chemoresistant 
and consequently the obtained results of our experiments were poor.  
In conclusion, our in vitro and in vivo results showed no clear SSR-mediated process 
of AN-238 on the CC2B cell line, despite the presence of SSRs. In contrast, therapy 
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with [177Lu-DOTA0-Tyr3]octreotate resulted in highly effective anti-tumor activity in 
the same rat liver metastases model with the same CC2B cell line. 
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SUMMARY 
Chapter 1 is the general introduction of this thesis. An overview of somatostatin, the 
effect of somatostatin on cell growth, somatostatin receptors (SSRs) and principles of 
gene therapy, concerning vectors, targeting and cancer gene therapy strategies is 
given. 
 
In Chapter 2 the aims of the thesis are summarized. 
 
SSRs have been found on a variety of neuroendocrine tumors like carcinoids, 
paragangliomas, as well as on most pancreatic endocrine and breast tumors. SSR 
scintigraphy with a radionuclide labeled somatostatin analog, [111In-DTPA0]octreotide 
(Octreoscan®), is a sensitive and specific technique to visualise in vivo the presence 
of SSRs on various tumors. Chapter 3 is an introduction of Octreoscan®. Both 
diagnostic, but also therapeutic purposes are discussed. Material was identified from 
previous review articles, references citated in original papers and a Medline search of 
the literature. Additional material was obtained from recently published abstracts of 
meetings. 
SSR imaging of neuroendocrine tumors is essential in the diagnostic work up for most 
of these tumors. The expression of SSR in vivo not only predicts the outcome of 
somatostatin analog treatment but also opens the possibility for new therapeutic 
strategies. Since better information about spread of the disease can be obtained, more 
justified therapy options can be proposed, like Peptide Receptor Radionuclide 
Therapy (PRRT). PRRT results in a highly effective treatment for SSR-positive 
tumors in both experimental but also clinical setting. 
 
Unfortunately, not all human tumors express SSRs on their cell surface, thus 
consequently PRRT is not applicable for these tumors. 
However, recent developments in molecular biology have made it possible to transfect 
the SSR-gene on SSR-negative tumor cells. In Chapter 4, SSR-negative colon 
carcinoma cells (CC531) were transfected with a SSR-gene in vitro and named CC2B 
hereafter. Scatchard analysis showed high expression of SSRs and a high binding 
affinity of CC2B cells. Moreover, the transfected SSR was also functional as it could 
internalize radiolabeled octreotide. Growth speed and other growth characteristics of 
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CC2B did not differ significantly in vitro compared with their parental tumor cell line 
CC531. 
All the above mentioned features of the CC2B cell line fulfil to the conditions to 
apply this SSR-transfected cell line in an in vivo model to perform future experiments 
in which PRRT will be tested. 
 
Chapter 5 evaluates the effect of PRRT with 370 MBq (0.5 µg) [111In-
DTPA0]octreotide on SSR-negative CC531 and SSR-transfected CC2B liver 
metastases in the rat. 
Liver metastases were caused by injection of CC531 or CC2B cells in the portal vein 
in rats on day 0. On day 7 in half of the rats 370 MBq (0.5 µg) [111In-
DTPA0]octreotide was administered, while the other half of the rats did not receive 
treatment. On day 28 all rats were sacrificed so tumorscores could be counted. 
No significant difference in tumorscore was seen in rats treated with PRRT vs. control 
animals with CC531 liver metastases. However, also no significant diffence in 
tumorscore was seen in CC2B liver metastases (PRRT vs. control). Autoradiography 
confirmed high SSR expression in CC2B liver metastases tissue, while absent in 
CC531 liver metastases. High uptake and retention of radioactivity in CC2B tumor 
was measured, indicating that the transfected receptor was functional. Moreover, the 
measured radioactivity and radiation dose was comparable with our positive control 
tumor CA20948, indicating that at our given dosage CC2B is not radiosensitive, 
which we could demonstrate in a clonogenic assay of our tumor cell lines treated with 
external radiation. 
Although no antiproliferative effect of PRRT was seen on SSR transfected CC531 
cells, we conclude that (1) SSR adherence, (2) internalization and (3) retention of 
radioactivity in the tumor cell did take place, indicating we transfected a functional 
receptor, but unfortunely the cell line was radioresistant to the given dosages. 
 
177Lutetium is a β-emitting radionuclide, which emits β-particles in a range of 
approximately 2 mm with high energy (0.5 MeV). As a result of this higher energy 
and consequently larger tissue penetration, this radionuclide could be more 
advantegeous compared with 111Indium for PRRT in the treatment of 
micrometastases. As most SSR-positive tumors are heterogeneous in expression the 
use of 177Lu in PRRT results in radiation of these SSR-negative clones after the 
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radionuclide is internalized in neighbouring SSR-positive clones of the tumor. In 
addition, the use of octreotate in stead of octreotide results in a 3 to 4 times higher 
uptake in SSR-positive tumors, which consequently may lead to a more effective 
antitumor activity as well. 
In Chapter 6, a study is presented in which the effect of [177Lu-DOTA0, 
Tyr3]octreotate on SSR-positive CA20948 rat pancreas carcinoma cells in an in vitro 
and in vivo experiment was evaluated. 
CA20948 (SSR-positive) cells was injected in the portal vein of rats, and subsequently 
liver metastases developed. Treated rats (185 or 370 MBq [177Lu-
DOTA0,Tyr3]octreotate) had significant less liver metastases compared to control rats 
(p<0.001) 21 days after injection of tumor cells. Moreover, treated rats showed a 
significant increase in survival (p<0.05). Finally, an in vitro PRRT single cell model 
with [177Lu-DOTA0,Tyr3]octreotate showed also a dose-dependent toxicity of  
CA20948 in contrast to SSR-negative CC531 tumor cells, underlining the importance 
of the SSR with this kind of therapy. 
In conclusion, [177Lu-DOTA0,Tyr3]octreotate was shown to be a very promising new 
treatment modality for disseminated SSR-positive tumors 
 
As described in Chapter 5, PRRT with [111In-DTPA0]octreotide was not effective in 
SSR-transfected liver metastases, because the transfected cell line was relatively 
radioresistant to our given dosages. Chapter 6 clearly shows the advantages of  [177Lu-
DOTA0,Tyr3]octreotate, a β-emitting radionuclide with higher energy compared to 
111Indium, for the treatment of SSR-positive liver metastases. The aim of the study, 
described in Chapter 7, was to evaluate the effect of [177Lu-DOTA0,Tyr3]octreotate 
on SSR-transfected colon carcinoma cells in a rat liver metastases model.  Liver 
metastases were developed after intraportal injection of these tumor cells 
(CC2B/CC2B) in rats. On day 7, animals were treated with 185 or 370 MBq [177Lu-
DOTA0, Tyr3]octreotate, while control animals did not receive treatment. After 21 
days rats were sacrificed and liver metastases were counted.  
Treatment with 370 MBq [177Lu-DOTA0, Tyr3]octreotate showed an impressive anti-
tumor response in rats with CC2B liver metastases (SSR-positive) in comparison to 
controls (p<0.001), while no significant anti-tumor effect was seen in PRRT treated 
rats with CC531 liver metastases (SSR-negative). Also a (dose-dependent) tumor 
response was seen in rats with CC2B liver metastases treated with lower dose, 185 
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MBq [177Lu-DOTA0, Tyr3]octreotate compared with controls (p<0.01). In addition, 
rats with mixed liver metastases (half SSR-positive/half SSR-negative) treated with 
185 MBq [177Lu-DOTA0, Tyr3]octreotate had significant less metastases compared 
with controls (p<0.05), which may be due to a radiological bystander effect of [177Lu-
DOTA0, Tyr3]octreotate. This phenomenon is beneficial in the concept of in vivo gene 
therapy. 
 
AN-238, a cytotoxic somatostatin analog, is made of 2-pyrrolinodoxorubicin (AN-
201) linked to the somatostatin analog, RC-121. AN-201 is claimed to be 500-1000 
times more potent than doxorubicin in vitro. In Chapter 8 an overview of the current 
literature about the cytotoxic somatostatin analog, AN-238, is given. Synthesis, 
mechanism of action and oncological studies with AN-238 performed by the Schally 
group are discussed. 
Summarizing, just like PRRT, AN-238 also had impressive tumor growth inhibition 
on various SSR-positive tumor cell lines. 
 
As impressive results were shown with AN-238 on various SSR-positive tumors, we 
were curious whether AN-238 was also effective in the treatment of SSR-transfected 
liver metastases, in which we previously shown highly effective treatment with 
PRRT. This was evaluated in Chapter 9.  
SSR-positive (transfected) CC2B and their parental SSR-negative CC531 cell line 
were tested in vitro with AN-238, AN-201 and doxorubicin (DOX) with and without 
addition of cyclosporin A (CsA). Hereafter two in vivo experiments were performed 
in which CC2B or CC531 cells were injected in the portal vein of rats. A single 
injection of AN-238 at 200 nmol/kg or PBS (controls) on day  7 was administered i.v. 
in the first experiment. In the second experiment two injections of AN-238 at 250 
nmol/kg or PBS (controls) on day 5 and 13 was administered i.v.. WBC and body 
weight was measured twice a week to observe toxicity of the treatment. 
In vitro exposure of CC531 or CC2B cells with AN-238 showed an equal IC50 for 
both cell lines, despite the presence of SSRs on CC2B cells. An attempt to make both 
cell lines more sensitive for AN-201/AN-238 with the p-glycoprotein pump inhibitor, 
CsA, was not effective. The use of AN-238 in vivo had no anti-tumor effect in both 
experiments. The severe (myelo)toxicity observed in AN-238 treated rats in the 
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second in vivo experiment even resulted in a significant higher tumorscore compared 
with controls. 
In conclusion, nor our in vitro either our in vivo data showed superior anti-tumor 
effect of AN-238 despite the presence of SSRs on CC2B cells compared with CC531 
cells. These results are discrepant with the data of the group of Schally et al.. 
 
CONCLUSIONS 
• In vitro SSR-transfection of CC531 is possible. After transfection a high 
expression of functional SSRs with a high binding affinity is found.  
• PRRT with [111In-DTPA0]octreotide is not effective for SSR-transfected 
CC531 cells in a rat liver metastases model, as the cell line is relatively 
radioresistant. 
• PRRT with [177Lu-DOTA0, Tyr3]octreotate is highly effective for SSR-positive 
CA20948 cells in a rat liver metastases model. Treatment of animals resulted 
in an increased survival. 
• PRRT with [177Lu-DOTA0, Tyr3]octreotate is highly effective for SSR-
transfected CC531 cells in a rat liver metastases model. Even in mixed (SSR-
positive/SSR-negative) tumors PRRT with this agent is effective, probably due 
to a radiological bystander effect. 
• Targeted therapy with the cytotoxic somatostatin analog, AN-238, is not 
effective for SSR-transfected CC531 cells in a rat liver metastases model. Nor 
in vitro nor in vivo any SSR-targeting of AN-238 could be shown. 
 
FUTURE ASPECTS 
As stated above, SSR gene therapy combined with PRRT seems to be a promising 
strategy for the treatment of liver metastases. In our studies the SSR-gene was 
transfected in vitro. However, if this method wants to have clinical relevance, SSR 
gene therapy has to be performed in vivo. In this case the hypotheses is applicable 
that, if higher transduction rates are achieved in vivo better response of the gene 
therapy is to be expected. This can be achieved through many factors, such as better 
vectors with the use of specific promotors. These promotors could enhance 
transduction rates in metastases tissue specifically. Also methods in which the vector 
is delivered locally, such as isolated hepatic perfusion or intrahepatic artery infusion, 
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could contribute to higher transduction rates, consequently leading to better results of 
the treatment. The developments in gene therapy are currently very rapid. With every 
month more than hunderds of newly published articles, in which new methods and 
strategies of gene therapy are described, improvements in this field are to be expected 
in the near future. 
For PRRT, besides 111In and 177Lu, other radionuclides such as 90Y (Yttrium) have 
also been proposed for coupling to somatostatin analogs. 90Y, with a half-life of 2.7 
days, is a pure high-energy β emitter with a tissue range up to 12 mm. 177Lu works 
optimally in small tumors where 90Y is better for larger tumors1,2. In a study 
combinations of these two radionuclides in PRRT resulted in a significant longer 
survival in rats bearing small and large tumors simultaneously, mimicing the clinical 
situation, in which small and large metastases are usually present in the same patient3. 
Moreover, also new stable somatostatin analogs with high affinity for different SSRs 
are currently being developed. An example is [DOTA, 1-NaI3]octreotide, which has a 
high affinity for  sst1, sst3 and sst54. Through this compound PRRT can also bind to 
tumors expressing sst3 and sst5, which receptors can not bind with such a high affinity 
on octreotide or octreotate. 
A major problem in PRRT is caused by the uptake of radioactivity in the kidneys: 
small peptides in the blood plasma are filtered through the glomerular capillaries in 
the kidneys and subsequently reabsorbed by and retained in the proximal tubular cells. 
Renal uptake of the radioactivity can be reduced by 40 percent by intravenous 
administration of a combination of L-lysine and L-arginine. Clinically PRRT with 
somatostatin analogs should be carried out with co-infusion of these aminoacids5. 
Other methods to reduce toxicity are currently under investigation. 
Also the concept of surgery in combination of PRRT is an interesting option in the 
treatment of SSR-positive tumors. The use of radiolabeled octreotide may be 
considered in an adjuvantal setting to eradicate occult metastases, possibly originating 
from tumor spill after surgery. Starting therapy, directly after surgery is favourable, 
because of the small tumor burden. However, the application of PRRT can be also 
given at a later stage. For example, in patients with non-resectable SSR-positive 
tumor(s), PRRT can be applied as a first step to reduce tumor size or number, 
followed by surgery. 
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SAMENVATTING 
Hoofdstuk 1 is de algemene introductie van dit proefschrift. Er wordt een overzicht 
over somatostatine, het effect van somatostatine op celgroei, somatostatinereceptoren 
(SSRs) en principes van gentherapie, betreffende vectoren, targeting en kanker 
gentherapie-strategieen gegeven. 
 
In Hoofdstuk 2 zijn de doelstellingen van dit proefschrift samengevat. 
 
SSRs worden op verscheidene neuroendocriene tumoren, zoals carcinoiden, 
paragangliomen, maar ook op de meeste endocriene alvleesklier- en borsttumoren, 
gevonden. SSR scintigrafie met behulp van radionuclide gelabelde somatostatine 
analoog, [111In-DTPA0]octreotide (Octreoscan®), is een sensitieve en speciefieke 
techniek om de aanwezigheid van SSRs op vershillende tumoren te visualizeren. 
Hoofdstuk 3 is een introductie over Octreoscan®. Zowel diagnostische maar ook 
therapeutische doeleinden worden besproken. Materiaal werd geidentificeerd uit 
voorgaande review-artikelen, geciteerde referenties van originele stukken en een 
Medline-zoekopdracht van literatuur. Additionele materiaal werd gebruikt uit recent 
gepubliceerde abstracts van congressen. 
SSR imaging van neuroendocriene tumoren is essentieel in de diagnostische 
uitwerking van de meeste van deze tumoren. De expressie van SSRs in vivo voorspelt 
niet alleen de uitkomst van behandeling met een somatostatine analoog, maar geeft 
ook mogelijkheden om nieuwe therapeutische strategieen te gebruiken. Aangezien 
betere informatie over de uitgebreidheid van de ziekte verschaft kan worden, kunnen 
meer verantwoorde behandelingsmogelijkheden voorgesteld worden, zoals Peptide 
Receptor Radionuclide Therapie (PRRT). PRRT resulteert in een zeer effectieve 
behandeling van SSR-positieve tumoren in zowel experimentele maar ook klinische 
kaders. 
 
Helaas brengen niet alle humane tumoren SSRs tot expressie op hun celoppervlak, 
waardoor behandeling middels PRRT voor deze tumoren ook niet toepasbaar is. 
Echter is het tegenwoordig zeer goed mogelijk door recente ontwikkelingen in de 
moleculaire biologie om de SSR-gen op SSR-negatieve tumoren te transfecteren. In 
Hoofdstuk 4 worden SSR-negatieve colon carcinoom cellen (CC531) in vitro 
getransfecteerd met een SSR-gen, waarna ze CC2B genoemd worden. Scatchard 
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analyse van CC2B cellen laat een zeer hoge expressie van SSRs en een hoge 
bindingsaffiniteit zien. Verder wordt aangetoond dat de getransfecteerde SSR ook 
functioneel is, aangezien het radiogelabeld octreotide kan internaliseren. Groei 
snelheid en groeikarakteristieken van CC2B cellen zijn in vitro niet significant 
verschillend ten opzichte van hun moeder tumor cellijn, CC531. 
De bovengenoemde kenmerken van CC2B voldoen aan alle voorwaarden om deze 
SSR-getransfecteerde tumor cellijn te gebruiken in een in vivo model, waarbij 
toekomstige experimenten met PRRT uitgetest zullen worden. 
 
Hoofdstuk 5 evalueert het effect van PRRT met 370 MBq (0.5 µg) [111In-
DTPA0]octreotide op SSR-negatieve CC531 en SSR-positieve CC2B levermetastasen. 
Levermetastasen werden veroorzaakt door injectie van CC531 of CC2B cellen in de 
poortader in ratten op dag 0. 370 MBq (0.5 µg) [111In-DTPA0]octreotide werd op dag 
7 aan de helft van de ratten toegediend, terwijl de andere helft van de ratten geen 
behandeling kregen. Op dag 28 werden alle ratten opgeofferd, zodat de tumorscore 
vastgesteld kon worden. 
Er werden geen significante verschillen in tumorscore gevonden in PRRT-behandelde 
ratten ten opzichte van de controle ratten met CC531 levermetastasen. Echter ook 
werden er geen significante verschillen in tumorscore gevonden in ratten met CC2B 
levermetastasen (PRRT vs. Controle). Autoradiografie bevestigde een hoge expressie 
van SSRs op CC2B levermetastasen, terwijl deze afwezig was in CC531 
levermetastasen. Een hoge opname en retentie van radioactiviteit in CC2B tumoren 
werd gemeten, hetgeen aantoont dat de getransfecteerde receptor functioneel was. 
Tevens was de opgemeten radioactiviteit en toegediende doses radiatie vergelijkbaar 
met onze positieve controle tumor, CA20948, hetgeen aantoont dat CC2B niet 
radiosensitief is voor de door ons gegeven dosis. Dit werd tevens bevestigd in een 
clonogene assay van onze tumorcellen die door externe radiatie bestraald waren. 
Alhoewel er geen antiproliferatief effect van PRRT gezien werd van SSR-
getransfecteerde CC531 cellen, kunnen we concluderen dat (1) SSR aanhechting, (2) 
internalisatie en (3) retentie van radioactiviteit in de tumorcel wel plaats vond, 
hetgeen aantoont dat we een functionele receptor getransfecteerd hebben, maar 
onfortuinlijk de gebruikte cellijn radioresistent bleek te zijn voor de door ons gegeven 
dosis. 
 
Summary, Discussion and Future Aspects 
___________________________________________________________________________________ 
 157
In Hoofdstuk 6 wordt een studie gepresenteerd, waarbij het effect van [177Lu-DOTA0, 
Tyr3]octreotate op SSR-positieve CA20948 rat pancreas carcinoom cellen in zowel 
een in vitro als in vivo model geevalueerd werden. 
177Lutetium is een β-emitterende radionuclide, die β-partikels in een straal van 
ongeveer 2 mm met hoge energie (0.5 MeV) uitstraalt. Als gevolg van deze hogere 
energie en tevens grotere weefsel penetratie kan dit radionuclide voordeliger zijn dan 
111Indium voor PRRT bij de behandeling van micrometastasen. Aangezien de meeste 
SSR-positieve tumoren heterogeen in expressie zijn, resulteert het gebruik van 177Lu 
bij PRRT in bestraling van deze SSR-negatieve klonen, nadat het radionuclide 
geinternaliseerd is door naburige SSR-positieve klonen van de tumor. Tevens zorgt 
het gebruik van octreotate in plaats van octreotide voor een 3 tot 4 maal hogere 
opname in SSR-positieve tumoren, wat ook tot een meer effectievere antitumor 
activiteit kan leiden. 
CA20948 (SSR-positief) tumor cellen werden in de poortader van ratten geinjecteerd, 
zodat levermetastasen veroorzaakt werden. 21 dagen na inductie van de 
levermetastasen hadden behandelde ratten (185 of 370 MBq [177Lu-DOTA0, 
Tyr3]octreotate) significant minder levermetastasen in vergelijking met de controle 
ratten (p<0.001). Tevens hadden behandelde ratten een significante langere overleving 
(p<0.05). Tenslotte liet een in vitro PRRT één-cel model met [177Lu-DOTA0, 
Tyr3]octreotate een dosis-afhankelijke toxiciteit van CA20948 zien in tegenstelling tot 
SSR-negatieve CC531 tumorcellen. Dit onderstreept het belang van de SSR bij deze 
vorm van therapie. 
Concluderend kunnen we stellen dat [177Lu-DOTA0, Tyr3]octreotate een zeer 
veelbelovende nieuwe behandelingsmodaliteit is voor SSR-positieve tumoren, 
inclusief de behandeling van gedissemineerde ziekte. 
 
Zoals in Hoofdstuk 5 beschreven wordt is PRRT met [111In-DTPA0]octreotide niet 
effectief voor SSR-getransfecteerde levermetastasen, aangezien de getransfecteerde 
cellijn relatief radioresistent was voor de door ons gegeven dosis. Hoofdstuk 6 laat 
duidelijk de voordelen van [177Lu-DOTA0, Tyr3]octreotate, een β-emmiterende 
radionuclide met hogere energie in vergelijking met 111Indium, zien voor de 
behandeling van SSR-positieve levermetastasen. De doel van de studie, beschreven in 
Hoofdstuk 7, was het evalueren van het effect van [177Lu-DOTA0, Tyr3]octreotate op 
SSR-getransfecteerde colon carcinoom cellen in een rat levermetastase model. 
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Levermetastasen ontstonden door intraportale injectie van tumorcellen (CC2B en 
CC531) in ratten. Op dag 7 werden de dieren behandeld met 185 of 370 MBq [177Lu-
DOTA0, Tyr3]octreotate, terwijl controle dieren geen behandeling kregen. Na 21 
dagen werden de ratten opgeofferd en de levermetastasen geteld. 
Behandeling met 370 MBq [177Lu-DOTA0, Tyr3]octreotate liet een duidelijke 
antitumor effect zien in ratten met CC2B levermetastasen in vergelijking met de 
controle dieren (p<0.001), terwijl er geen antitumor effect waar werd genomen in 
PRRT behandelde ratten met CC531 levermetastasen. Ook werd er een (dosis-
afhankelijke) tumorrespons gezien in ratten met CC2B levermetastasen, die 
behandeled waren met een lagere (185 MBq) dosis [177Lu-DOTA0, Tyr3]octreotate in 
vergelijking met de controle dieren (p<0.01). Tevens hadden ratten met gemixte 
levermetastasen (half SSR-positief/half SSR-negatief) behandeld met 185 MBq 
[177Lu-DOTA0, Tyr3]octreotate significant minder levermetastasen vergeleken met de 
controle dieren (p<0.05), hetgeen verklaard zou kunnen worden door een radiologisch 
“bystander” effect van [177Lu-DOTA0, Tyr3]octreotate. Dit fenomeen is zeer voordelig 
in het concept van in vivo gentherapie. 
 
AN-238, een cytotoxisch somatostatine analoog, bestaat uit 2-pyrrolinodoxorubicin 
(AN-201) gekoppeld aan het somatostatine analoog, RC-121. Over AN-201 wordt 
beweerd dat het 500-1000 maal potenter is in vitro dan doxorubicin. In Hoofdstuk 8 
wordt een overzicht over de huidige literatuur over het cytotoxisch somatostatine 
analoog, AN-238, gegeven. Synthese, werkingsmechanismen en oncologische studies 
met AN-238 uitgevoerd door de groep van Schally worden besproken. 
Samenvattend kan worden gesteld dat AN-238, net als PRRT, ook een zeer 
indrukwekkende tumorgroei inhibitie op verscheidene SSR-positieve tumor cellijnen 
had. 
 
Aangezien indrukwekkende resultaten met AN-238 op verschillende SSR-positieve 
tumoren aangetoond waren, waren wij benieuwd of AN-238 ook effectief zou kunnen 
zijn voor de behandeling van SSR-getransfecteerde levermetastasen, alwaar wij eerder 
zeer effectieve behandeling met behulp van PRRT hadden aangetoond. Dit werd 
geevalueerd in Hoofdstuk 9. 
SSR-positieve (getransfecteerde) CC2B en zijn moeder SSR-negatieve CC531 cellijn 
werden getest in vitro met AN-238, AN-201 en doxorubicin (DOX) met en zonder 
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toevoeging van cyclosporine A (CsA). Hierna werden twee in vivo experimenten 
uitgevoerd, waarbij levermetastasen werden veroorzaakt door intraportale injectie van 
CC2B of CC531 cellen. Een enkele intraveneuze toediening van AN-238 bij 200 
nmol/kg of PBS (controle) op dag 7, werd bij het eerste experiment gegeven. In het 
tweede experiment werden twee intraveneuze injecties van AN-238 bij 250 nmol/kg 
of PBS (controle) gegeven op dag 5 en 13. WBC en lichaamsgewicht werd twee keer 
per week gemeten om toxiciteit van de behandeling te observeren. 
In vitro blootstelling van CC531 of CC2B cellen aan AN-238 liet een gelijke IC50 
voor beide cellijnen zien, ondanks de aanwezigheid van SSRs op CC2B cellen. Een 
poging om de beide cellijnen chemosensitiever te maken voor AN-238/AN-201 met 
behulp van de p-glycoproteine pomp remmer, CsA, was niet effectief. Het gebruik 
van AN-238 in vivo had in beide experimenten geen antitumor effect. De ernstige 
(beenmerg)toxiciteit, dat geobserveerd werd bij AN-238 behandelde ratten in het 
tweede in vivo experiment, resulteerde zelfs in significant hogere tumorscore 
vergeleken met de controle dieren. 
Concluderend kunnen we stellen dat zowel onze in vitro data als onze in vivo geen 
superieure antitumor effect van AN-238 heeft kunnen aantonen, ondanks de 
aanwezigheid van SSRs op CC2B cellen vergeleken met CC531 cellen. Deze 
resultaten zijn tegenstrijdig met de resultaten van de groep van Schally en anderen. 
 
CONCLUSIES 
• In vitro transfectie van CC531 is mogelijk. Na transfectie werd een hoge 
expressie van SSRs met een hoge bindingsaffiniteit gevonden. Tevens is de 
getransfecteerde receptor functioneel en zijn de groeisnelheid en 
karakteristieken niet veranderd. 
• PRRT met [111In-DTPA0]octreotide is niet effectief voor SSR-getransfecteerde 
CC531 cellen in een rat levermetastase model, aangezien de cellijn relatief 
radioresistent is. 
• PRRT met [177Lu-DOTA0, Tyr3]octreotate is erg effectief voor SSR-positieve 
CA20948 cellen in een rat levermetastase model. Bovendien hadden 
behandelde ratten een significant langere overleving. 
• PRRT met [177Lu-DOTA0, Tyr3]octreotate is erg effectief voor SSR-
getransfecteerde CC531 cellen in een rat levermetastase model. Zelfs als 
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transfectie-percentages lager zijn, is PRRT met dit middel effectief, 
waarschijnlijk door een radiologische bystander effect. 
• Doelgerichte behandeling met het cytotoxische somatostatine analoog, AN-
238, is niet effectief voor SSR-getransfecteerde CC531 cellen in een rat 
levermetastase model.  Noch in vitro noch in vivo werd een SSR-targeting van 
AN-238 waargenomen. 
 
 
 
 
 
 
 161
DANKWOORD 
Toen ik in februari 1999 begon aan dit onderzoek, kreeg ik met een enthousiaste 
groep onderzoekers en begeleiders te maken, die elk op hun manier wat hebben 
bijgedragen tot de realisatie van dit proefschrift. Een aantal  van hen wil ik in het 
bijzonder noemen. 
 
Mijn co-promotor, Dr. C.H.J. van Eijck, Casper, jij was de grote initiator van het 
gehele onderzoeksproject. Jouw ongekend groot enthousiasme en optimisme, ook als 
het een keer wat tegenzat, hebben mij zeer gestimuleerd om tot een goed einde te 
komen. Ook jouw aanwezigheid op de vele congressen samen met de “van Eijck-
onderzoeksgroep” waren niet alleen leerzaam maar bovenal gezellig. Ik verheug mij 
zeer op mijn komende Dijkzigt-jaren, alwaar ik nog veel van je hoop te mogen leren. 
 
Mijn promotor, Prof. dr. J. Jeekel: Al velen zijn mij voorgegaan als promovendus. Uw 
enthousiasme voor onderzoek is ongekend en zeer aanstekelijk. Na de vele discussies 
over mijn onderzoek, die wij gehouden hadden, wilde ik het liefst zo snel mogelijk 
terug naar het lab, om nieuwe experimenten uit te voeren. Ook de samenwerking met 
betrekking tot andere activiteiten, zoals de wintersport en Chirurgencup, stelde ik zeer 
op prijs. 
 
Mijn tweede promotor, Prof. dr. E.P. Krenning: U bent de “vader” van de Octreoscan 
en alle nieuw ontwikkelde radiogelabelde somatostatine analoga. De waarde van dit 
middel laat fantastische resultaten zien en heeft nog veel meer potentie. De 
samenwerkingsverband tussen het chirurgische en uw nucleaire lab was zeer 
vruchtbaar en heeft al meerdere promoties opgeleverd. 
 
Prof. dr. H.W. Tilanus en Prof. dr. S.W.J. Lamberts wil ik danken voor het kritisch 
doornemen van het manuscript. Tevens wil ik jullie en de overige leden  danken voor 
de bereidheid om deel uit te maken van de promotiecommissie.  
 
Dr. R.L. Marquet: Richard, jouw ervaring in het uitvoeren van experimenten, maar 
ook op andere dagelijkse zaken, is van onschatbare waarde geweest voor de 
totstandkoming van dit proefschrift. Ik heb als zeer bijzonder ervaren om in het lab 
onder jouw leiding gewerkt te mogen hebben. 
 162
 
Dr. W.A.P. Breeman: Wout, hoe verder het onderzoek vorderde, hoe meer jij een 
gedeelte van de begeleiding naar jou toe trok. Op het moment dat mijn onderzoek vast 
zat, heb jij mij grotendeels “erdoorheen” getrokken. Mede dankzij jouw 
verhelderende uitleg, ben ik steeds meer over de moeilijke materie van de Nucleaire 
Geneeskunde gaan begrijpen. Ook je (vele) correcties in mijn manuscripten heb ik 
altijd zeer gewaardeerd. Mijn dank hiervoor is groot. 
 
Dr. L.J. Hofland: Leo, zonder jouw hulp was ik nergens. De hele transfectie van de 
tumor cellijn en de meeste in vitro onderzoeken zijn in jouw lab uitgevoerd. Jouw 
kritische kijk op zaken was zeer waardevol en van aanvulling op mijn misschien wel 
iets te chirurgische kijk op zaken. 
 
Dr. G.D. Slooter: Gerrit, jij was mijn voorganger. Veel voorwerk had je al voor mijn 
tijd opgeknapt. Ook van je “levenslessen” heb ik zeer genoten. Ik hoop dat ik een 
waardige SIO ben! 
 
Een speciale dank naar alle medewerkers en collegae van het Laboratorium voor 
Experimentele Chirurgie, alwaar ik 3 jaar lang met veel plezier heb gewerkt. Elma 
van Rossen, Arend Aalbers, Caroline Verbakel, Helma van Grevenstein, Ingrid Boere, 
Türkan Terkivatan, Miranda ten Kate, Pim Burger, Dennis Sousa en Sander ten Raa, 
jullie waren fantastische collegae en nooit beroerd om een handje te helpen. Fred 
Bonthuis en Rob Meijer wil ik danken voor de “cursus microchirurgie”. Ton 
Boijmans en Pim van Schalkwijk voor de analyse van de bloedmonsters. Ron de 
Bruin, veel dank voor de inhoudelijke commentaar van mijn onderzoek. Monique 
Moor heeft als analist veel belangrijk werk verzet. Tevens wil ik al mijn collegae van 
“het Z-gebouw” bedanken voor een vaak heerlijke lunch en een hoop lol. 
 
Alle medewerkers van het Laboratorium van Interne Geneeskunde III: ik hoop dat ik 
niet teveel overlast heb veroorzaakt. Ook in drukke tijden stonden jullie altijd open 
om mij te helpen. Peter van Koetsveld, bij alle, soms acute, problemen kon ik bij je 
terecht. Dank voor je geweldige hulp en begeleiding in jullie lab. 
 
 163
Ook zijn vele experimenten in het Centraal Isotopen Lab (CIL) uitgevoerd. Ook hier 
wil ik alle medewerkers danken. In het bijzonder, Bert Bernard bij de hulp van de 
behandeling van de ratten. Ook Arthur van Gameren heeft veel werk voor mij verzet 
in het uitvoeren en uitwerken van vele “nucleaire” experimenten. Ik heb met veel 
plezier met je samengewerkt en hoop dat je in de toekomst je onderzoek tot een goed 
einde brengt. 
 
Mijn paranimfen, Arend Aalbers en Eric Hazebroek. Arend, toen ik in februari 1999 
begon met mijn onderzoek stond jij direct klaar om mij te helpen en te begeleiden. Ik 
hoop dat jij spoedig, als een ware SIO, ook achter het katheder staat. 
Eric, wij zijn ongeveer tegelijkertijd begonnen met ons onderzoek. Het was een 
genoegen om met jou laparoscopische operaties bij ratten (“a new modified technique 
by Hazebroek & Mearadji”) uit te voeren met op de achtergrond muziek van de “Lab 
Classics”. Arend en Eric, ik hoop na mijn promotie weer (met Niels) snel te “Peren 
met de Heeren”! 
 
Mijn ouders zou ik willen danken voor hun onvoorwaardelijke steun en interesse voor 
mijn onderzoek. Pap, je toewijding voor je vak is bewonderenswaardig. Ik hoop ook 
dat ik het ooit zo ver kan schoppen als jij. 
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